Trials

Saner and Fricker, 3000   DDD versus VVIR in AV block or SSS   PDF

Davis, 3000   VDD versus VVI in AV block   PDF

Capucci, 3000   DDD,DDDR versus VVI in AV block or SSS or both   PDF

TAxi (diabetics), 3000   sirolimus eluting stent versus paclitaxel eluting stent in   PDF

Lopaciuk, 3000   subcutaneous heparin versus intravenous heparin in   PDF

Study 541, 3000   versus in   PDF

Gardecki, 3000   Ticlopidine versus placebo in Elective orthopaedic surgery   PDF

CL3-018 15mg, 3000   ivabradine 15mg versus placebo on top of amlodipine in   PDF

CL3-018 10mg, 3000   ivabradine 10mg versus placebo on top of amlodipine in   PDF

GEICAM/2006-10, 3000   (NCT00543127)   fulvestrant + anastrozole versus anastrozole in Postmenopausal women with hormone receptor positive and negative Her2 tumours   PDF

D6997L00021, 3000   (NCT01300351)   fulvestrant 500mg versus fulvestrant 250mg in Chinese postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed a prior endocrine treatment   PDF

Lyon-II, 3000   Ticlopidine versus placebo in Elective orthopaedic surgery   PDF

Keynote 061, 2018   (NCT02370498)   pembrolizumab versus paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine and who had a PD-L1 CPS of 1 or higher   PDF

COMMANDER HF, 2018   (NCT01877915)   rivaroxaban versus placebo in patients who had chronic heart failure, a left ventricular ejection fraction of 40% or less, coronary artery disease, and elevated plasma concentrations of natriuretic peptides and who did not have atrial fibrillation   PDF

SELECT D, 2018   rivaroxaban versus dalteparin in patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lowerextremity proximal deep vein thrombosis (DVT)   PDF

NAVIGATE ESUS, 2018   (NCT02313909)   rivaroxaban versus aspirin in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source   PDF

CABANA, 2018   (NCT00911508).)   catheter ablation versus control in patients with untreated or incompletely treated AF   PDF

DECLARE TIMI 58, 2018   (NCT01730534)   dapagliflozin versus placebo in adults with T2D at risk of CV events, including patients with multiple CV risk factors or established CV disease   PDF

ODYSSEY OUTCOMES, 2018   (NCT01663402)   alirocumab versus placebo (on top statins) in Post-ACS patients (1 to 12 months)with elevated levels of atherogenic lipoproteins despite intensive or maximum-tolerated statin therapy   PDF

CheckMate 227 (nivolumab + CT), 2018   (NCT02477826)   nivolumab + CT versus platinum-based CT in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer <1% tumor PD-L1 expression   PDF

Keynote 042 (>=20%), 2018   (NCT02220894)   pembrolizumab versus platinum-based CT in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer   PDF

Keynote 042 (>=50%), 2018   (NCT02220894)   pembrolizumab versus platinum-based CT in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer   PDF

Keynote 407, 2018   (NCT02775435)   pembrolizumanb + CT versus platinum-based CT in adults with first line metastatic squamous non-small cell lung cancer   PDF

IMpower150 (Teff), 2018   (NCT02366143)   atezolizumab + bevacizumab versus bevacizumab (on top platinum-based CT) in chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer and expression of a tumour T-effector gene signature (Teff) and EGFR et ALK negative (wild type)   PDF

ARCTIC PD-L1 negative, 2018   (NCT02352948)   durvalumab + tremelimumab versus Standard of Care in patients with PD-L1 negative Locally Advanced or Metastatic Non Small Cell Lung Cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC   PDF

Keynote 189, 2018   (NCT02578680)   pembrolizumab + platinum-based CT versus platinum-based CT in participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and without sensitizing EGFR or ALK mutations   PDF

ASPREE, 2018   (NCT01038583)   aspirin versus placebo in   PDF

ASCEND, 2018   (NCT00135226)   aspirin versus placebo in   PDF

JUNIPER, 2018   (NCT02152631)   abemaciclib versus erlotinib in patients with stage IV NSCLC with a detectable KRAS mutation who progressed after platinum-based chemotherapy and who may have received 1 additional systemic therapy   PDF

CheckMate 227 (High Tumor Mutational Burden), 2018   (NCT02477826)   nivolumab + ipilimumab versus platinum-based CT in patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy and high tumor mutational burden (>=10 mutations per megabase), irrespective of PD-L1 expression level   PDF

MARINER, 2018   (NCT02111564)   rivaroxaban versus placebo in high-risk medical patients : medically ill patients who were at increasedrisk for venous thromboembolism on the basis of a modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) score of 4 or higher (scores range from 0 to 10, with higher scores indicating a higher risk of venous thromboembolism) or a score of 2 or 3 plus a plasma d-dimer level of more than twice the upper limit of the normal range (defined according to local laboratory criteria)   PDF

IMpower150 (WT), 2018   (NCT02366143)   atezolizumab + bevacizumab versus bevacizumab (on top platinum-based CT) in wild type chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (EGFR et ALK negative)   PDF

Keynote 042 (>=1%), 2018   (NCT02220894)   pembrolizumab versus platinum-based CT in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer   PDF

KEYNOTE-185, 2018   (NCT02579863)   pembrolizumab, lenalidomide, dexametahsone versus lenalidomide, dexamethasone in newly diagnosed and treatment naïve Multiple Myeloma who are ineligible for autologous stem cell transplant   PDF

KEYNOTE-183, 2018   (NCT02576977)   pembrolizumab + pomadoline + dexamethasone versus pomadoline + dexamethasone in refractory or relapsed and refractory Multiple Myeloma (rrMM)   PDF

BRIM 8, 2018   (NCT01667419)   vemurafenib versus placebo in patients with resected,BRAFV600 mutation-positive melanoma: IC–IIIA–IIIB (cohort 1) or stage IIIC (cohort 2)   PDF

COLUMBUS, 2018   (NCT01909453)   encorafenib plus binimetinib versus vemurafenib in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation   PDF

KEYNOTE-054, 2018   (NCT02362594)   pembrolizumab versus placebo in patients with complete Resection of High-Risk Stage III Melanoma   PDF

IMpassion130, 2018   atezolizumab + Nab-Paclitaxel versus Nab-Paclitaxel in patients with untreated metastatic triple-negative breast cancer   PDF

SANDPIPER, 2018   (NCT02340221)   taselisib + fulvestrant versus fulvestrant alone in postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, PIK3CA-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy   PDF

EINSTEIN CHOICE (10mg), 2017   (NCT02064439)   rivaroxaban 10mg versus aspirin in Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation   PDF

Hokusai-VTE Cancer, 2017   (NCT02073682)   edoxaban versus dalteparin in patients with cancer who had acute symptomatic or incidental venous thromboembolism   PDF

EINSTEIN CHOICE (20mg), 2017   (NCT02064439)   rivaroxaban 20mg versus aspirin in Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation   PDF

CANVAS, 2017   (NCT01032629)   canagliflozin versus placebo in participants with type 2 diabetes and high cardiovascular risk   PDF

EXSCEL, 2017   (NCT01144338)   exenatide versus placebo in patients with type 2 diabetes, with or without previous cardiovascular disease   PDF

ACCELERATE, 2017   (NCT01687998)   evacetrapib versus placebo in Patients at a High-Risk for Vascular Outcomes who had at least one of the following conditions: an acutecoronary syndrome within the previous 30 to 365 days, cerebrovascular atheroscleroticdisease, peripheral vascular arterial disease, or diabetes mellitus with coronaryartery disease   PDF

REVEAL HPS-3 TIMI-55, 2017   (NCT01252953)   anacetrapib versus placebo in high risk patients already taking statins   PDF

ATTRACTION-2, 2017   (NCT02267343)   nivolumab versus placebo in patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens   PDF

ENGOT-OV16/NOVA gBRCA, 2017   (NCT01847274)   niraparib versus placebo in patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation   PDF

KEYNOTE-052, 2017   (NCT02335424)   pembrolizumab versus in cisplatin-ineligible patients with advanced urothelial cancer who had not been previously treated with systemic chemotherapy   PDF

KEYNOTE-045, 2017   (NCT02256436)   pembrolizumab versus chemotherapy in patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy   PDF

CABOSUN, 2017   (NCT01835158)   cabozantinib versus sunitinib in untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria   PDF

CheckMate-214, 2017   (NCT02231749)   nivolumab + ipilimumab versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma   PDF

FOURIER, 2017   (NCT01764633)   evolocumab versus placebo (on top statins) in patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy   PDF

COMPASS (rivaroxaban alone), 2017   (NCT01776424)   rivaroxaban versus aspirin in Patients With Coronary or Peripheral Artery Disease   PDF

COMPASS (rivaroxaban + aspirin), 2017   (NCT01776424)   rivaroxaban + aspirin versus aspirin in Patients With Coronary or Peripheral Artery Disease   PDF

Govindan, 2017   (NCT01285609)   ipilimumab + chemotherapy versus placebo + chemotherapy in Patients with stage IV or recurrent chemotherapy-naïve squamous NSCLC   PDF

FLAURA, 2017   (NCT02296125)   osimertinib versus placebo in previously untreated patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer   PDF

ASCEND 5, 2017   (NCT01828112)   ceritinib versus pemetrexed or docetaxel in patients previously treated with chemotherapy (platinum doublet) and crizotinib   PDF

ALEX, 2017   (NCT02075840)   alectinib versus crizotinib in patients with stage IIIB or IV, ALK-positive NSCLC who had not received prior systemic therapy   PDF

ASCEND-4, 2017   (NCT01828099)   ceritinib versus chemotherapy in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC   PDF

AURA 3, 2017   (NCT02151981)   osimertinib versus platinum-based therapy plus pemetrexed in patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed after 1st-line EGFR tyrosine kinase inhibitor (TKI) therapy.   PDF

PACIFIC, 2017   (NCT02125461)   durvalumab versus placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy   PDF

FOCUS, 2017   (NCT01302392)   carfilzomib versus low-dose corticosteroids in relapsed and refractory multiple myeloma (RRMM)   PDF

COMBI-AD, 2017   (NCT01682083)   trametinib and dabrafenib versus placebo in Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanoma   PDF

CheckMate 238, 2017   (NCT02388906)   nivolumab versus ipilimumab in patients with Complete Resection of Stage IIIb/c or Stage IV Melanoma   PDF

OlympiAD, 2017   (NCT02000622)   olaparib versus Physician s choice chemotherapy in women with human epidermal growth factor 2 (HER2)–negative metastatic breast cancer with a germline BRCA mutation   PDF

MONARCH 3, 2017   (NCT02246621)   Abemaciclib +nsAI versus nsAI in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting   PDF

CANTOS, 2017   (NCT01327846)   canakinumab versus placebo in Stable Post-myocardial Infarction Patients With Elevated hsCRP   PDF

Checkmate-141, 2016   (NCT02105636)   nivolumab versus standard treatment in patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy   PDF

CUPID 2b, 2016   (NCT01643330)   Bone marrow derived stem cell versus control in patients with advanced heart failure   PDF

ixCELL-DCM, 2016   (NCT01670981)   ixmyelocel-T versus placebo in patients with New York Heart Association class III or IV symptomatic heart failure due to ischaemic dilated cardiomyopathy, who had left ventricular ejection fraction 35% or less, an automatic implantable cardioverter defibrillator, and who were ineligible for revascularisation procedures   PDF

IRIS, 2016   (NCT00091949)   pioglitazone versus placebo in   PDF

SUSTAIN 6, 2016   (NCT01720446)   semaglutide versus placebo in patients with type 2 diabetes who were on a standardcare regimen   PDF

Leiter, 2016   (NCT01042977)   dapagliflozin versus placebo (on top standard treatment) in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care   PDF

MB102034, 2016   (NCT00859898)   dapagliflozin + merformin versus metformin or dapa in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control   PDF

LEADER, 2016   (NCT01179048)   liraglutide versus placebo in subjects with type 2 diabetes   PDF

Demetri, 2016   (NCT01343277)   trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen   PDF

Eribulin phase 3 (Schöffski ), 2016   eribulin versus dacarbazine in patients aged 18 years or older with intermediate-grade or high-grade advanced liposarcoma or leiomyosarcoma who had received at least two previous systemic regimens for advanced disease (including an anthracycline)   PDF

HOPE 3, 2016   (NCT00468923)   rosuvastatin versus placebo in subjects who did not have cardiovascular disease and were at intermediate risk   PDF

KEYNOTE-021 phase 2, 2016   (NCT02039674)   pembrolizumab + platinum-based CT versus platinum-based CT in patients with stage IIIB/IV, chemotherapy-naive, nonsquamous non-small-cell lung cancer   PDF

Reck, 2016   (NCT01450761)   ipilimumab + chemotherapy versus placebo + chemotherapy in patients with newly diagnosed extensive-stage disease SCLC   PDF

APEX, 2016   (NCT01583218)   betrixaban versus enoxaparin in Patients who were hospitalized for acute medical illnesses and with an elevated d-dimer level   PDF

OAK, 2016   (NCT02008227)   atezolizumab versus docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy   PDF

CheckMate 026, 2016   (NCT02041533)   nivolumab versus platinum-based CT in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at >5% (>1%???). Patients with EGFR activating mutations and ALK translocations, which are sensitive to targeted therapy, were excluded.   PDF

POPLAR Phase 2 atezolizumab, 2016   (NCT01903993)   atezolizumab versus docetaxel in patients with locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Th   PDF

ENDEAVOR, 2016   (NCT01568866)   carfilzomib versus bortezomib in patients with relapsed or refractory multiplemyeloma who had one to three previous treatments   PDF

MONALEESA-2, 2016   (NCT01958021)   ribociclib (LEE011) + letrozole versus letrozole alone in postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease   PDF

PALOMA-2, 2016   (NCT01740427)   palbociclib + letrozole versus letrozole alone in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease   PDF

ExteNET, 2016   (NCT00878709)   neratinib versus placebo in Women With Early Stage Breast Cancer   PDF

INCL, 2015   (NCT00333827)   Bone marrow derived stem cell versus placebo in patients with dilated cardiomyopathy and heart failure in NYHA class III or IV   PDF

PADIS-PE (Couturaud), 2015   (NCT00740883)   VKA versus placebo in patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist   PDF

Ross, 2015   (e2012-000905-53)   empagliflozin versus placebo (add-on MET) in patients with type 2 diabetes inadequately controlled on metformin   PDF

Kadowaki, 2015   (NCT01193218)   empagliflozin versus placebo in Japanese patients with type 2 diabetes   PDF

Lewin, 2015   (NCT01422876)   empagliflozin versus linagliptin (monotherapy) in   PDF

Mathieu, 2015   (NCT01646320)   dapagliflozin versus placebo (add on MET + SAXA) in   PDF

Matthaei, 2015   (NCT01392677)   dapagliflozin versus placebo (add on MET+SU) in   PDF

Yang, 2015   (NCT01095666)   dapagliflozin versus in   PDF

Rosenstock, 2015   (NCT01606007)   dapagliflozin versus Saxagliptin (add on MET) in   PDF

DeFronzo, 2015   (NCT01422876)   empagliflozin versus linagliptin (add-on MET) in subjects with type 2 diabetes inadequately controlled on metformin   PDF

Araki, 2015   (NCT01368081)   empagliflozin versus placebo (add-on standard treatment) in Japanese patients with type 2 diabetes mellitus   PDF

EMPA-REG OUTCOME, 2015   (NCT01131676)   empagliflozin versus placebo in patients with type 2 diabetes at high cardiovascular risk   PDF

TECOS, 2015   (NCT00790205)   sitagliptin versus placebo in patients with Type 2 Diabetes Mellitus having a history of cardiovascular disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%   PDF

Schumm-Draeger , 2015   (NCT01217892)   dapagliflozin versus placebo (add on MET) in Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy   PDF

Cefalu, 2015   (NCT01031680)   dapagliflozin versus placebo (on top standard treatment) in   PDF

CSPPT, 2015   (NCT00794885)   folic acid versus placebo in patients with primary hypertension   PDF

Chekmate 025 (Motzer), 2015   (NCT01668784)   nivolumab versus everolimus in patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy   PDF

ODYSSEY Long-Term, 2015   (NCT01507831)   alirocumab versus placebo (on top statins) in patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy   PDF

METEOR, 2015   (NCT01865747)   cabozantinib versus everolimus in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy   PDF

CheckMate 025, 2015   (NCT01668784)   nivolumab versus everolimus in patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy   PDF

PEGASUS 60mg, 2015   (NCT01225562)   ticagrelor versus placebo (on top aspirin) in patients who had had a myocardial infarction 1 to 3 years earlier   PDF

RUTHERFORD-2, 2015   (NCT01763918)   evolocumab versus placebo (on top statins) in heterozygous familial hypercholesterolaemia   PDF

PEGASUS 90mg, 2015   (NCT01225562)   ticagrelor versus placebo (on top aspirin) in patients who had had a myocardial infarction 1 to 3 years earlier   PDF

REALIZE, 2015   (NCT01524289)   anacetrapib versus placebo in patients aged 18-80 years with a genotype-confirmed or clinical diagnosis of heterozygous familial hypercholesterolaemia, on optimum lipid-lowering treatment for at least 6 weeks, and with an LDL-C concentration of 2·59 mmol/L or higher without cardiovascular disease or 1·81 mmol/L or higher with cardiovascular disease   PDF

Keynote 010 10mg, 2015   (NCT01905657)   pembrolizumab 10mg versus docetaxel in patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells   PDF

Keynote 010 2mg, 2015   (NCT01905657)   pembrolizumab 2mg versus docetaxel in patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells   PDF

LUX-LUNG 6, 2015   afatinib versus cisplatin-based chemotherapy in EGFR mutation-positive lung adenocarcinoma   PDF

LUX-LUNG 3, 2015   afatinib versus cisplatin-based chemotherapy in EGFR mutation-positive lung adenocarcinoma   PDF

Keynote 024, 2015   (NCT02142738)   pembrolizumab versus platinum-based CT in previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene   PDF

CheckMate 017, 2015   (NCT01642004)   nivolumab versus docetaxel in patients with advanced SQ NSCLC who fail platinum-based doublet chemotherapy   PDF

CheckMate 057, 2015   (NCT01673867)   nivolumab versus docetaxel in patients with advanced nonsquamous nonsmall cell lung cancer (NSCLC) who had progressed on platinum-doublet chemotherapy   PDF

ASPIRE, 2015   (NCT01080391)   carfilzomib versus placebo (on top lenalidomide and dexamethasone) in patients with relapsed multiple myeloma   PDF

ELOQUENT 2, 2015   (NCT01239797)   elotuzumab versus placebo (on top lenalidomide and dexamethasone) in patients with Relapsed or Refractory Multiple Myeloma   PDF

COMBI-V (Robert), 2015   (NCT01597908)   trametinib and dabrafenib versus vemurafenib in patients with metastatic melanoma with a BRAF V600 mutation   PDF

EORTC 18071 (Eggermont), 2015   (NCT00636168)   ipilimumab versus placebo in high risk patients who had undergone complete resection of stage III melanoma   PDF

KEYNOTE 002 (10mg/kg Q3W), 2015   (NCT01704287)   pembrolizumab 10mg/kg versus chemotherapy in patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAFV600 mutation positive, a BRAF inhibitor   PDF

KEYNOTE-006 (every 3W), 2015   (NCT01866319)   pembrolizumab (every 3W) versus ipilimumab in patients with unresectable stage III or IV advanced melanoma and who had received no more than one previous systemic therapy for advanced disease   PDF

CheckMate 067 (nivo + ipi vs nivo), 2015   (NCT01844505)   nivolumab + ipilimumab versus nivolumab in Previously Untreated Advanced Melanoma   PDF

CheckMate 067 (nivo vs ipi), 2015   (NCT01844505)   nivolumab versus ipilimumab in Previously Untreated Advanced Melanoma   PDF

Postow, 2015   (NCT01927419)   nivolumab + ipilimumab versus ipilimumab in patients with metastatic melanoma who had not previously received treatment,   PDF

KEYNOTE 002 (2mg/kg Q3W), 2015   (NCT01704287)   pembrolizumab 2mg/kg versus chemotherapy in patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAFV600 mutation positive, a BRAF inhibitor   PDF

KEYNOTE-006 (every 2W), 2015   (NCT01866319)   pembrolizumab (every 2W) versus ipilimumab in patients with advanced melanoma who had received no more than one previous systemic therapy for advanced disease   PDF

CheckMate 037 (Weber), 2015   (NCT01721746)   nivolumab versus chemotherapy in patients with advanced melanoma who progressed after ipilimumab, or ipilimumab and a BRAF inhibitor if they were BRAFV mutation-positive (second-line or later-line treatment)   PDF

CheckMate 066 (Robert), 2015   (NCT01721772)   nivolumab versus dacarbazine in previously untreated patients who had unresectable metastatic melanoma without a BRAF mutation (stage III or IV)   PDF

CheckMate 067 (nivo + ipi vs ipi), 2015   (NCT01844505)   nivolumab + ipilimumab versus ipilimumab in Previously Untreated Advanced Melanoma   PDF

Dickler (CALGB 40503°, 2015   Letrozole plus bevacizumab versus letrozole in   PDF

Badwe, 2015   locoregional treatment versus no treatment of the primary tumour in   PDF

Trial 301 (Kaufman), 2015   (NCT00337103)   eribulin versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane   PDF

PALOMA 1/TRIO-18, 2015   (NCT00721409)   palbociclib + letrozole versus letrozole alone in postmenopausal women with advanced oestrogen receptor-positive and HER2-negative breast cancer who had not received any systemic treatment for their advanced disease   PDF

PALOMA 3, 2015   (NCT01942135)   palbociclib + fulvestrant versus fulvestrant alone in women with HR+, HER2 negative metastatic breast cancer whose disease has progressed after prior endocrine therapy   PDF

SPRINT, 2015   (NCT01206062)   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in high-risk hypertensive adults 50 years of age and older with one additional cardiovascular risk factor or preexisting kidney disease   PDF

PAST-BP, 2015   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in   PDF

TAC-HFT, 2014   (NCT00768066)   Stem cells versus control in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction   PDF

IMPACT-DCM, 2014   (NCT00765518)   ixmyelocel-T versus control in patients with dilated cardiomyopathy   PDF

PARADIGM-HF, 2014   (NCT01035255)   sacubitril/valsartan versus enalapril in   PDF

Catheter-DCM, 2014   (NCT01020968)   ixmyelocel-T versus control in patients with dilated cardiomyopathy   PDF

EMPA-REG MET (Haring), 2014   (NCT01159600)   empagliflozin versus placebo (add-on MET) in Patients with HbA1c levels of ¡Ý7% to ¡Ü 10% (¡Ý53 to ¡Ü86 mmol/mol) while receiving metformin (¡Ý1,500 mg/day)   PDF

Kadowaki , 2014   empagliflozin versus in   PDF

Kaku, 2014   (NCT01294423)   dapagliflozin versus placebo in   PDF

Ridderstrale, 2014   (NCT01167881)   empagliflozin versus Glimepiride + MET in   PDF

Rosenstock (1245.49), 2014   (NCT01306214)   empagliflozin versus placebo (add-on INS+/-MET) in Patients inadequately controlled on MDI insulin ± metformin   PDF

Barnett, 2014   (NCT01164501)   empagliflozin versus placebo in Patients With Mild or Moderate Renal Impairment   PDF

ALECARDIO, 2014   (NCT01042769)   aleglitazar versus placebo in patients hospitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes   PDF

IMPROVE-IT, 2014   (NCT00202878)   ezetimibe versus placebo (on top statins) in subjects with stabilized high-risk acute coronary syndrome   PDF

Powles, 2014   apitolisib versus everolimus in   PDF

SOLID-TIMI 52, 2014   (NCT01000727)   darapladib versus placebo in participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-elevation myocardial infarction   PDF

DESCARTES, 2014   (NCT01516879)   evolocumab versus placebo (on top statins) in   PDF

YUKAWA-1, 2014   evolocumab versus in   PDF

LAPLACE 2, 2014   (NCT01763866)   evolocumab versus placebo (on top statins) in   PDF

Reck, 2014   (NCT00805194)   Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer   PDF

Laurie, 2014   cediranib versus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer   PDF

Heist CALGB 30704 (Alliance): , 2014   sunitinib versus pemetrexed in second-line treatment of advanced non-small-cell lung cancer   PDF

PROFILE 1014, 2014   (NCT01154140)   crizotinib versus chemotherapy in patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease   PDF

ASPIRE, 2014   (NCT01080391)   carfilzomib lenalidomide dexamethasone versus lenalidomide and dexamethasone alone in patients with relapsed multiple myeloma   PDF

COMBI-D (Long), 2014   (NCT01584648)   trametinib and dabrafenib versus dabrafenib in previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation   PDF

Larkin, 2014   (NCT01689519)   vemurafenib and cobimetinib versus vemurafenib in patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma   PDF

KEYNOTE-001, 2014   (NCT01295827)   pembrolizumab 2mg/kg versus pembrolizumab 10mg/kg in patients (aged ¡Ý18 years) with advanced melanoma whose disease had progressed after at least two ipilimumab doses   PDF

INTORSECT, 2014   (NCT00474786)   temsirolimus versus sorafenib in Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib   PDF

RECORD 3, 2014   (NCT00903175)   everolimus versus sunitinib in patients with metastatic renal cell carcinoma   PDF

SIGNIFY, 2014   (ISRCTN61576291)   ivabradine 20mg versus placebo in patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more   PDF

BOLERO-3, 2014   (NCT01007942)   everolimus + trastuzumab + vinorelbine versus trastuzumab + vinorelbine alone in women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy   PDF

Beelen, 2014   tamoxifen versus no systemic treatment in   PDF

TH3RESA, 2014   (NCT01419197)   trastuzumab emtansine versus usual care in patients with progressive HER2-positive advanced breast cancer who had received two or more HER2-directed regimens in the advanced setting   PDF

Symplicity HTN-3, 2014   (NCT01418261)   Symplicity system versus sham procedure in patients with resistant hypertension   PDF

TOPCAT, 2014   (NCT00094302)   spironolactone versus placebo in patients with heart failure and a preserved left ventricular ejection fraction of 45% or more   PDF

CHAMPION PHOENIX, 2013   (NCT01156571)   cangrelor versus clopidogrel in patients undergoing PCI for stable angina or for acute coronary syndromes, including ST-elevation MI   PDF

REVIVE II, 2013   (NCT00048425)   levosimendan versus placebo in patients with decompensated chronic heart failure   PDF

ASTRONAUT, 2013   (NCT00894387)   Aliskiren versus placebo in stable patients with heart failure, an LVEF <40% (mean 28%), and elevated natriuretic peptides who had been discharged from a heart-failure hospitalization an average of five days before   PDF

RELAX-AHF, 2013   (NCT00520806)   serelaxin versus placebo in patients admitted to hospital for acute heart failure   PDF

C CURE, 2013   (NCT00810238)   Cardiopoietic stem cell versus control in patients with heart failure of ischemic origin   PDF

Vrtovec, 2013   (NCT01350310)   Bone marrow progenitor cells versus control in patients with dilated cardiomyopathy   PDF

TASTE (Fröbert), 2013   (NCT01093404)   thrombectomy versus PCI only in patients with STEMI undergoing PCI   PDF

INFUSE AMI, 2013   thrombectomy versus conventional PCI in patients with ST-segment-elevation myocardial infarction caused by proximal or mid left anterior descending artery occlusion undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation   PDF

AMPLIFY EXT 5mg, 2013   apixaban 5mg versus placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy   PDF

AMPLIFY EXT 2.5mg, 2013   apixaban 2.5mg versus placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy   PDF

RESONATE, 2013   dabigatran versus placebo in   PDF

REMEDY, 2013   dabigatran versus warfarin in   PDF

Edoxaban Hokusai VTE, 2013   (NCT00986154)   heparin/edoxaban versus heparin/VKA in patients with acute venous thromboembolism, who had initially received heparin,   PDF

AMPLIFY, 2013   (NCT00643201)   apixaban (without LMWH) versus LMWH/VKA in patients with deep vein thrombosis or pulmonary embolism   PDF

EMPA-REG MONO (Roden) vs sitagliptin, 2013   (NCT01177813)   empagliflozin versus sitagliptin in   PDF

Rosenstock DOUBLON ???, 2013   empagliflozin versus placebo (add-on INS) in   PDF

Rosenstock, 2013   (NCT00749190 )   empagliflozin versus placebo (add-on MET) in   PDF

EMPA-REG MONO (Roden) vs placebo, 2013   (NCT01177813)   empagliflozin versus placebo in   PDF

EMPA-REG PIO (Kovacs), 2013   (NCT01210001)   empagliflozin versus placebo (add on MET+/-PIO) in   PDF

Kadowaki, 2013   empagliflozin versus in Japanese patients with type 2 diabetes   PDF

Ferrannini, 2013   (NCT00789035)   empagliflozin versus placebo in   PDF

ENGAGE-AF TIMI 48 High dose, 2013   (NCT00781391)   edoxaban high dose versus warfarin standard dose in AF patients (CHADS2 >=2)   PDF

SAVOR TIMI, 2013   (NCT01107886)   saxagliptin versus placebo in patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events   PDF

EXAMINE, 2013   (NCT00968708)   alogliptin versus placebo in patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days   PDF

Explore-Xa, 2013   (NCT00742859)   betrixaban versus warfarin in   PDF

ENGAGE-AF TIMI 48 Low dose, 2013   (NCT00781391)   edoxaban low dose versus warfarin standard dose in AF patients (CHADS2 >=2)   PDF

PREDIMED (olive oil), 2013   (ISRCTN35739639)   Mediterranean diet with EOVV versus control in participants who were at high cardiovascular risk, but with no cardiovascular disease   PDF

PREDIMED (nuts), 2013   (ISRCTN35739639)   Mediterranean diet with nuts versus control in participants who were at high cardiovascular risk, but with no cardiovascular disease   PDF

COMPARZ, 2013   (NCT00720941)   pazopanib versus sunitinib in patients with clear-cell, metastatic renal-cell carcinoma, first line   PDF

Risk and Prevention Study, 2013   (NCT00317707.))   omega-3 Fatty acids versus placebo in men and women with multiple cardiovascular risk factors or atherosclerotic vascular disease but not myocardial infarction   PDF

TIVO-1, 2013   (NCT01030783)   tivozanib versus sorafenib in initial targeted therapy in patients with metastatic renal cell carcinoma   PDF

Ahn, 2013   vandetanib maintenance versus in advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy   PDF

Aisner, 2013   vandetanib versus in patients with advanced non-small-cell lung cancer   PDF

Scagliotti, 2013   pazopanib versus pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer   PDF

Hanna, 2013   versus in   PDF

Dy, 2013   cediranib versus gemcitabine and carboplatin in first-line therapy in advanced non-small-cell lung cancer   PDF

Groen, 2013   sunitinib versus erlotinib in second-line treatment of metastatic non-small-cell lung cancer   PDF

Sun, 2013   (NCT00391274)   pemetrexed versus docetaxel in second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer   PDF

NEJ002, 2013   gefitinib versus carboplatin-paclitaxel in chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations   PDF

NCIC CTG BR19 (Goss), 2013   gefitinib versus placebo in completely resected non-small-cell lung cancer   PDF

CTONG0806 (Yang), 2013   gefitinib versus in   PDF

Shaw, 2013   (NCT00932893)   crizotinib versus chemotherapy in patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen   PDF

Robert, 2013   Selumetinib +dacarbazine versus placebo plus dacarbazine in   PDF

Cui, 2013   endostatin +dacarbazine versus in   PDF

Vahdat, 2013   (NCT00879086)   eribulin versus ixabepilone in patients with metastatic breast cancer   PDF

ENCORE 301, 2013   (NCT00676663)   Entinostat + exemestane versus exemestane in Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor   PDF

Gradishar, 2013   sorafenib + paclitaxel versus paclitaxel alone in first-line therapy in patients with HER2-negative advanced breast cancer   PDF

Schwartzberg, 2013   (NCT00493636)   sorafenib + gemcitabine or capecitabine versus gemcitabine or capecitabine alone in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab   PDF

HORIZON, 2013   (NCT00083993)   temsirolimus + letrozole versus letrozole alone in first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer   PDF

SPS3, 2013   (NCT00059306.)   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in patients lived in North America, Latin America, and Spain and had recent, MRI-defined symptomatic lacunar infarctions   PDF

Wei, 2013   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in Chinese hypertensive patients older than 70 years   PDF

Edlemann, 2013   versus in   PDF

MOPETT, 2012   half-dose t-PA versus no fibrinolysis in patients presenting with moderate PE   PDF

CASSIOPEA, 2012   (NCT00345618)   idrabiotaparinux versus warfarin in adults with objectively documented acute symptomatic pulmonary embolism   PDF

FAME II, 2012   (NCT01132495)   FFR-guided PCI versus no PCI in patients patients with stable CAD found on FFR to have hemodynamically relevant disease   PDF

TWENTE, 2012   (NCT01066650)   zotarolimus eluting stent versus everolimus eluting stent in "real-world" patients   PDF

SORT OUT IV, 2012   (NCT00552877)   everolimus eluting stent versus sirolimus eluting stent in unselected patients with coronary artery disease   PDF

PROTECT, 2012   (NCT00476957)   zotarolimus eluting stent versus sirolimus eluting stent in unselected patients (patients 18 years or older who were undergoing stenting for elective, unplanned, or emergency procedures in native coronary arteries)   PDF

WARCEF, 2012   (NCT00041938)   aspirin versus warfarin in patients with left ventricular ejection fraction <35%   PDF

FOCUS-CCTRN, 2012   (NCT00824005)   Bone marrow derived stem cell versus control in patients with chronic ischemic heart failure   PDF

POSEIDON, 2012   (NCT01087996)   Mesenchymal stem cells versus allogeneic mesenchymal stem cells in patients with LV dysfunction due to ICM   PDF

Perin, 2012   Bone marrow progenitor cells versus control in patients with advanced ischemic heart failure   PDF

IABP SHOCK II, 2012   (NCT00491036)   IABP versus non-IABP in patients with cardiogenic shock complicating acute myocardial infarction   PDF

CADUCEUS, 2012   (NCT00893360)   Cardiopoietic stem cell versus control in patients with left ventricular dysfunction after myocardial infarction   PDF

ASPIRE, 2012   aspirin versus placebo in patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism   PDF

WARFASA, 2012   aspirin versus placebo in patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment   PDF

AMPLIFY-EXT 5mg, 2012   (NCT00633893)   apixaban 5mg versus discontinuation in patients who have completed their intended treatment for deep vein thrombosis or pulmonary embolism   PDF

ASPIRE, 2012   (ACTRN12605000004662)   aspirin versus discontinuation in patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism   PDF

WARFASA, 2012   (NCT00222677)   aspirin versus discontinuation in patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment   PDF

AMPLIFY-EXT 2.5mg, 2012   (NCT00633893)   apixaban 2.5mg versus discontinuation in patients who have completed their intended treatment for deep vein thrombosis or pulmonary embolism   PDF

Einstein-PE Evaluation, 2012   (NCT00439777)   rivaroxaban (without LMWH) versus LMWH/VKA in patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis   PDF

GRACE - ORIGIN (glargine), 2012   insulin glargine versus placebo in subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes   PDF

Rosenstock, 2012   (NCT00683878)   dapagliflozin versus placebo (add on TZD) in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone   PDF

Wilding, 2012   (NCT00673231)   dapagliflozin versus placebo (add on insulin) in Type 2 Diabetes With Inadequate Glycaemic Control on Insulin   PDF

Gallwitz, 2012   (NCT00622284)   linagliptin versus glimepiride (add on MET) in type 2 diabetes mellitus with insufficient glycaemic control with metformin   PDF

CAROLINA, 2012   (NCT01243424)   linagliptin versus glimepiride in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care   PDF

Bolinder, 2012   (NCT00855166)   dapagliflozin versus placebo (add on MET) in   PDF

TRILOGY ACS (overall population), 2012   (NCT00699998)   prasugrel versus clopidogrel in patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index event   PDF

TRA-2P TIMI 50, 2012   (NCT00526474)   vorapaxar versus placebo (on top aspirin) in patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)   PDF

Ledermann, 2012   (NCT00753545)   olaparid versus placebo in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations, who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen   PDF

dal-OUTCOMES, 2012   (NCT00658515)   dalcetrapib versus placebo in patients with recent acute coronary syndrome   PDF

TRA-2P TIMI 50 (no prior stroke sub group), 2012   vorapaxar versus placebo (on top aspirin) in patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease), sub group of patient with no prior stroke   PDF

TRA-2P TIMI 50 (MI subgroup), 2012   (NCT00526474)   vorapaxar versus placebo (on top aspirin) in prespecified subgroup of patients with a qualifying myocardial infarction among the overall population of patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)   PDF

Qin, 2012   axitinib versus sorafenib in   PDF

Mendel 1, 2012   (NCT01375777)   evolocumab versus in   PDF

GAUSS 1, 2012   (NCT01375764)   evolocumab versus placebo in statin-intolerant patients   PDF

phase 2 (phased ipilimumab), 2012   ipilimumab + chemotherapy versus placebo + chemotherapy in Patients with chemotherapy-naive non-small-cell lung cancer   PDF

Ramlau, 2012   Aflibercept and Docetaxel versus Docetaxel in platinum-pretreated patients with advanced or metastatic nonsquamous non-small-cell lung cancer   PDF

Lee ZEPHYR, 2012   Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor   PDF

Scagliottib MONET1, 2012   motesanib plus carboplatin/paclitaxel versus in patients with advanced nonsquamous non-small-cell lung cancer   PDF

Scagliottia, 2012   Sunitinib plus erlotinib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer   PDF

Paz-Ares, 2012   sorafenib versus in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer   PDF

Wakelee, 2012   sorafenib versus in   PDF

Li, 2012   pemetrexed versus docetaxel in patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks   PDF

INFORM; C-TONG 0804, 2012   (NCT00770588)   gefitinib versus placebo in maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer   PDF

SAVE-HIP 2, 2012   (NCT00721760)   semuloparin versus enoxaparin in hip fracture surgery   PDF

SAVE-KNEE, 2012   (NCT00718224)   semuloparin versus enoxaparin in   PDF

SAVE-HIP1, 2012   (NCT00697099)   semuloparin versus enoxaparin in   PDF

FREEDOM, 2012   (NCT00086450)   PCI with drug-eluting stents versus CABG in patients with diabetes and multivessel coronary artery disease   PDF

Kirkwood, 2012   selumetinib versus temozolomide in   PDF

Hersh, 2012   Nab-paclitaxel versus in   PDF

Flaherty, 2012   (NCT01072175)   trametinib and dabrafenib versus dabrafenib in patients with metastatic melanoma and BRAF V600 mutations   PDF

Hauschild, 2012   (NCT01227889)   dabrafenib versus dacarbazine in subjects with BRAF mutant advanced (Stage III) or metastatic (Stage IV) melanoma   PDF

SoFEa (Johnston) fluvestrant alone, 2012   (NCT00253422)   fluvestrant 250mg versus exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors   PDF

Baselga, 2012   sorafenib + capecitabine versus capecitabine alone in HER2-negative locally advanced or metastatic breast cancer   PDF

Mehta(SWOG-S0226), 2012   (NCT00075764)   fulvestrant + anastrozole versus anastrozole in Postmenopausal women with previously untreated with hormone-receptor (HR)-positive   PDF

FACT (Bergh), 2012   (NCT00256698)   fulvestrant + anastrozole versus anastrozole in first-line therapy for patients with receptor-positive postmenopausal breast cancer   PDF

SoFEa (Johnston) combination, 2012   (NCT00253422)   fulvestrant + anastrozole versus exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors   PDF

Huober, 2012   trastuzumab + letrozole versus letrozole alone in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer   PDF

TAMRAD , 2012   (NCT01298713)   everolimus + tamoxifen versus tamoxifen alone in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, AI-resistant mBC   PDF

EMILIA, 2012   (NCT00829166)   trastuzumab emtansine versus lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane   PDF

neoSphere (Group B), 2012   (NCT00545688)   pertuzumab + trastuzumab +docetaxel versus trastuzumab + docetaxel in women with locally advanced, inflammatory, or early HER2-positive breast cancer   PDF

CLEOPATRA, 2012   (NCT00567190)   pertuzumab + trastuzumab +docetaxel versus trastuzumab + docetaxel in patients with HER2-positive metastatic breast cancer   PDF

HOMED-BP, 2012   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in with an untreated systolic/diastolic HBP of 135-179/85-119 mm Hg   PDF

PARAMOUNT, 2012   (NCT00887588)   LCZ696 versus valsartan in   PDF

SAMMPRIS, 2011   (NCT00576693)   carotid artery stenting versus medical treatment in patients who had a recent transient ischemic attack or stroke attributed to stenosis of 70 to 99% of the diameter of a major intracranial artery   PDF

OTPE (Aujesky), 2011   (NCT00425542)   outpatient treatment versus inpatient treatment in patients with acute, symptomatic pulmonary embolism and a low risk of death (pulmonary embolism severity index risk classes I or II)   PDF

STICH (vs med), 2011   (NCT00023595)   CABG versus medical treatment in patients with congestive heart failure and severe LV dysfunction   PDF

RESET, 2011   (NCT01035450)   everolimus eluting stent versus sirolimus eluting stent in   PDF

ISAR-CABG, 2011   (NCT00611910)   DES versus bare-metal stent in patients with Bypass Graft Lesions   PDF

PRECOMBAT, 2011   (NCT00422968)   sirolimus eluting stent versus CABG in patients with unprotected left main coronary artery stenosis   PDF

PLATINUM, 2011   (NCT00823212)   everolimus eluting stent versus everolimus eluting stent in patients with up to 2 de novo atherosclerotic coronary artery lesions   PDF

ASCEND-HF, 2011   (NCT00475852)   nesiritide versus placebo in Patients hospitalized for heart failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF)   PDF

CUPID, 2011   gene therapy versus placebo in patients NYHA class 3-4 heart failure and an LVEF <35%   PDF

WARCEF, 2011   (NCT00041938)   aspirin versus warfarin in patients with a left ventricular ejection fraction (LVEF) of less than 35% in sinus rhythm   PDF

FOCUS-HF, 2011   (NCT00203203.)   Bone marrow mononuclear cells versus placebo in patients with chronic HF   PDF

SCIPIO, 2011   (NCT00474461)   Cardiac stem cells versus control in Patients With Ischemic Cardiomyopathy   PDF

SEISMIC, 2011   myoblasts versus control in Patienst with heart failure patients with implanted cardioverter-defibrillators   PDF

MARVEL, 2011   (NCT00526253 )   myoblasts versus placebo in patients with class II to IV HF and ejection fraction <35%   PDF

Vrtovec, 2011   (NCT00629018)   Bone marrow progenitor cells versus control in patients with dilated cardiomyopathy   PDF

Ciszewski, 2011   thrombectomy versus conventional PCI in high risk patients with STEMI and angiographic evidence of thrombus   PDF

PRODIGY, 2011   (NCT00611286)   24 months of dual antiplatelet treatment versus 6 months dual antiplatelet in patients (74 with acute coronary syndromes and 26 with stable angina) who underwent stenting   PDF

EXCELLENT, 2011   (NCT00698607)   6-month dual antiplatelet therapy versus 12 months dual antiplatelet in patients with coronary artery disease   PDF

DECLARE-LONG II , 2011   versus in   PDF

GRAVITAS, 2011   (NCT00645918)   high-dose clopidogrel versus normal-dose clopidogrel in patients receiving drug-eluting stents with high residual platelet activity (PRU>=230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)   PDF

Van Gogh (subgroup), 2011   idraparinux versus standard treatment in non-active and active cancer patients with deep venous thrombosis and without pulmonary embolism, included in the Van Gogh DVT clinical trial   PDF

RE-SONATE, 2011   (NCT00558259)   dabigatran versus discontinuation in Secondary prevention of VTE in patients with VTE who had completed 6-18 months of anticoagulant therapy   PDF

RE-MEDY, 2011   (NCT00329238)   dabigatran versus warfarin in Secondary prevention of VTE in patients with VTE who had initially received 3 to 12 months of anticoagulant therapy   PDF

RE-COVER II, 2011   (NCT00680186)   heparin/dabigatran versus heparin/VKA in patients with acute VTE, treated with low molecular weight or unfractionated heparin for 5 to 11 days   PDF

ARISTOTLE, 2011   (NCT00412984)   apixaban versus warfarin standard dose in subjects with atrial fibrillation and risk factors for stroke   PDF

AVERROES, 2011   (NCT00496769)   apixaban versus aspirin in patients with atrial fibrillation who have failed or are unsuitable for vitamin K antagonist treatment   PDF

PALLAS, 2011   (NCT01151137)   dronedarone versus placebo in patients with permanent atrial fibrillation and additional risk factors   PDF

ROCKET (2nd prevention subgroup) , 2011   rivaroxaban versus warfarin in patients with a prior stroke or transient ischemic attack   PDF

Strojek, 2011   (NCT00680745)   dapagliflozin + Glimepiride versus glimepiride in Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone   PDF

Nauck, 2011   (NCT00660907)   dapagliflozin versus dlipizide add on metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone   PDF

Buse, 2011   (NCT00765817)   exenatide 20µg/d versus placebo (add on insulin) in Adults with type 2 diabetes and an HbA1c level of 7.1% to 10.5% who were receiving insulin glargine alone or in combination with metformin or pioglitazone (or both agents)   PDF

ATLAS ACS 2 - TIMI 51 (2.5mg), 2011   (NCT00809965)   rivaroxaban 2.5mg versus placebo in patients with a recent ACS   PDF

APPRAISE 2, 2011   (NCT00831441)   apixaban versus placebo in patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events   PDF

AIM-HIGH, 2011   (NCT00120289)   niacin versus placebo (on top statin) in patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol   PDF

ATLAS ACS 2 - TIMI 51 (5mg), 2011   (NCT00809965)   rivaroxaban 5mg versus placebo in patients with a recent ACS   PDF

Nicholls, 2011   (NCT01058018)   RVX-208 versus placebo in statin-treated patients with coronary artery disease   PDF

Spanish Group for Research on Sarcomas , 2011   gemcitabine plus dacarbazine versus dacarbazine in   PDF

dal-VESSEL, 2011   dalcetrapib versus placebo in men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dL   PDF

AXIS (Rini), 2011   (NCT00678392)   axitinib versus sorafenib in second-line therapy in patients with metastatic renal cell cancer   PDF

de Boer, 2011   Vandetanib plus pemetrexed versus in second-line treatment of advanced non-small-cell lung cancer   PDF

Natale, 2011   Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer   PDF

Spigel, 2011   sorafenib and erlotinib versus erlotinib in previously treated advanced non-small-cell lung cancer   PDF

Jose, 2011   pemetrexed plus carboplatin versus docetaxel plus carboplatin in first-line treatment for advanced, nonsquamous non-small cell lung cancer   PDF

MAGELLAN, 2011   (NCT00571649)   rivaroxaban versus enoxaparin in patients 40 years of age or older who were hospitalized for anacute medical illness   PDF

De Boer, 2011   vandetanib plus pemetrexed versus pemetrexed in   PDF

ADOPT, 2011   (NCT00457002)   apixaban versus enoxaparin in acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days   PDF

Herbst, 2011   bevacizumab + erlotinib versus erlotinib alone in   PDF

EORTC 08021/ILCP 01/03, 2011   (NCT00091156)   gefitinib versus placebo in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy   PDF

Nordic IFN Trial, 2011   ID IFN alpha-2b (I M) versus observation in patients with stage IIB-IIC or III resected cutaneous melanoma.   PDF

LIFENOX, 2011   (NCT00622648)   enoxaparin versus placebo in hospitalized, acutely ill medical patients   PDF

PROTECT, 2011   (NCT00182143)   dalteparin versus UFH in critically ill patients   PDF

Patel, 2011   Temozolomide versus in   PDF

O'Day, 2011   Intetumumab versus in   PDF

BRIM 3, 2011   (NCT01006980)   vemurafenib versus dacarbazine in previously untreated patients with metastatic melanoma   PDF

Robert, 2011   (NCT00324155)   ipilimumab + dacarbazine versus dacarbazine in patients with previously untreated metastatic melanoma (stage III (unresectable) orstage IV)   PDF

EMBRACE (Cortes), 2011   (NCT00388726)   eribulin versus treatment of physician in patients with metastatic breast cancer who had received between two and fi ve previous chemotherapy regimens (two or more for advanced disease), including an anthracycline and a taxane, unless contraindicated.   PDF

HERNATA, 2011   docetaxel + trastuzumab versus vinorelbine, trastuzumab in first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer   PDF

Martin (motesanib), 2011   (NCT00356681)   motesanib + paclitaxel versus paclitaxel in patients with untreated HER2-negative metastatic breast cancer   PDF

Xu et al., 2011   (NCT00327769)   fulvestrant 250mg versus anastrozole in receptor positive postmenopausal advanced breast cancer.   PDF

Martin bevacizumab, 2011   bevacizumab + paclitaxel versus paclitaxel in patients with HER2-negative locally recurrent or metastatic breast cancer   PDF

Seidman, 2011   gemcitabine + docetaxel versus capecitabine + docetaxel in   PDF

Brufsky, 2011   gemcitabine + paclitaxel + bevacizumab versus paclitaxel + bevacizumab in   PDF

Nielsen, 2011   gemcitabine + docetaxel versus docetaxel in   PDF

BOLERO-2, 2011   (NCT00863655)   everolimus + exemestane versus exemestane alone in patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both).   PDF

PARTNER cohort A, 2011   (NCT00530894)   transcatheter aortic valve implantation versus surgical valve replacement in high risk, symptomatic patients with severe aortic stenosis   PDF

ACCELERATE, 2011   (NCT00797862)   aliskiren versus amlodipine in essential hypertension, were aged 18 years or older, and had systolic blood pressure between 150 and 180 mm Hg   PDF

OSCAR, 2011   (NCT00134160)   olmesartan 40 mg versus olmesartan 20 mg plus a calcium-channel blocker in high-risk elderly Japanese hypertension patients   PDF

NAGOYA HEART, 2011   (NCT00129233)   valsartan versus amlodipine in patients with hypertension with type 2 diabetes or impaired glucose tolerance   PDF

ICSS, 2010   (ISRCTN25337470)   carotid artery stenting versus surgery in patients with symptomatic carotid stenosis of greater than 50% within last six months   PDF

CREST, 2010   (NCT00004732)   carotid artery stenting versus surgery in patients with both asymptomatic and symptomatic extracranial carotid stenosis   PDF

CALISTO, 2010   (NCT00443053)   fondaparinux versus placebo in patients with acute symptomatic isolated superficial thrombophlebitis of the lower limbs   PDF

Otero, 2010   (NCT00214929)   outpatient treatment versus inpatient treatment in low-risk patients with acute symptomatic PE   PDF

CURRENT-OASIS 7 clopidogrel PCI subgroup, 2010   (NCT00335452)   double dose clopidogrel versus clopidogrel in ACS patients referred for an invasive strategy. subgroup of patients who eventually underwent PCI   PDF

ATOLL, 2010   enoxaparin versus UFH in patients undergoing PCI for acute STEMI   PDF

ARMYDA-4 RELOAD, 2010   reloading clopidogrel versus placebo in patients already receiving chronic clopidogrel undergoing PCI   PDF

STATIN STEMI, 2010   high-dose atorvastatin versus low-dose atorvastatin in patients with ST-elevation myocardial infarction   PDF

ADVANCE 2, 2010   (NCT00452530)   apixaban versus enoxaparin (europe regimen) in patients undergoing elective unilateral or bilateral total knee replacement   PDF

CRESCENDO, 2010   (NCT00263042)   rimonabant versus placebo in patients patients with abdominal obesity and with previously manifest or increased risk of vascular disease   PDF

ADVANCE 3, 2010   (NCT00423319)   apixaban versus enoxaparin in patients undergoing elective total hip replacement surgery   PDF

ART, 2010   (ISRCTN46552265)   bilateral internal mammary artery grafting versus single internal mammary artery grafting in   PDF

PROMISS (Uva), 2010   off-pump versus on-pump in patients between 30 and 90 years of age with multi-vessel coronary artery disease undergoing CABG with at least three distal coronary anastomoses   PDF

VA CABG, 2010   (NCT00054847)   radial artery grafts versus saphenous vein grafts in patients with stable coronary artery disease   PDF

BBS (Moller), 2010   (NCT00120991)   off-pump versus on-pump in patients > 54 years of age with three-vessel coronary artery disease with EuroSCORE of 5-16 undergoing elective or sub-acute coronary artery bypass grafting   PDF

BASKET-PROVE (EES), 2010   (ISRCTN72444640)   everolimus eluting stent versus bare-metal stent in patients needing stents 3.0 mm or larger   PDF

BASKET-PROVE (SES), 2010   (ISRCTN72444640)   sirolimus eluting stent versus bare-metal stent in patients needing stents 3.0 mm or larger   PDF

Kim, 2010   abciximab-coated stent versus bare-metal stent in patients undergoing PCI for de novo coronary lesions   PDF

RESOLUTE All comers, 2010   (NCT00617084.))   zotarolimus eluting stent versus everolimus eluting stent in adult patients with chronic, stable coronary artery disease or acute coronary syndromes, including myocardial infarction with or without ST-segment elevation   PDF

SORT-OUT-3, 2010   (NCT00660478)   zotarolimus eluting stent versus sirolimus eluting stent in Patients With Coronary Artery Disease undergoing PCI for any indication   PDF

ISAR-DESIRE-2, 2010   (NCT00598715)   sirolimus eluting stent versus paclitaxel eluting stent in coronary restenosis in sirolimus-eluting stents   PDF

SPIRIT IV, 2010   (NCT00307047)   everolimus eluting stent versus paclitaxel eluting stent in patients with de novo native coronary artery lesions and reference vessel diameters between 2.5 mm to 4.25 mm and lesion lengths <= 28 mm   PDF

GISSOC II, 2010   (NCT00220558)   sirolimus eluting stent versus bare-metal stent in patients with Chronic Total Occlusion older than 1 month, and successful recanalization   PDF

SCOUT, 2010   (NCT00234832)   sibutramine versus placebo in overweight or obese patients with diabetes or a history of coronary or peripheral vascular disease or stroke, along with other CV risk factors   PDF

BLOOM, 2010   (NCT00395135)   lorcaserin versus placebo in   PDF

EMPHASIS-HF, 2010   (NCT00232180)   eplerenone versus placebo in patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35%   PDF

ABCD, 2010   Bone marrow derived stem cell versus placebo in Patients with nonischemic dilated cardiomyopathy   PDF

PROTECT, 2010   (NCT00328692)   rolofylline versus placebo in patients hospitalized for acute heart failure with impaired renal function   PDF

Pokushalov (DOUBLON DIB), 2010   Bone marrow derived stem cell versus control in patients with severe ischemic heart failure   PDF

RAFT, 2010   (NCT00251251)   Combined CRT + ICD versus ICD alone in patients with New York Heart Association (NYHA) class II or III heart failure, a left ventricular ejection fraction of 30% or less, and an intrinsic QRS duration of 120 msec or more or a paced QRS duration of 200 msec or more   PDF

TELE-HF, 2010   telemonitoring versus control in patients with an HF hospitalization within the previous month   PDF

JETSTENT, 2010   AnjioJet versus conventional PCI in patients with ST-elevation MI and at least moderate thrombus burden   PDF

HEBE III, 2010   epoetin alfa versus placebo in patients with a first ST-elevation MI and a successful PCI   PDF

REAL-LATE, ZEST-LATE, 2010   (NCT00484926)   clopidogrel+aspirin versus aspirin in patients who had received drugeluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months   PDF

DES-LATE, 2010   (NCT00484926)   prolonged dual antiplatelet therapy versus 12 months dual antiplatelet in patients who had received drug eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months   PDF

CILON-T, 2010   triple antiplatelet versus dual antiplatelet therapy in real-world patients undergoing PCI   PDF

VITATOPS, 2010   (NCT00097669ÐX&)   folic acid, vit B12 and vit B6 versus placebo in patients with recent stroke or TIA (within the past seven months)   PDF

CLOSURE I, 2010   (NCT00201461)   Starflex versus medical treatment in patients with a stroke and/or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale   PDF

EISNTEIN EXT, 2010   rivaroxaban 20mg versus placebo in patients who had completed 6 to 12 months of treatment for venous thromboembolism   PDF

ROCKET-AF, 2010   (NCT00403767)   rivaroxaban versus warfarin standard dose in Subjects With Non-Valvular Atrial Fibrillation   PDF

Einstein-DVT Evaluation, 2010   (NCT00440193)   rivaroxaban (without LMWH) versus LMWH/VKA in Patients with Confirmed Acute Symptomatic Deep-Vein Thrombosis without Pulmonary Embolism   PDF

STOP-AF, 2010   (NCT00523978)   catheter ablation versus control in patients with paroxysmal atrial fibrillation   PDF

RACE II, 2010   (NCT00392613)   lenient rate control versus strict rate control in patients with permanent atrial fibrillation   PDF

RE-LY 110mg (2nd prevention subgroup) , 2010   dabigatran 100mg versus warfarin in patients with a prior stroke or transient ischemic attack   PDF

Forst, 2010   (NCT00309608)   linagliptin versus in patients with type 2 diabetes mellitus who are not at goal with their HbA1c levels   PDF

Pratley 1.8mg, 2010   (NCT00700817)   liraglutide 1.8mg versus sitagliptin in patients with type 2 diabetes who did not have adequate glycemic control with metformin   PDF

Seino, 2010   (NCT00393718)   liraglutide other doses versus glibenclamide in Japanese subjects with type 2 diabetes, inadequately controlled with diet therapy or oral antidiabetic drug monotherapy   PDF

Lewin, 2010   (NCT00819091)   linagliptin versus placebo (add on SU) in patients with type 2 diabetes and insufficient glycaemic control   PDF

Ferrannini (MB102013), 2010   (NCT00528372)   dapagliflozin versus placebo in treatment-naive patients with type 2 diabetes   PDF

DURATION-2 (Bergenstal) (vs pioglitazone), 2010   (NCT00637273)   exenatide weekly versus pioglitazone in   PDF

DURATION-2 (Bergenstal) (vs sitagliptin), 2010   (NCT00637273)   exenatide weekly versus sitagliptin in patients treated with metformin   PDF

DURATION-3 (Diamant), 2010   (NCT00641056)   exenatide weekly versus insulin glargine in adults with type 2 diabetes who had suboptimum glycaemic control despite use of maximum tolerated doses of blood-glucose-lowering drugs for 3 months or longer   PDF

Bailey (MB102014), 2010   (NCT00528879)   dapagliflozin versus placebo (add on MET) in adults with type 2 diabetes who were receiving daily metformin (¡Ý1500 mg per day) and had inadequate glycaemic control   PDF

ROADMAP, 2010   (NCT00185159)   olmesartan versus placebo in patients with diabetes and at least one additional cardiovascular risk factor, but no evidence of renal dysfunction   PDF

CANOE, 2010   (NCT00116932)   rosiglitazone and metformin versus placebo in patients with impaired glucose tolerance   PDF

SHARP, 2010   (NCT00125593)   ezetimibe+simvastatin versus placebo in patients with established chronic kidney disease (dialysis or pre-dialysis)   PDF

Pratley 1.2mg, 2010   (NCT00700817)   liraglutide 1.2mg versus sitagliptin in patients with type 2 diabetes who did not have adequate glycemic control with metformin   PDF

NAVIGATOR nateglinide, 2010   (NCT00097786)   nateglinide versus placebo in subjects with impaired glucose tolerance and either CV disease or CV risk factors   PDF

NAVIGATOR valsartan, 2010   (NCT00097786)   valsartan versus placebo in subjects with impaired glucose tolerance and either CV disease or CV risk factors   PDF

SEARCH, 2010   (NCT00124072)   simvastatin high dose versus simvastatin in MI survivors   PDF

CURRENT OASIS 7 (clopidogrel), 2010   (NCT00335452)   clopidogrel high-dose regimen versus clopidogrel standard-dose in ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization)   PDF

CURRENT - OASIS 7 (ASA), 2010   (NCT00335452)   ASA high dose versus ASA low dose in ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization)   PDF

ARBITER-HALTS 6, 2010   ezetimibe versus niacin in patients at high risk for vascular disease but with LDL-cholesterol levels <100 mg/dL and moderately low HDL-cholesterol levels (<50 mg/dL)   PDF

ACCORD lipid, 2010   (NCT00000620)   fenofibrate versus placebo (on top simvastatine) in high-risk patients with type 2 diabetes   PDF

J-LANCELOT, 2010   atopaxar versus placebo in patients with acute coronary syndrome (unstable angina and NSTEMI)   PDF

DYNAMIT, 2010   (NCT00627783)   screening for CAD versus no screening in diabetic patients with no evidence of coronary artery disease and at least 2 additional cardiovascular risk factors   PDF

DEFINE, 2010   (NCT00685776)   anacetrapib versus placebo in patients with coronary heart disease or at high risk for coronary heart disease   PDF

ALPHA OMEGA (EPA DHA), 2010   (NCT00127452)   omega-3 Fatty acids versus placebo in men and women with a history of myocardial infarction   PDF

ALPHA OMEGA (ALA), 2010   (NCT00127452)   alpha-linolenic acid versus placebo in men and women with a history of myocardial infarction   PDF

ADDITION, 2010   (NCT00237549)   intensive glycemic control versus conventional treatment in patients with newly diagnosed type 2 diabetes   PDF

SU.FOL.OM3, 2010   (ISRCTN41926726)   omega 3 Fatty acids versus in patients with a history of myocardial infarction, unstable angina, or ischaemic stroke   PDF

CALGB 90206, 2010   bevacizumab plus interferon alfa versus interferon alpha in Patients with previously untreated, metastatic clear cell RCC   PDF

VEG105192, 2010   (NCT00334282)   pazopanib versus placebo in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma   PDF

Sternberg, 2010   pazopanib versus placebo in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma   PDF

Goss, 2010   cediranib versus carboplatin and paclitaxel in initial therapy for advanced non-small-cell lung cancer   PDF

Scagliotti, 2010   sorafenib versus placebo in chemotherapy-naïve patients with unresectable stage IIIB or IV non-small-cell lung cancer   PDF

Scagliotti (pemetrexed vs bortezomib), 2010   pemetrexed versus bortezomib in   PDF

Socinski, 2010   (NCT00308750)   pemetrexed plus carboplatin versus docetaxel plus carboplatin in Patients with stage IIIB (with pleural effusion) or IV non-small cell lung cancer and performance status 0 or 1   PDF

Scagliotti, 2010   bortezomib and pemetrexed versus pemetrexed in   PDF

Schiller, 2010   matuzumab plus pemetrexed versus pemetrexed in   PDF

Chiappori, 2010   enzastaurin plus pemetrexed versus pemetrexed in   PDF

Lynch, 2010   cetuximab versus CT in chemotherapy-naïve patients with stage IIIB (pleural effusion) or IV NSCLC, without restrictions by histology or epidermal growth factor receptor expression   PDF

Reck, 2010   bevacizumab versus in   PDF

WJTOG3405 (Mitsudomi), 2010   gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor   PDF

WJTOG0203 (Takeda), 2010   gefitinib versus continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer   PDF

IFCT-0301 study (Morère), 2010   gefitinib versus docetaxel in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3   PDF

Maemondo, 2010   (UMIN-CTR C000000376)   gefitinib versus carboplatin-paclitaxel in patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy   PDF

ISTANA (Lee), 2010   gefitinib versus docetaxel in previously treated advanced nonsmall-cell lung cancer   PDF

Hodi (ipi + gp100), 2010   (NCT00094653)   ipi + gp100 versus gp100 in patients with previously treated metastatic melanoma patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease   PDF

Kefford, 2010   Bosentan + dacarbazine versus in   PDF

CERTIFY, 2010   certoparin versus UFH in   PDF

EXCLAIM, 2010   (NCT00077753)   Extended-duration prophylaxis versus error in Acutely Ill Medical Patients With Recently Reduced Mobility   PDF

Hodi (ipi alone), 2010   (NCT00094653)   ipilimumab 3 mg/kg versus gp100 in patients with previously treated metastatic melanoma patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease   PDF

Alba, 2010   maintenance versus control in Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m(2)) followed by three cycles of docetaxel (100 mg/m(2)) both every 21 days   PDF

Blohmer, 2010   docetaxel + epirubicin versus epirubicin, cyclophosphamide in first-line therapy for women with metastatic breast cancer   PDF

FIRST (Robertson), 2010   (NCT00274469)   fulvestrant 500mg versus anastrozole in First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer   PDF

FINDER 2, 2010   (NCT00313170)   fulvestrant 500mg versus fulvestrant 250mg in Western postmenopausal women recurring or progressing after prior endocrine therapy   PDF

FINDER 1 (Ohno), 2010   fulvestrant 500mg versus fulvestrant 250mg in postmenopausal Japanese women with advanced breast cancer   PDF

Blackwell, 2010   trastuzumab + lapatinib versus lapatinib alone in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer   PDF

CONFIRM (Di Leo), 2010   (NCT00099437)   fulvestrant 500mg versus fulvestrant 250mg in women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment   PDF

AVADO (Miles) 7.5mg, 2010   bevacizumab + docetaxel versus docetaxel in first-line treatment of HER2-negative metastatic breast cancer   PDF

Sparano, 2010   ixabepilone (on top capecitabine) versus no ixabepilone in patients with metastatic breast cancer previously treated with anthracycline and taxanes   PDF

Mavroudis, 2010   capecitabine versus docetaxel + epirubicin in women with advanced breast cancer   PDF

GeparQuattro, 2010   (NCT00288002)   capecitabine docetaxel versus docetaxel in Patients with large operable or locally advanced tumors, with hormone receptor-negative tumors, or with receptor-positive tumors but also clinically node-positive disease   PDF

ACCORD (blood pressure), 2010   (NCT00000620)   intensive versus usual in high-risk patients with type 2 diabetes, high HbA1c concentrations (>7.5%), and cardiovascular disease (or >=2 cardiovascular risk factors)   PDF

Ruilope, 2010   LCZ696 versus placebo in patients with mild to moderate hypertension   PDF

ACCOMPLISH (diabetic subgroup), 2010   (NCT00170950)   benazepril + amlodipine versus benazepril + hydrochlorothiazide in patients with diabetes (subgroup) and hypertension at high risk of cardiovascular and related events   PDF

PARTNER, 2010   (NCT00530894)   transcatheter aortic valve implantation versus standard therapy in patients with severe aortic stenosis considered not to be suitable candidates for surgery   PDF

ASTRONOMER, 2010   (ISRCTN 32424163)   rosuvastatin versus placebo in asymptomatic patients with mild to moderate aortic stenosis and no clinical indications for cholesterol lowering   PDF

Symplicity HTN-2, 2010   (NCT00888433)   Symplicity system versus control in patients with baseline systolic blood pressure of 160 mm Hg or more (¡Ý150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs   PDF

VANLISH, 2010   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in patients aged 70 to 84 years with isolated systolic hypertension (sitting blood pressure 160 to 199 mm Hg)   PDF

Jost, 2010   compressions first versus defibrillation first in   PDF

Svensson, 2010   (CT20080012)   compression-only CPR versus standard CPR in Patients with suspected, witnessed, out-of-hospital cardiac arrest   PDF

Rea, 2010   (NCT00219687)   compression-only CPR versus standard CPR in persons 18 years of age or older with out-of-hospital cardiac arrest   PDF

Tebbe, 2009   desmoteplase versus alteplase in acute massive pulmonary thromboembolism   PDF

TRITOM TIMI 38 (PCI subgroup), 2009   prasugrel versus clopidogrel in subgroup of patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction   PDF

NAPLES (Tavano), 2009   bivalirudin versus UFH plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention   PDF

PACA, 2009   pantoprazole versus omeprazole in patients undergoing coronary stenting for non–ST-segment elevation acute coronary syndrome   PDF

CLOTS, 2009   GCS versus no prophylaxis in Acute Stroke patients   PDF

COGENT, 2009   (NCT00557921)   omeprazole versus placebo in patients requiring clopidogrel for at least 12 months, typically following non-ST-segment-elevation ACS, STEMI, or stent implantation   PDF

ARMYDA-RECAPTURE, 2009   atorvastatin reload versus placebo in patient with long-term atorvastatin treatment thereafter (40 mg/day) undergoing PCI (for stable angina or NSTEMI ACS)   PDF

Kaneda, 2009   pioglitazone versus control in diabetic or non-diabetic patients with STEMI (<12 h from onset) successfully treated with primary BMS implantation   PDF

CHAMPION-PCI, 2009   (NCT00305162)   cangrelor up front versus clopidogrel up front in high risk patients requiring PCI   PDF

CHAMPION-PLATFORM, 2009   (NCT00385138)   cangrelor up front versus delayed clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention   PDF

NAPLES II (Briguori), 2009   atorvastatin versus control in Patients with coronary artery disease scheduled for elective PCI and not on statin therapy   PDF

TRA-PCI, 2009   (NCT00132912)   SCH 530348 versus placebo in patients aged 45 years or older and undergoing non-urgent PCI or coronary angiography with planned PCI   PDF

CARRPO, 2009   (NCT00159991)   artery grafts versus saphenous vein grafts in patients with multivessel or isolated left main disease referred for elective or urgent CABG   PDF

ROOBY (Shroyer), 2009   (NCT00032630)   off-pump versus on-pump in patients scheduled for urgent or elective coronary bypass surgery   PDF

DOORS, 2009   (NCT00123981)   off-pump versus on-pump in elderly patients   PDF

STICH (ventricular reconstruction), 2009   (NCT00023595)   CABG+surgical ventricular reconstruction versus CABG in patients with anterior-apical regional left ventricular dysfunction   PDF

CASCADE, 2009   (NCT00228423)   clopidogrel+aspirin versus aspirin in patients after CABG involving at least two saphenous vein grafts   PDF

SYNTAX (unprotected left main sub group), 2009   DES versus CABG in patients with left main coronary artery disease   PDF

CACTUS , 2009   double stenting with SES versus single stenting in patients with true coronary bifurcation lesions   PDF

SPIRIT III (small vessel subgroup), 2009   everolimus eluting stent versus paclitaxel eluting stent in patients included in SPIRIT III that received at least one 2.5-mm stent   PDF

ESSENTIAL (I and II), 2009   (NCT00051285)   enoximone versus placebo in Patients with New York Heart Association class III–IV HF symptoms, left ventricular ejection fraction 30%, and one hospitalization or two ambulatory visits for worsening HF in the previous year   PDF

PAINT (sirolimus), 2009   (NCT00752362)   biodegradable-polymer versus BMS in patients with de novo coronary lesions in native vessels scheduled for stent implantation   PDF

Astrup (NN8022-1807 ), 2009   (NCT00422058)   liraglutide versus placebo in obese individuals without type 2 diabetes   PDF

DEBATER (SES vs BMS), 2009   sirolimus eluting stent versus bare-metal stent in patients undergoing PCI for STEMI withon 12 hours   PDF

Nordic-Baltic Bifurcation Study III, 2009   (NCT00914199)   kissing balloon versus no kissing balloon in patients with bifurcation lesions   PDF

COMPARE, 2009   (NCT01016041)   everolimus eluting stent versus paclitaxel eluting stent in unselected patients   PDF

ISAR-TEST-4 (biodegradable polymer), 2009   (NCT00598676).)   sirolimus biodegradable polymer versus sirolimus eluting stent in patients with stable coronary disease or acute coronary syndromes with de novo native-vessel stent implantation   PDF

Juwana, 2009   (ISRCTN90526229)   sirolimus eluting stent versus paclitaxel eluting stent in patients with STEMI undergoing primary PCI   PDF

PASEO, 2009   drug-eluting stents versus bare-metal stent in patients with ST-elevation myocardial infarction within 12 hours from symptom onset   PDF

ZEST (vs PES), 2009   (NCT00418067)   zotarolimus eluting stent versus paclitaxel eluting stent in Patients with coronary artery disease   PDF

GENIUS-STEMI, 2009   Genous stent versus bare-metal stent in patients with ST-elevation myocardial infarction   PDF

ISAR TEST 3 (PF), 2009   polymer free sirolimus stent versus sirolimus eluting stent in Patients with de novo coronary lesions in native vessels   PDF

ISAR TEST 3 (BP), 2009   sirolimus biodegradable polymer versus sirolimus eluting stent in Patients with de novo coronary lesions in native vessels   PDF

TITAX AMI, 2009   (NCT00495664)   titanium-nitride-oxide coated stent versus paclitaxel eluting stent in patients with acute myocardial infarction   PDF

ISAR TEST 2 (vs ZES), 2009   (NCT00332397)   dual sirolimus, probucol eluting stent versus zotarolimus eluting stent in patients with De novo lesions in native coronary arteries   PDF

ISAR TEST 2 (vs SES), 2009   (NCT00332397)   dual sirolimus, probucol eluting stent versus sirolimus eluting stent in patients with De novo lesions in native coronary arteries   PDF

ZEST AMI (vs SES), 2009   (NCT00422565)   zotarolimus eluting stent versus sirolimus eluting stent in Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours   PDF

HIJ-CREATE, 2009   Candesartan versus usual care in hypertension with angiographically documented coronary artery disease (acute or stable)   PDF

WATCH (warfarin vs aspirin), 2009   (NCT00007683)   warfarin versus aspirin in symptomatic heart failure patients in sinus rhythm with ejection fractions 35% taking angiotensin-converting enzyme inhibitors (unless not tolerated) and diuretics   PDF

ZEST AMI (vs PES), 2009   (NCT00422565)   zotarolimus eluting stent versus paclitaxel eluting stent in Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours   PDF

ZEST (vs SES), 2009   (NCT00418067)   zotarolimus eluting stent versus sirolimus eluting stent in Patients with coronary artery disease   PDF

ISAR-LEFT-MAIN, 2009   (NCT00133237)   sirolimus eluting stent versus paclitaxel eluting stent in Unprotected Left Main Coronary Artery Disease   PDF

ENDEAVOR IV, 2009   (NCT00217269)   zotarolimus eluting stent versus paclitaxel eluting stent in single de novo lesions in native coronary arteries with a reference vessel diameter of 2.5-3.5 mm   PDF

SYNTAX, 2009   (NCT00114972)   paclitaxel eluting stent versus CABG in patients with previously untreated three-vessel or left main coronary artery disease (or both) (complex lesions)   PDF

BLOSSOM (10mg bid), 2009   (NCT00603902)   lorcaserin versus placebo in obese and overweight patients   PDF

HEAAL, 2009   (NCT00090259)   losartan 150mg versus losartan 50mg in patients with systolic heart failure who couldn't tolerate ACE inhibitors   PDF

TIME CHF, 2009   BNP-guided management versus control in patients with heart failure, with the specific inclusion of patients ¡Ý75 years of age   PDF

Pre-RELAX-AHF, 2009   (NCT00520806)   serelaxin versus placebo in Patients hospitalized with acute heart failure   PDF

Parissis, 2009   darbepoetin alfa versus placebo in patients with CHF (LV ejection fraction [LVEF] <40%, hemoglobin <12.5 g/dl, and serum creatinine <2.5 mg/dl   PDF

Patwala, 2009   structured exercise training versus control in patients with chronic systolic heart failure receiving a Cardiac Resynchronization Therapy device   PDF

MADIT CRT, 2009   (NCT00180271)   Combined CRT + ICD versus ICD alone in patients with asymptomatic or mildly symptomatic heart failure (NYHA I/II), LEVF<=30% and QRS>=130ms   PDF

B-CONVINCED, 2009   (NCT00162565).)   beta-blockade continuation versus discontinuation in acutely decompensated heart failure in patients with LVEF below 40% previously receiving stable beta-blocker therapy   PDF

JCHF 2.5mg, 2009   carvedilol low dose versus carvedilol in Japanese patients with with NYHA class 2-3 heart failure   PDF

FAIR-HF (Anker), 2009   ferric carboxymaltose versus placebo in patients with systolic heart failure and iron deficiency   PDF

JCHF 5mg, 2009   carvedilol low dose versus carvedilol in Japanese patients with with NYHA class 2-3 heart failure   PDF

PROTECT, 2009   (NCT00351390)   BNP-guided management versus control in patients with NYHA class 2-4 heart failure, LVEF <40%, and history of at least one admission or outpatient diuretic dose increase for heart-failure destabilization in the previous six months   PDF

BATTLESCARRED, 2009   (ANZCTR12605000735651)   BNP-guided management versus control in patients admitted to hospital for HF   PDF

NORDISTEMI, 2009   (NCT00161005)   thrombolysis + angioplasty versus immediate thrombolysis in patients with STEMI of less than 6 hours of duration and more than 90 minutes expected time delay to PCI   PDF

TRIANA, 2009   (NCT00257309)   primary ballon angioplasty versus tenecteplase in >=75 years old with ST-segment elevation or LBBB AMI <6 hours of evolution without contraindications for thrombolytic therapy   PDF

IRIS, 2009   (NCT00157768)   early implantation of ICD after MI versus control in patients patients at increased risk 5 to 31 days after AMI   PDF

HeartMate II, 2009   (NCT00121485)   continuous-flow HeartMate II versus pulsatile-flow HeartMate XVE in patients with advanced heart failure not eligible for heart transplantation   PDF

ERASE-MI, 2009   elinogrel versus placebo in STEMI patients   PDF

Liistro, 2009   thrombectomy versus conventional PCI in patients with ST-segment elevation myocardial infarction   PDF

Lipiecki, 2009   Export versus conventional PCI in   PDF

ISAR-SAFE, 2009   (NCT00661206)   12 months dual antiplatelet versus 6 months dual antiplatelet in Patients on clopidogrel therapy at least 6 months after DES implantation, who do not require a reintervention   PDF

OVER, 2009   (NCT00094575)   endovascular repair versus open repair in men (aged >=49 years) with abdominal aortic aneurysms candidate for both both elective endovascular repair and open repair   PDF

AUREC FVII, 2009   VKA versus control in patients with first spontaneous VTE and FVIII levels >230 IU/dl after 6 montsh of VKA   PDF

Vitotec, 2009   warfarin versus control in patients with idiopathic DVT After 6 months of standard therapy (heparin/LMWH, warfarin with target INR 2-3) and persistent echogenic masses of over 20% of venous diameter   PDF

RE-LY (150mg), 2009   (NCT00262600)   dabigatran 150mg versus warfarin standard dose in Patients With Non-Valvular Atrial Fibrillation   PDF

EINSTEIN-extension, 2009   (NCT00439725)   rivaroxaban versus discontinuation in patients who had completed six to 12 months of anticoagulant treatment for an acute episode of VTE   PDF

EURIDIS ADONIS (pooled analysis), 2009   dronedarone versus placebo in AF documented in the previous 3 months   PDF

RE-COVER, 2009   (NCT00291330)   heparin/dabigatran versus heparin/VKA in patients with acute venous thromboembolism , treated with low molecular weight or unfractionated heparin for 5 to 11 days   PDF

Romera, 2009   Tinzaparin versus acenocoumarol in patients with symptomatic proximal DVT of the lowerlimbs confirmed by compression duplex ultrasound scan   PDF

APD356-004, 2009   lorcaserin versus placebo in   PDF

RECORD 4, 2009   (NCT00362232)   rivaroxaban versus enoxaparin (US regimen) in patients who had undergone total-knee-replacement surgery   PDF

ATHENA, 2009   (NCT00174785)   dronedarone versus placebo in patients (>70y) with paroxysmal or persistent atrial fibrillation and additional risk factors for death   PDF

ACTIVE A, 2009   (NCT00249873)   aspirin + clopidogrel versus aspirin in Patients with AF and at least one risk factor for stroke and who are not candidates for warfarin therapy   PDF

GISSI-AF (Disertori), 2009   (NCT00376272)   valsartan versus placebo in patients in sinus rhythm but with either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks and with underlying cardiovascular disease, diabetes, or left atrial enlargement   PDF

ACTIVE I, 2009   (NCT00249795)   irbesartan versus placebo in patients with atrial fibrillation and with a systolic blood pressure of at least 110 mmHg associated with at least one major risk of vascular events   PDF

Almroth, 2009   atorvastatin versus placebo in patients with persistent atrial fibrillation undergoing electrical cardioversion   PDF

Forleo, 2009   catheter ablation versus control in patients with diabetes mellitus type 2 and paroxysmal or persistent AF   PDF

RE-LY (110mg), 2009   (NCT00262600)   dabigatran 110mg versus warfarin standard dose in Patients With Non-Valvular Atrial Fibrillation   PDF

Lip (phase 2 AZD0837), 2009   (NCT00684307)   AZD0837 versus warfarin standard dose in patients with non-valvular atrial fibrillation (AF) with one or more additional risk factors for stroke   PDF

List (MB102008), 2009   (NCT00263276)   dapagliflozin versus placebo in type 2 diabetic patients   PDF

Komoroski (MB102007), 2009   (NCT00162305)   dapagliflozin versus placebo in patients with type 2 diabetes mellitus   PDF

LEAD-2 (Nauck) (1.8mg vs placebo), 2009   (NCT00318461)   liraglutide 1.8mg versus placebo (add on MET) in subjects previously treated with oral antidiabetes therapy   PDF

LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009   (NCT00318461)   liraglutide 1.8mg versus glimepiride (add on MET) in patients with type 3 diabetes previously treated with oral antidiabetes (OAD) therap   PDF

LEAD-1 SU (1.8 vs rosiglitazone), 2009   (NCT00318422)   liraglutide other doses versus rosiglitazone (add on SU) in   PDF

LEAD-1 SU (1.8 mg vs placebo), 2009   (NCT00318422)   liraglutide 1.8mg versus placebo (add on SU) in patients with type 2 diabetes   PDF

LEAD-4 (1.8mg), 2009   (NCT00333151)   liraglutide 1.8mg versus placebo (add on TZD+MET) in patients with type 2 diabetes, A1C 7–11% (previous OAD monotherapy >=3 months) or 7–10% (previous OAD combination therapy >=3 months), and BMI 45 kg/m2   PDF

LEAD-3 mono 1.8mg (Garber), 2009   (NCT00294723)   liraglutide 1.8mg versus glimepiride in subjects with type 2 diabetes   PDF

Gao, 2009   (NCT00324363)   exenatide 20µg/d versus placebo (add on MET+/-SU) in Asian desccent with type 2 diabetes and inadequate glycemic control taking metformin alone or Met and sulfonylureas   PDF

Kaku, 2009   mitiglinide versus placebo (on top pioglitazone) in Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy   PDF

Wilding (MB102009), 2009   (NCT00357370)   dapagliflozin versus placebo (add on insulin) in patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents   PDF

LEAD-6, 2009   (NCT00518882)   liraglutide 1.8mg versus exenatide on top MET/SU/MET+SU in Adults with inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulphonylurea, or both   PDF

Li, 2009   nateglinide versus repaglinide in   PDF

LEAD-2 (Nauck) Sulf vs pbo, 2009   (NCT00318461)   glimepiride versus placebo (add on MET) in subjects previously treated with oral antidiabetes (OAD) therapy   PDF

Nauck, 2009   (NCT00286442)   alogliptin versus placebo (add on MET) in patients whose HbA(1c) levels were inadequately controlled on metformin alone   PDF

Goodman, 2009   vildagliptin versus placebo (add on MET) in patients inadequately controlled with metformin   PDF

Ferrannini, 2009   (NCT00106340)   vildagliptin versus Sulfonylurea (add on to MET) in Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5%)   PDF

DeFronzo, 2009   (NCT00121667)   saxagliptin versus placebo (add on MET) in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone   PDF

LEAD-5 (vs Glargine), 2009   (NCT00331851)   liraglutide 1.8mg versus insulin glargine (add on SU+MET) in adult patients with type 2 diabetes   PDF

LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009   (NCT00318461)   liraglutide 1.2mg versus glimepiride (add on MET) in patients with type 3 diabetes previously treated with oral antidiabetes (OAD) therap   PDF

Kadowaki (trial 8683), 2009   exenatide 10µg/d versus placebo (add on SU+/-MET/TZD) in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic dose of sulfonylurea, SU+biguanide or SU+thiazolidinedione   PDF

LEAD-5 (vs placebo), 2009   (NCT00331851)   liraglutide 1.8mg versus placebo (add on SU+MET) in adult patients with type 2 diabetes   PDF

LEAD-4 (1.2mg), 2009   (NCT00333151)   liraglutide 1.2mg versus placebo (add on TZD+MET) in patients with type 2 diabetes, A1C 7–11% (previous OAD monotherapy >=3 months) or 7–10% (previous OAD combination therapy >=3 months), and BMI 45 kg/m2   PDF

LEAD-1 SU (1.2 mg vs placebo), 2009   (NCT00318422)   liraglutide 1.2mg versus placebo (add on SU) in subjects with Type 2 diabetes   PDF

LEAD-2 (Nauck) (1.2mg vs placebo), 2009   (NCT00318461)   liraglutide 1.2mg versus placebo (add on MET) in subjects previously treated with oral antidiabetes therapy   PDF

LEAD-3 mono 1.2mg (Garber), 2009   (NCT00294723)   liraglutide 1.2mg versus glimepiride in patients with early type 2 diabetes   PDF

APPRAISE-1 (10mg od), 2009   (NCT00313300)   apixaban versus placebo in patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days)   PDF

APPRAISE-1 (2.5 mg bid), 2009   (NCT00313300 )   apixaban versus placebo in patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days)   PDF

TIMACS, 2009   (NCT00552513)   early invasive management versus delayed invasive strategy in patients with unstable angina or non-ST-segment-elevation MI (NSTEMI)   PDF

ABOARD, 2009   (NCT00442949)   immediate invasive management versus delayed invasive strategy in patient with non ST-elevation acute coronary syndrome   PDF

PLATO, 2009   (NCT00391872)   ticagrelor versus clopidogrel in patients with an acute coronary syndrome, with or without ST-segment elevation (onset of symptoms within the previous 24h).   PDF

JAPAN ACS, 2009   (NCT00242944)   pitavastatin versus atorvastatin in patients with acute coronary syndrome undergoing IVUS-guided percutaneous coronary intervention   PDF

SEPIA-ACS1 TIMI 42, 2009   (NCT00317395)   otamixaban versus unfractionated heparin in patients with non-ST-elevation acute coronary syndromes   PDF

OMEGA, 2009   (NCT00251134)   omega-3 Fatty acids versus control in Patients within 3-14 days after a non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI)   PDF

AURORA, 2009   rosuvastatin versus placebo in in patients with end-stage renal disease on hemodialysis   PDF

CAPTIVATE, 2009   (NCT00151788)   pactimibe versus placebo in patients with familial hypercholesterolemia and carotid atherosclerosis   PDF

REDEEM, 2009   (NCT00621855)   dabigatran versus placebo in patients with recent acute coronary syndromes (ST- or non-ST-elevation myocardical infarction)   PDF

JELIS, 2009   (NCT00231738)   omega-3 Fatty acids versus control (on top statin) in patients with a total cholesterol of 6·5 mmol/L or greater   PDF

AAA, 2009   (ISRCTN66587262)   aspirin versus placebo in men and women aged 50 to 80 years with asymptomatic atherosclerosis detected by low ankle brachial index (<=0.95)   PDF

JUPITER (elderly sub group), 2009   rosuvastatin versus placebo in healthy individuals aged >=70 years with normal LDL cholesterols but with CRP levels >=2.0 mg/dL   PDF

Oxford Niaspan Study, 2009   (NCT00232531)   niacin versus placebo (on top statin) in patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis   PDF

ARBITER 2, 2009   niacin versus placebo (on top statin) in patients with known coronary artery disease and well controlled on statin therapy   PDF

ARBITER 6-HALTS (niacin vs ezetimibe), 2009   (NCT00397657)   niacin versus ezetimibe in patients with known coronary or vascular disease or coronary risk equivalents   PDF

OPTIMA, 2009   (ISRCTN80874637)   immediate invasive management versus delayed invasive strategy in patients with non-ST-segment elevation acute coronary syndromes eligible for percutaneous coronary intervention   PDF

Emmerich, 2009   etofibrate versus placebo in patients with type 2 diabetes mellitus and concomitant diabetic retinopathy   PDF

TIPS, 2009   (NCT00443794)   polypill versus error in subjects aged 45 to 80 years of age with at least one additional cardiovascular risk factor   PDF

ATLAS ACS-TIMI 46 (5mg), 2009   (NCT00402597)   rivaroxaban 5mg versus placebo in recent ACS patients treated with aspirin alone (n=761) or aspirin plus clopidogrel (n=2730)   PDF

ATLAS ACS-TIMI 46 (2.5mg), 2009   (NCT00402597)   rivaroxaban 2.5mg versus placebo in recent ACS patients treated with aspirin alone (n=761) or aspirin plus clopidogrel (n=2730)   PDF

Voglibose Ph-3, 2009   (UMIN 000001109-)   voglibose versus placebo in patients with impaired fasting glucose   PDF

Kooy (HOME), 2009   metformin versus placebo in Patients with type 2 diabetes   PDF

DIAD, 2009   (NCT00769275)   screening for CAD versus no screening in participants with type 2 diabetes and no symptoms of CAD   PDF

RECORD, 2009   (NCT00379769)   rosiglitazone versus standard glucose-lowering drugs in patients with type 2 diabetes onmonotherapy with either metformin or sulfonylurea andin less than optimal blood glucose control (HbA1c >7·0–9·0%)   PDF

HOME, 2009   (NCT00375388)   metformin versus placebo in patients with DM2 treated with insulin   PDF

Escudier, 2009   sorafenib versus interferon alpha in patients with untreated, advanced renal cancer.   PDF

Natale, 2009   Vandetanib versus gefitinib versus in   PDF

Smit, 2009   pemetrexed plus carboplatin versus pemetrexed in   PDF

FLEX (Pirker), 2009   (NCT00148798)   cetuximab + CT versus CT alone in chemotherapy-naive patients with advanced EGFR-expressing histologically or cytologically proven stage wet IIIB or stage IV non-small-cell lung cancer   PDF

Nishio, 2009   bevacizumab versus platinum based CT in   PDF

Goss, 2009   gefitinib versus placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status   PDF

IPASS (Mok), 2009   (NCT00322452)   gefitinib versus carboplatin-paclitaxel in previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers   PDF

BARI 2D, 2009   (NCT00006305)   CABG or PCI versus medical treatment in patients with type 2 diabetes and heart disease   PDF

O'Day, 2009   versus in Patients with stage IV metastatic malignant melanoma   PDF

Thiele, 2009   (NCT00299429)   PCI withsirolimus ES versus MIDCAB in isolated LAD disease   PDF

Nishimura, 2009   nicorandil versus control in Maintenance hemodialysis patients who underwent percutaneous coronary artery intervention and had complete coronary revascularization (absence of both restenosis and de novo coronary lesion) at coronary arteriography 6 months later   PDF

ASSOCIATE (Tardif), 2009   (NCT00202566)   ivabradine 15mg versus placebo on top of atenolol in patients with stable angina receiving atenolol 50 mg/day or another beta-blocker at equivalent doses for at least 3 months   PDF

ASSOCIATE (Tardif), 2009   (NCT00202566)   ivabradine versus placebo (on top atenolol) in patients with stable angina   PDF

Gradishar, 2009   (NCT00274456)   nab-paclitaxel versus docetaxel in first-line treatment in patients with MBC   PDF

Mayordomo, 2009   versus in   PDF

Yardley, 2009   versus in   PDF

von Minckwitz, 2009   trastuzumab + capecitabine versus capecitabine alone in Patients with HER-2-positive breast cancer that progresses during treatment with trastuzumab   PDF

TAnDEM (Kaufman), 2009   trastuzumab + anastrozole versus anastrozole alone in postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer   PDF

Baselga, 2009   everolimus + letrozole versus letrozole alone in postmenopausal women with operable ER-positive breast cancer   PDF

Chan, 2009   gemcitabine + docetaxel versus capecitabine plus docetaxel in   PDF

Papadimitriou, 2009   gemcitabine + weekly docetaxel versus weekly docetaxel in   PDF

Johnston (EGF30008) , 2009   (NCT00073528)   lapatinib + letrozole versus letrozole alone in hormone receptor-positive metastatic breast cancer   PDF

RIBBON-2 (Brufsky), 2009   bevacizumav + CT versus CT alone in second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer   PDF

Joensuu, 2009   (NCT00114816)   capecitabine versus control in women with axillary node-positive or high-risk node-negative breast cancer   PDF

RIBBON-I (Robert) on top Tax or anthra, 2009   bevacizumab + taxanes versus taxanes in irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer   PDF

RIBBON-I (Robert) on top capecitabine, 2009   bevacizumab + capecitabine versus capecitabine in irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer   PDF

AVADO (Miles) 15mg , 2009   bevacizumab + docetaxel versus docetaxel in first-line treatment of HER2-negative metastatic breast cancer   PDF

Schmieder (vs HCTZ), 2009   aliskiren versus hydrochlorothiazide in patients with essential hypertension   PDF

ALLAY, 2009   (NCT00219141)   aliskiren versus losartan in patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m2   PDF

Gradishar , 2009   Weekly Paclitaxel versus Every three weeks Docetaxel in Metastatic   PDF

Cardio-Sis, 2009   (NCT00421863)   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in nondiabetic patients with hypertension and with SBP of 150 mm Hg or higher confirmed at two different times   PDF

DORADO, 2009   (NCT00330369)   darusentan versus placebo in patients with treatment-resistant hypertension   PDF

ASTRAL, 2009   angioplasty versus medical therapy in patients with atherosclerotic renovascular disease   PDF

STAR, 2009   angioplasty versus medical therapy in patients with atherosclerotic renal artery stenosis and impaired renal function   PDF

NITER, 2009   angioplasty versus medical therapy in   PDF

HIJ-CREATE, 2009   candesartan versus conventional treatment in patients with angiographically documented coronary artery disease and hypertension   PDF

VTACH, 2009   (NCT00919373)   catheter ablation before ICD versus no ablation in Patients undergoing implantation of an ICD Patients undergoing implantation of an ICD   PDF

INSTEAD, 2009   (NCT00525356)   error versus error in patients with stable uncomplicated type-B aortic dissection (dissection of the descending aorta)   PDF

TROICA, 2008   (NCT00157261)   tenecteplase versus placebo in adults with witnessed out-of-hospital cardiac arrest of presumed cardiac origin and with initiation of basic or advanced life support within 10 minutes after collapse   PDF

Steinbauer, 2008   carotid artery stenting versus surgery in   PDF

OCLA, 2008   (NCT00349661)   omeprazole versus placebo in patients undergoing coronary artery stent implantation   PDF

STRADIVARIUS, 2008   (NCT00124332)   rimonabant versus placebo in patients with abdominal obesity and the metabolic syndrome   PDF

Bodi, 2008   radial versus femoral in Patients with STEMI for primary PCI   PDF

HORIZONS-AMI (Stone), 2008   (NCT00433966)   bivalirudin versus heparin + GP2b3a inhibitors in patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI   PDF

ISAR-REACT 3, 2008   (NCT00262054)   bivalirudin versus UFH in troponin-negative patients undergoing PCI   PDF

LIMB, 2008   buflomedil versus placebo in Patients >40 years with documented peripheral arterial obstructive disease, intermittent claudication, and an ankle-brachial index between 0.30 and 0.80   PDF

RSVP, 2008   (NCT00139399)   radial artery grafts versus saphenous vein grafts in patient undergoing CABG for a stenosed branch of the native left circumflex coronary artery   PDF

Boudriot, 2008   DES versus CABG in   PDF

Ferenc, 2008   double stenting with SES versus single stenting in patients with a coronary bifurcation lesion   PDF

BBC ONE, 2008   (NCT00351260)   double stenting with PES versus single stenting in patients with significant coronary bifurcation lesions   PDF

DES-DIABETES, 2008   sirolimus eluting stent versus paclitaxel eluting stent in diabetic patients with angina pectoris and/or a positive stress test and a native coronary lesion   PDF

COSTAR II diabetic (sub group), 2008   CoStar stent versus paclitaxel eluting stent in patients with de novo single- or multivessel coronary disease   PDF

ZoMaxx I, 2008   zotarolimus eluting stent versus paclitaxel eluting stent in patients with single de novo coronary lesions and with lesion length 10-30 mm and reference vessel diameter 2.5-3.5 mm   PDF

RIBS-II, 2008   sirolimus eluting stent versus PTCA in patients with bare metal in-stent restenosis   PDF

SOS, 2008   (NCT00247208)   paclitaxel eluting stent versus bare-metal stent in patients undergoing percutaneous coronary intervention of saphenous vein bypass grafts   PDF

FAME, 2008   (NCT00267774)   FFR-guided PCI versus no PCI in patients with multivessel coronary artery disease   PDF

ADVANCE-1, 2008   (NCT00371683)   apixaban versus enoxaparin (US regimen) in patients undergoing knee-replacement surgery   PDF

HORIZONS-AMI Stent, 2008   paclitaxel eluting stent versus bare-metal stent in ST-elevation myocardial infarction   PDF

DEDICATION, 2008   (NCT00192868)   drug-eluting stents versus bare-metal stent in patients referred within 12 hours from symptom onset of an ST-elevation myocardial infarction   PDF

FINESSE (combination-facilitated PCI), 2008   (NCT00046228)   Abciximab + reteplase versus primary intervention in patients with acute ST-segment elevation myocardial infarction; symptom duration <6h   PDF

Kim, 2008   sirolimus eluting stent versus paclitaxel eluting stent in Korean diabetic patients with high-grade de novo coronary lesions (stenosis of>70 percent of the luminal diameter) requiring <3 stents   PDF

DESSERT, 2008   sirolimus eluting stent versus bare-metal stent in de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >3 months   PDF

ONTARGET/Tel+Ram, 2008   Telmisartan + ramipril versus Ramipril in patients with vascular disease or high-risk diabetes   PDF

ONTARGET/Tel, 2008   Telmisartan versus Ramipril in patients with vascular disease or high-risk diabetes   PDF

Wessely, 2008   sirolimus eluting stent versus paclitaxel eluting stent in   PDF

TRIAS-HR, 2008   (ISRCTN74297220)   Genous stent versus paclitaxel eluting stent in high-risk patients (long lesions, small vessels, chronic total occlusions, or any lesion in a diabetic patient)   PDF

Costar II, 2008   (NCT00165035)   CoStar stent versus paclitaxel eluting stent in patient undergoing percutaneous coronary intervention for a single lesion per vessel in up to three native epicardial vessels   PDF

I-PRESERVE (McMurray), 2008   (NCT00095238)   ibesartan versus placebo in patients with NYHA II, III, or IV heart failure and an ejection fraction of at least 45%   PDF

SPIRIT III, 2008   (NCT00180479)   everolimus eluting stent versus paclitaxel eluting stent in lesions 28 mm or less in length and with reference vessel diameter between 2.5 and 3.75 m   PDF

LEADERS, 2008   (NCT00389220)   biolimus eluting stent versus sirolimus eluting stent in patients aged 18 years or older with chronic stable coronary artery disease or acute coronary syndromes   PDF

FUSION 2, 2008   (NCT00091520)   nesiritide versus placebo in patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40%, and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/min   PDF

GISSI-HF rosuvastatine, 2008   (NCT00336336)   rosuvastatin versus placebo in Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterollowering therapy   PDF

SORT OUT II, 2008   (NCT00388934)   sirolimus eluting stent versus paclitaxel eluting stent in Unselected patients (included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina)   PDF

ANDROMEDA, 2008   (NCT00543699)   dronedarone versus placebo in patients hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction   PDF

Seino, 2008   (NCT00154414)   liraglutide other doses versus placebo in Japanese subjects with type 2 diabetes   PDF

MISSION, 2008   (ISRCTN62825862)   sirolimus eluting stent versus bare-metal stent in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h)   PDF

GISSI HF fatty acid, 2008   (NCT00336336.)   omega-3 fatty acids versus placebo in Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterollowering therapy   PDF

HF-ACTION, 2008   (NCT00047437)   structured exercise training versus control in heart-failure patients (NYHA class 2-4, ejection fraction <35%)   PDF

TAPAS, 2008   (ISRCTN16716833)   Export versus conventional PCI in patients with myocardial infarction   PDF

CARESS, 2008   thrombolysis + angioplasty versus immediate thrombolysis in STEMI patients under 75 years old within 12 hours of symptom onset who had been admitted to hospitals without PCI facilities   PDF

Tomai, 2008   sirolimus eluting stent versus paclitaxel eluting stent in diabetic patient with multiple de novo coronary artery lesions   PDF

STAMINA-HeFT (Ghali), 2008   (NCT00049985)   darbepoetin alfa versus placebo in Patients with symptomatic HF, left ventricular ejection fraction < or = 40%, and hemoglobin > or = 9.0 g/dL and < or = 12.5 g/dL   PDF

ACCLAIM, 2008   (NCT00111969)   Celacade™ system versus placebo in patients with NYHA functional class II-IV chronic heart failure, left ventricular (LV) systolic dysfunction, and hospitalisation for heart failure or intravenous drug therapy in an outpatient setting within the past 12 months.   PDF

Parissis, 2008   darbepoetin alfa versus placebo in CHF patients NYHA II-III, LV ejection fraction [EF] <40%, hemoglobin level <12.5 g/dL, serum creatinine level <2.5 mg/dL   PDF

Kourea, 2008   darbepoetin alfa versus placebo in CHF patients NYHA II-III; left ventricular ejection fraction <40%; hemoglobin<12.5 g/dl; serum creatinine<2.5 mg/dl   PDF

REVERSE, 2008   (NCT00271154).)   CRT versus no CRT in patients with NYHA functional class I or II heart failure with a QRS >=120 ms and a LV ejection fraction <=40%   PDF

RE-MOBILIZE (220mg), 2008   dabigatran 220mg versus enoxaparin (US regimen) in Total knee replacement   PDF

Export (Chevalier), 2008   Export versus conventional PCI in patients with acute myocardial infarction   PDF

DEDICATION, 2008   FilterWireg versus conventional PCI in patients with STEMI referred within 12 h to have PCI   PDF

Tahk, 2008   GuardWire versus conventional PCI in AMI patients presenting within 12 h of onset of symptoms   PDF

Seyfarth, 2008   Impella LP2.5 versus intra-aortic balloon pump in patients with cardiogenic shock   PDF

ASPARAGUS, 2008   Guardwire versus conventional PCI in patients with acute myocardial infarction   PDF

Yao, 2008   Bone marrow mononuclear cells versus control in patients with stable ischaemic heart disease due to a previous MI   PDF

Ang, 2008   Bone marrow mononuclear cells versus control in Elective CABG patients with established myocardial scars diagnosed as akinetic or dyskinetic segments by dobutamine stress echocardiography and confirmed at surgery   PDF

Chao, 2008   thrombectomy versus conventional PCI in STEMI patients within 12 h from onset   PDF

PROFESS, 2008   telmisartan versus placebo in   PDF

DACUS (Siragusa), 2008   (NCT00438230)   VKA versus control in with a first episode of deep vein thrombosis, treated with OAT for 3 months and with Residual vein thrombosis   PDF

AMADEUS, 2008   (NCT00070655)   idraparinux versus warfarin standard dose in patients with atrial fi brillation at risk for thromboembolism   PDF

González-Fajardo, 2008   Enoxaparin versus coumarin in patients with symptomatic, unilateral, first-episode DVT   PDF

Botticelli DVT, 2008   (NCT00252005)   apixaban (without LMWH) versus LMWH/VKA in patients with symptomatic deep vein thrombosis   PDF

Einstein-DVT Dose-Ranging Study, 2008   rivaroxaban (without LMWH) versus LMWH/VKA in patients with deep vein thrombosis   PDF

ERATO, 2008   (18760136)   dronedarone versus placebo in patients with permanent AF   PDF

A4 (Jais), 2008   (NCT00540787)   catheter ablation versus control in patients with paroxysmal AF resistant to at least 1 antiarrhythmic drug.   PDF

RECORD 3, 2008   (NCT00361894)   rivaroxaban versus enoxaparin (europe regimen) in patients undergoing total knee arthroplasty   PDF

RECORD 2, 2008   (NCT00332020)   rivaroxaban (long duration) versus enoxaparin (short duration) in patients undergoing elective total hip replacement   PDF

ThermoCool AF, 2008   (NCT00116428)   catheter ablation versus control in patients with AF who were nonresponsive to previous treatment with antiarrhythmic drugs   PDF

RECORD 1, 2008   (NCT00329628)   rivaroxaban versus enoxaparin in patients undergoing total hip arthroplasty   PDF

ACCORD, 2008   (NCT00000620)   intensive glycemic control versus conventional treatment in patients with type 2 diabetes mellitus at high risk of death and stroke (pre-existing heart disease or two or more additional risk factors for heart disease)   PDF

ADVANCE, 2008   (NCT00145925)   intensive glycemic control versus conventional treatment in patients with type 2 diabetes   PDF

Enhance, 2008   ezetimibe versus placebo (on top statins) in patients with familial hypercholesterolemia   PDF

ONTARGET (telmisartan alone), 2008   (NCT00153101)   telmisartan versus ramipril in patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage   PDF

ONTARGET (association vs ramipril), 2008   (NCT00153101)   telmisartan + ramipril versus ramipril in patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage   PDF

JUPITER, 2008   (NCT00239681)   rosuvastatin versus placebo in apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher)   PDF

Tuttle, 2008   low fat diet versus mediterranean-style diet in First MI survivors   PDF

Hamann, 2008   SU versus rosiglitazone (add on MET) in overweight individuals with inadequately controlled type 2 diabetes mellitus.Individuals with inadequate glycaemic control (HbA (1c)> or =7%) while on metformin monotherapy (> or =0.85 g/day)   PDF

DRIVE, 2008   (NCT00338897)   SR123781A versus enoxaparin in patients undergoing total hip replacement surgery   PDF

Khanolkar, 2008   gliclazide versus rosiglitazone (add on MET) in   PDF

Moretto (DOUBLONS avec druker), 2008   (NCT00381342)   exenatide other doses versus placebo in   PDF

Bolli, 2008   (NCT00237237)   vildagliptin versus pioglitazone (add on MET) in patients with type 2 diabetes inadequately controlled with metformin monotherapy   PDF

ONTARGET (association vs telmisartan), 2008   (NCT00153101)   telmisartan + ramipril versus telmisartan in patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage   PDF

TRANSCEND, 2008   (NCT00153101)   telmisartan versus placebo in high-risk patients intolerant to angiotensin-converting enzyme inhibitors   PDF

POPADAD aspirin, 2008   (ISRCTN53295293)   aspirin versus placebo in patients with diabetes mellitus and asymptomatic peripheral arterial disease   PDF

PHS II vitamin C, 2008   (NCT00270647)   vitamin C versus placebo in US male physicians aged 50 years or older   PDF

WAFACS, 2008   (NCT00000541)   folic acid, vit B12 and vit B6 versus placebo in women aged 42 years or older, with either a history of CVD or 3 or more coronary risk factors   PDF

PHS II vitamin E, 2008   (NCT00270647)   vitamin E versus placebo in US male physicians aged 50 years or older   PDF

Scherbaum [2], 2008   (NCT00101712)   vildagliptin versus placebo in drug-naïve patients with type 2 diabetes and mild hyperglycaemia   PDF

JPAD, 2008   (NCT00110448)   aspirin versus no treatment in patients with type 2 diabetes without a history of atherosclerotic disease   PDF

SANDS, 2008   (NCT00047424)   aggressive treatment versus standard teatment in adults with type 2 diabetes   PDF

VADT, 2008   (NCT00032487)   intensive glycemic control versus conventional treatment in military veterans who had a suboptimal response to therapy for type 2 diabetes   PDF

Nonaka, 2008   (NCT00371007)   sitagliptin monotherapy versus placebo in Japanese patients with type 2 diabetes   PDF

ARISE, 2008   (NCT00066898)   succinobucol versus placebo in patients with recent (14-365 days) acute coronary syndromes already managed with conventional treatments   PDF

WENBIT (folic ac,B12), 2008   (NCT00354081)   folic acid, B12 versus placebo in adult participants undergoing coronary angiography   PDF

WENBIT (vit B6), 2008   (NCT00354081)   vit B6 versus placebo in adult participants undergoing coronary angiography   PDF

JUPITER (women subgroup) , 2008   Rosuvastatin versus placebo in apparently healthy men and women with low-density lipoprotein cholesterol levels of less than 130 mg/dL and high-sensitivity C-reactive protein levels of 2.0 mg/L or higher - subgroup of women   PDF

APPROACH, 2008   (NCT00116831)   rosiglitazone versus glipizide in patients with type 2 diabetes and coronary artery disease   PDF

PERISCOPE, 2008   (NCT00225277)   pioglitazone versus glimepiride in patients with coronary disease and type 2 diabetes   PDF

Paterna, 2008   sodium reduction versus control in compensated CHF patients   PDF

Giles, 2008   (NCT00521820)   glitazone versus glyburide in patients with type 2 diabetes, systolic dysfunction, and NYHA functional Class II/III HF   PDF

PERISCOPE, 2008   (NCT00225277)   glitazone versus glimepiride in patients with coronary disease and type 2 diabetes   PDF

Heymach, 2008   versus in   PDF

Chen, 2008   pemetrexed versus docetaxel in   PDF

Rosell, 2008   cetuximab + CT versus CT alone in first-line therapy in EGFR-expressing advanced non-small-cell lung cancer   PDF

SWOG S0023 (Kelly), 2008   gefitinib versus placebo in inoperable stage III non-small-cell lung cancer   PDF

INVITE (Crinò), 2008   (NCT00256711)   gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer   PDF

INTEREST (Kim), 2008   gefitinib versus docetaxel in previously treated advanced nonsmall-cell lung cancer   PDF

V-15-32 (Maruyama), 2008   gefitinib versus docetaxel in previously treated advanced nonsmall-cell lung cancer   PDF

CARDia (PCI), 2008   (ISRCTN19872154)   stent versus CABG in Patients with diabetes and symptomatic multivessel coronary artery disease or complex single-vessel disease.   PDF

EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M) versus observation in patients with resected stage III melanoma   PDF

BEAUTIFUL, 2008   (NCT00143507)   ivabradine versus placebo in patients with coronary artery disease and left-ventricular systolic dysfunction (LVEF <=40%)   PDF

McDermott , 2008   sorafenib versus in   PDF

BEAUTIFUL, 2008   (NCT00143507)   ivabradine 15mg versus placebo in patients with coronary artery disease and left-ventricular systolic dysfunction (LVEF <=40%)   PDF

RECORD-1, 2008   (NCT00410124)   everolimus versus placebo in Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both   PDF

Meier, 2008   versus in   PDF

Roy, 2008   (NCT00110084)   nab-paclitaxel +gencotabine versus gencitabine in patients with previously untreated metastatic breast cancer   PDF

Meier, 2008   docetaxel versus vinorelbine in after failing anthracycline treatment   PDF

Albain, 2008   gemcitabine + paclitaxel versus paclitaxel monotherapy in   PDF

Di Leo, 2008   (NCT00075270)   lapatinib + paclitaxel versus paclitaxel alone in first-line treatment for metastatic breast cancer   PDF

KANT (14 days), 2008   nadroparin 14d versus control in patients undergoing knee arthroscopy   PDF

Lee, 2008   capecitabine + docetaxel versus doxorubicin + cyclophosphamide in women with axillary node positive, stage II/III breast cancer   PDF

EORTC 10001 (Pajk), 2008   capecitabine versus vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer   PDF

KANT (7 days), 2008   nadroparin versus control in patients undergoing knee arthroscopy   PDF

ACCOMPLISH, 2008   (NCT00170950)   amlodipine plus benazepril versus hydrochlorothiazide plus benazepril in patients with hypertension who were at high risk for cardiovascular events   PDF

HYVET, 2008   (NCT00122811)   indapamide versus placebo in patients 80 years or older with persistent hypertension defined as a sustained systolic BP of 160 mm Hg or higher   PDF

Camporese, 2008   GCS versus LMWH in patients undergoing knee arthroscopy   PDF

PROPHESS, 2008   (NCT00153062)   telmisartan versus placebo in patients who recently had an ischemic stroke   PDF

RE-MOBILIZE (150mg), 2008   dabigatran 150mg versus enoxaparin (US regimen) in Total knee replacement   PDF

Suzuki et al, 2008   candesartan versus usual care in patients undergoing hemodialysis   PDF

Tepel et al, 2008   (NCT00124969)   amlodipine versus placebo in hypertensive haemodialysis patients   PDF

AVOID, 2008   (NCT00097955)   aliskiren versus placebo in patients with hypertension and type 2 diabetes with nephropathy   PDF

Andersen, 2008   aliskiren versus ramipril in   PDF

Fountzilas , 2008   Weekly Paclitaxel versus Every three weeks Docetaxel in Metastatic   PDF

CLGB 9840 (Seidman), 2008   Weekly Paclitaxel versus Every three weeks Paclitaxel in Metastatic   PDF

ACCORD blood pressure, 2008   (NCT00000620)   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in patients with a median glycated hemoglobin level of 8.1% at high risk for cardiovascular events   PDF

Rivera , 2008   Weekly Docetaxel versus Every three weeks Docetaxel in Metastatic patients with metastatic breast cancer   PDF

Aschwanden, 2008   compression stockings versus no compression in patients with a first or recurrent proximal deep vein thrombosis who received 6 months of standard treatment   PDF

CASE-J, 2008   candesartan versus amlodipine in high-risk Japanese hypertensive patients   PDF

SEAS, 2008   (NCT00092677)   ezetimibe+simvastatin versus placebo in patients with mild-tomoderate, asymptomatic aortic stenosis   PDF

Suzuki, 2008   ARBs versus control in patients with diabetes and chronic kidney disease on dialysis   PDF

ASCOT (subgroup), 2008   amlodipine versus atenolol in Patients with untreated hypertension or treated hypertension; diabetic subgroup with two additionnal risk factors   PDF

PROFESS, 2008   telmisartan versus placebo in   PDF

DREAM, 2008   ramipril versus placebo in people aged >=30 years, with Impaired glucose tolerance and/or impaired fasting glucose without known CVD or renal insufficiency   PDF

JATOS, 2008   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in elderly hypertensive patients with essential hypertension (65-85 years old, with a pretreatment systolic blood pressure of above 160 mmHg)   PDF

Baker, 2008   compressions first versus defibrillation first in   PDF

ARMYDA-ACS, 2007   atorvastatin versus placebo in patients with non-ST-segment elevation ACS   PDF

Li , 2007   radial versus femoral in Coronary angiography or PCI   PDF

RADIAMI , 2007   radial versus femoral in Patients with STEMI for primary or rescue PCI   PDF

FARMI , 2007   radial versus femoral in Patients with STEMI for primary or rescue PCI   PDF

APEX-AMI, 2007   (NCT00091637)   pexelizumab versus placebo in primary angioplasty fo high risk STEMI   PDF

DELTA (Grossman), 2007   Del-1 versus placebo in patients with bilateral intermittent claudication and peak walking time (PWT) between 1 and 10 minutes on 2 qualifying treadmill tests   PDF

CLIPS, 2007   aspirin versus placebo in outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6   PDF

Ozkara, 2007   off-pump versus on-pump in patients admitted for elective CABG   PDF

Kunes, 2007   off-pump versus on-pump in patient undergoing CABG   PDF

Hausenloy, 2007   (NCT00397163)   remote ischemic preconditioning versus control in patients undergoing elective coronary artery bypass graft surgery   PDF

Ali, 2007   remote ischemic preconditioning versus no RIPC in patients undergoing elective open abdominal aortic aneurysm repair   PDF

Losordo, 2007   (NCT00081913)   stem cells CD34+ versus placebo in Patientswith Canadian Cardiovascular Society class 3 or 4 angina who were undergoing optimal medical treatment and who were not candidates for mechanical revascularization   PDF

BNP-CARDS, 2007   (NCT00186329)   nesiritide versus placebo in acute decompensated heart failure with moderate to severe renal insufficiency   PDF

EVEREST Clinical Status , 2007   (NCT00071331)   tolvaptan versus placebo in patients hospitalized with heart failure   PDF

EVEREST Outcome, 2007   tolvaptan versus placebo in patients hospitalized with heart failure   PDF

VALIDD, 2007   (NCT00170924)   valsartan versus no valsartan in Patients with hypertension and evidence of diastolic dysfunction   PDF

CORONA, 2007   (NCT00206310)   rosuvastatin versus placebo in patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failure   PDF

OASIS 6, 2007   (NCT00064428)   GIK infusion versus control in patients with acute STEMI   PDF

Glucose-insulin-potassium study II, 2007   GIK infusion versus control in STEMI patients without signs of heart failure   PDF

Pan, 2007   sirolimus eluting stent versus paclitaxel eluting stent in patients with bifurcation lesions   PDF

Erglis, 2007   paclitaxel eluting stent versus bare-metal stent in percutaneous coronary intervention for unprotected left main artery stenosis   PDF

Díaz de la Llera, 2007   sirolimus eluting stent versus bare-metal stent in primary percutaneous coronary intervention for acute myocardial infarction with ST-segment elevation   PDF

Krum, 2007   rosuvastatin versus placebo in patients with systolic (LVEF<40%) CHF of ischemic or nonischemic etiology   PDF

VERITAS II, 2007   (NCT00525707)   tezosentan versus placebo in patients with acute heart failure admitted within the previous 24 hours with persisting dyspnea and a respiratory rate of 24/min or greater   PDF

Petronio et al, 2007   sirolimus eluting stent versus paclitaxel eluting stent in Complex lesions. Stable AP or documented ischaemia, no AMI   PDF

Ortolani et al, 2007   sirolimus eluting stent versus bare-metal stent in symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent   PDF

SCORPIUS, 2007   (NCT00495898)   sirolimus eluting stent versus bare-metal stent in patients with diabetes and de novo coronary artery lesions   PDF

SESAMI, 2007   (NCT00288210)   sirolimus eluting stent versus bare-metal stent in AMI   PDF

EMOTE, 2007   enoximone versus placebo in patients with ultra-advanced heart failure requiring IV inotropic therapy   PDF

Yamada, 2007   atorvastatin versus control in outpatients with mild to moderate CHF and radionuclide left ventricular ejection fraction (LVEF) <40%   PDF

Kochiadakis, 2007   sirolimus eluting stent versus bare-metal stent in one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm   PDF

SISR, 2007   (NCT00231257)   sirolimus eluting stent versus brachytherapy in restenosis within a bare metal stent   PDF

Udelson, 2007   (NCT00043758)   tovalpan versus placebo in patients with HF and reduced systolic function   PDF

van Veldhuisen, 2007   (NCT00086086)   darbepoetin alfa versus placebo in Patients with chronic heart failure (>=3 months), left ventricular ejection fraction <= 40%, and Hb 9.0 to 12.5 g/dL   PDF

Ponikowski, 2007   (NCT00117234)   darbepoetin alfa versus placebo in patients with Symptomatic Congestive Heart Failure (CHF) and Anemia   PDF

RethinQ, 2007   (NCT00132977)   Combined CRT + ICD versus no CRT in patients with standard indication for an implantable cardioverter-defibrillator, NYHA 3, EF<35%, QRS<130ms, and evidence of mechanical dyssynchrony   PDF

Posner (TAX324), 2007   (NCT00273546)   TPF versus PF in locally advanced (stage III/IV) squamous cell carcinoma of head and neck with unresectable tumor or candidates for organ preservation   PDF

STARS-BNP, 2007   BNP-guided management versus control in patients in NYHA functional class 2-3 with an LVEF <45%; optimally treated with angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and diuretics by CHF specialists   PDF

STARBRITE, 2007   (NCT00484770)   BNP-guided management versus control in patients in NYHA class 3-4 and with an LVEF <35%; enrolled prior to discharge following hospitalization for acute decompensation   PDF

SURVIVE, 2007   (NCT00348504)   levosimendan versus dobutamine in patients hospitalized with acute decompensated heart failure who required inotropic support   PDF

TAX324 (Larynx preservation subset), 2007   (NCT00273546)   TPF versus PF in locally advanced (stage III/IV) squamous cell carcinoma of larynx and hypopharynx, candidates for organ preservation   PDF

MICADO, 2007   GuardWire versus conventional PCI in Patients with AMI within 24 hours from onset   PDF

UpFlow MI, 2007   FilterWire versus conventional PCI in patients with STEMI and coronary angiographic evidence of thrombotic occlusion   PDF

PREMIAR, 2007   SpideRX versus conventional PCI in with acute ST-segment elevation myocardial infarction at high risk of embolic events (including only baseline Thrombolysis In Myocardial Infarction grade 0 to 2 flow)   PDF

Ochala, 2007   GuardWire versus conventional PCI in patients with ST elevation acute myocardial infarction referred for primary percutaneous coronary intervention   PDF

MAGIC 1 (Kang), 2007   G-CSF versus control in patients with myocardial infarction   PDF

Takano, 2007   G-CSF versus control in patients with AMI related with the left anterior descending coronary artery, who underwent successful percutaneous coronary intervention   PDF

RIGENERA (Leone), 2007   G-CSF versus control in patients with large anterior wall AMI at high risk of unfavorable remodeling and with successful primary or rescue percutaneous coronary intervention and LVEF<50%   PDF

Suarez de Lezo (G-CSF), 2007   G-CSF versus control in patients with revascularized anterior wall AMI and depressed left ventricular function (ejection fraction < 45%)   PDF

Suarez de Lezo (cell), 2007   autologous bone marrow stem cells versus control in patients with revascularized anterior wall AMI and depressed left ventricular function (ejection fraction < 45%)   PDF

Li, 2007   autologous bone marrow stem cells versus control in patients with AMI   PDF

Penicka, 2007   autologous bone marrow stem cells versus control in patients with large anterior acute myocardial infarction   PDF

Posner (TAX324), 2007   (NCT00273546)   TPF versus PF in locally advanced (stage III/IV) squamous cell carcinoma of head and neck with unresectable tumor or candidates for organ preservation   PDF

Manginas, 2007   Bone marrow progenitor cells versus control in patients with old, nonviable anterior myocardial infarction   PDF

APOLLO (Turpie), 2007   fondaparinux versus placebo (on top intermittent pneumatic comp.) in Patients aged at least 40 years undergoing abdominal surgery   PDF

Van Gogh, 2007   (NCT00071279)   idraparinux versus placebo in patients who had completed 6 months of prophylaxis with idraparinux or a vitamin K antagonist and in whom extended anticoagulation was warranted   PDF

Cohen (L8405), 2007   compression stocking group versus control (on top fondaparinux) in patients undergoing elective or emergency hip surgery   PDF

EURIDIS, 2007   (NCT00259428)   dronedarone versus placebo in patients with at least one episode of atrial fibrillation in the preceding 3 months, and in sinus rhythm for at least 1 hour before randomization   PDF

ADONIS, 2007   (NCT00259376)   dronedarone versus placebo in patients with at least one episode of atrial fibrillation in the preceding 3 months, and in sinus rhythm for at least 1 hour before randomization   PDF

PETRO (150mg), 2007   dabigatran 150mg versus warfarin standard dose in patients with AF at high risk for thromboembolic events   PDF

VanGogh PE, 2007   (NCT00062803)   idraparinux (without heparin) versus heparin/VKA in patients with pulmonary embolism   PDF

VanGogh extension, 2007   (NCT00071279)   idraparinux versus discontinuation in patients who had completed 6 months of prophylaxis with idraparinux or a vitamin K antagonist and in whom extended anticoagulation was warranted   PDF

VanGogh DVT, 2007   (NCT00067093)   idraparinux (without heparin) versus heparin/VKA in patients with deep-vein thrombosis   PDF

SEARCH, 2007   (NCT00124072)   folic acid, B12 versus placebo in patients survivors of myocardial infarction   PDF

DIONISOS, 2007   (NCT00489736)   dronedarone versus amiodarone in Patients with documented atrial fibrillation for more than 72 hours for whom cardioversion and antiarrhythmic treatment is indicated in the opinion of the investigator and under oral anticoagulation   PDF

CAPRAF (Tveit), 2007   (NCT00130975)   candesartan versus placebo in patients undergoing electrical cardioversion for persistent AF   PDF

METEOR, 2007   (NCT00225589)   rosuvastatin versus placebo in individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year Framingham risk score of less than 10%, modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol   PDF

SAGE, 2007   atorvastatin high dose versus pravastatin in Chronic coronary artery disease   PDF

NN2211-1571 (Vilsbøll), 2007   (NCT00154401)   liraglutide other doses versus placebo in subjects with type 2 diabetes   PDF

Kumashiro, 2007   mitiglinide versus on top insulin glargine in   PDF

WACS vitamin C, 2007   (NCT00000541)   vitamin C versus placebo in female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors)   PDF

Lund, 2007   repaglinide versus metformin in non-obese patients with type 2 diabetes   PDF

Li, 2007   nateglinide versus repaglinide in Chinese patients with type 2 diabetes   PDF

Nauck, 2007   glipizide versus sitagliptin (add on MET) in   PDF

MERLIN TIMI 36, 2007   (NCT00099788)   ranolazine versus placebo in Hospitalized with NSTE-ACS; ischemic symptoms at rest within 48 hours; and at least one indicator of moderate to high risk, defined as elevated troponin or creatine kinase-myocardial band, ST-depression >0.1 mV, diabetes, or TIMI risk score for unstable angina/NSTEMI >=3   PDF

ICTUS, 2007   (ISRCTN82153174)   routine invasive strategy versus concervative strategy in patients with non–ST-segment elevation acutec oronary syndrome and elevated cardiac troponin T   PDF

Kim, 2007   (NCT00103935)   exenatide weekly versus placebo (add on MET) in subjects with type 2 diabetes suboptimally controlled with metformin and/or diet and exercise   PDF

Zinman 20µg/j, 2007   (NCT00099320)   exenatide 20µg/d versus placebo (add on TZD+/-MET) in patients with type 2 diabetes that was suboptimally controlled with TZD treatment (with or without metformin)   PDF

Nauck, 2007   (NCT00082407)   exenatide 20µg/d versus insulin BIAsp twice daily add on SU+MET in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin   PDF

Barnett, 2007   (NCT00099619)   exenatide 20µg/d versus insulin (add on SU/MET) in patients with type 2 diabetes   PDF

Davis, 2007   (NCT00099333)   exenatide 20µg/d versus insulin (add on SU/MET) in patients with type 2 diabetes using insulin in combination with oral antidiabetes agents   PDF

Rosenstock** (vilda + pio vs pio), 2007   (NCT00101803)   vildagliptin versus placebo (add on TZD) in drug-naive patients with type 2 diabetes   PDF

Garber, 2007   (NCT00099853)   vildagliptin versus placebo (on top pioglitazone) in   PDF

Fonseca, 2007   (NCT00099931)   vildagliptin versus placebo (add on insulin) in type 2 diabetes that was inadequately controlled by insulin   PDF

Bosi, 2007   (NCT00099892)   vildagliptin versus placebo (add on MET) in patients with type 2 diabetes inadequately controlled with metformin   PDF

Schweizer, 2007   (NCT00099866)   vildagliptin versus metformin in drug-naïve patients with Type 2 diabetes   PDF

Rosenstock** (vilda vs pio), 2007   (NCT00101803)   vildagliptin monotherapy versus pioglitazone in drug-naive patients with type 2 diabetes   PDF

Rosenstock* (vilda vs rosi), 2007   (NCT00099918)   vildagliptin versus rosiglitazone in drug-naïve patients with type 2 diabetes   PDF

WACS vitamin E, 2007   (NCT00000541)   vitamin E versus placebo in female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors)   PDF

WACS beta-caroten, 2007   (NCT00000541)   beta carotene versus placebo in female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors)   PDF

Pi-Sunyer, 2007   (NCT00120536)   vildagliptin monotherapy versus placebo in drug-naïve patients with type 2 diabetes   PDF

Dejager [1], 2007   (NCT00099905)   vildagliptin monotherapy versus placebo in drug-naïve patients with type 2 diabetes   PDF

Scott** (sit vs pbo on top met), 2007   sitagliptin versus placebo (add on MET) in patients with type 2 diabetes who were inadequately on mET monotherapy   PDF

TRITON-TIMI 38, 2007   (NCT00097591)   prasugrel versus clopidogrel in patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention   PDF

Nauck, 2007   (NCT00094770)   sitagliptin versus placebo (add on MET) in   PDF

Hermansen, 2007   sitagliptin versus placebo (on-top glimepiride+/- metformine) in   PDF

Goldstein (sit+met vs met), 2007   sitagliptin versus metformin in   PDF

ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007   bivalirudin + GP2b3a inhibitors versus heparin + GP2b3a inhibitors in patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography.   PDF

ACUITY (sub groups PCI, bivalirudin alone) importé, 2007   bivalirudin versus heparin + GP2b3a inhibitors in patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography (sub group).   PDF

Scott* (sit vs glipi), 2007   sitagliptin 50mg bid monotherapy versus glipizide in patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise   PDF

Goldstein (sit vs met), 2007   sitagliptin versus metformin in   PDF

Scott* (sit vs pbo), 2007   sitagliptin 50mg bid monotherapy versus placebo in   PDF

DISPERSE-2 (90mg), 2007   ticagrelor versus clopidogrel in patients with NSTE-ACS, treated with aspirin and standard therapy for ACS   PDF

RADIANCE 1, 2007   (NCT00136981)   torcetrapib versus placebo in patients with heterozygous familial hypercholesterolemia   PDF

ILLUMINATE, 2007   (NCT00134264)   torcetrapib versus placebo in patients at highcardiovascular risk   PDF

RADIANCE 2, 2007   torcetrapib versus placebo in patients with mixed dyslipidaemia   PDF

ILLUSTRATE, 2007   (NCT00134173)   torcetrapib versus placebo in patients with coronary disease   PDF

AMIHOT, 2007   supersaturated oxygen versus control in patients with acute anterior or large inferior AMI undergoing primary or rescue PCI (<24 h from symptom onset) and successful PCI   PDF

Hanefeld, 2007   sitagliptin versus placebo in   PDF

Goldstein, 2007   (NCT00103857)   sitagliptin versus placebo in   PDF

APROPOS 2.5mg, 2007   (NCT00097357)   apixaban versus enoxaparin (US regimen) in patients undergoing elective total knee replacement surgery   PDF

ADVANCE, 2007   (NCT00145925)   perindopril and indapamide versus placebo in patients with type 2 diabetes irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs   PDF

WISDOM, 2007   (ISRCTN63718836)   combined estrogen and progestogen versus placebo in postmenopausal women aged 50-69   PDF

AVOREN, 2007   bevacizumab plus interferon alfa versus interferon alpha in patients with previously untreated mRCC   PDF

TARGET, 2007   (NCT00073307)   sorafenib versus placebo in patients with renal-cell carcinoma that was resistant to standard therapy   PDF

Motzer, 2007   (NCT00083889)   sunitinib versus interferon alpha in patients with previously untreated, metastatic renal-cell carcinoma   PDF

Heymach, 2007   vandetanib plus docetaxel versus placebo plus docetaxel in previously treated non small-cell lung cancer   PDF

Butts, 2007   cetuximab versus CT alone in chemotherapy-naïve patients with recurrent/metastatic NSCLC (stage IV or stage IIIB with malignant pleural effusion)   PDF

COURAGE, 2007   (NCT00007657)   PCI with or without stent versus medical treatment in patients with stable coronary artery disease   PDF

MASS II, 2007   PCI with or without stent versus medical treatment in patients with multivessel coronary artery disease with stable angina and preserved ventricular function   PDF

MASS II, 2007   CABG versus medical treatment in multivessel coronary artery disease with stable angina and preserved ventricular function.   PDF

Herbst, 2007   bevacizumab versus platinum based CT in   PDF

Ruzyllo, 2007   ivabradine versus amlodipine in   PDF

Marlovits, 2007   extended-duration thromboprophylaxis versus standard-duration thromboprophylaxis in patients who had undergone arthroscopic surgery of the anterior cruciate ligament   PDF

Eddicks, 2007   spinal cord stimulation versus placebo in patients with refractory angina   PDF

SWISSI II, 2007   (NCT00387231)   balloon angioplasty versus medical treatment in patients with a recent MI, silent myocardial ischemia verified by stress imaging, and 1- or 2-vessel coronary artery disease   PDF

MASS II, 2007   stent versus CABG in patients with multivessel coronary artery disease with stable angina and preserved ventricular function   PDF

Ruzyllo (CL3-023) 15mg, 2007   ivabradine 15mg versus amlodipine in Patients with a >/=3-month history of chronic, stable effort-induced angina   PDF

D-KAf (Selby), 2007   (NCT00187408)   dalteparin versus placebo in below-knee fractures repaired surgically   PDF

Ruzyllo (CL3-023) 20mg, 2007   ivabradine 20mg versus amlodipine in Patients with a >/=3-month history of chronic, stable effort-induced angina   PDF

Zhu, 2007   nicorandil versus isosorbide mononitrate in patients with stable AP   PDF

ARCC (Hudes) temsirolimus alone, 2007   (NCT00065468)   temsirolimus versus interferon alpha in patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma   PDF

Verma, 2007   versus in   PDF

Pajk, 2007   versus in   PDF

Martin, 2007   versus in   PDF

Lapidus, 2007   dalteparin versus placebo in patients undergoing ankle fracture surgery   PDF

Lapidus, 2007   dalteparin versus placebo in patients surgically treated for Achilles tendon rupture   PDF

Martín, 2007   gemcitabine + vinorelbine versus vinorelbine monotherapy in   PDF

Thomas, 2007   ixabepilone (on top capecitabine) versus no ixabepilone in patients with metastatic breast cancer progressing after anthracycline and taxane treatment   PDF

E2100 (Miller), 2007   (NCT00028990)   bevacizumab + taxanes versus taxanes in patients with metastatic breast cancer not previously treated   PDF

RE-NOVATE (150mg), 2007   (NCT00168818)   dabigatran 150mg versus enoxaparin in Total hip replacement   PDF

Nakao et al, 2007   carvedilol versus placebo in   PDF

Willemse , 2007   Weekly Docetaxel versus Every three weeks Docetaxel in Metastatic   PDF

RE-MODEL (150mg), 2007   dabigatran 150mg versus enoxaparin (europe regimen) in Total knee replacement   PDF

RE-NOVATE (220mg), 2007   (NCT00168818)   dabigatran 220mg versus enoxaparin in Total hip replacement   PDF

ADVANCE, 2007   (NCT00145925)   perindopril and indapamide versus placebo in individuals with type 2 diabetes   PDF

SMASH-VT, 2007   (ISRCTN62488166)   catheter ablation before ICD versus no ablation in patients with a history of a myocardial infarction undergoing defibrillator implantation for spontaneous ventricular tachycardia or fibrillation   PDF

RE-MODEL (220mg), 2007   dabigatran 220mg versus enoxaparin (europe regimen) in patients undergoing total knee replacement   PDF

ARISE, 2007   (NCT00066898)   succinobucol versus placebo in high-risk patients with recent acute coronary syndrome   PDF

HELAS (warfarin vs aspirin), 2006   warfarin versus aspirin in HF related to ischemic heart disease with LVFE<35%   PDF

SOFA , 2006   (NCT00110838)   fish oil versus placebo in   PDF

Raitt , 2006   (NCT00004558)   fish oil versus placebo in   PDF

TESCAS-C (Ling), 2006   carotid artery stenting versus surgery in   PDF

BACASS (Hoffman), 2006   carotid artery stenting versus surgery in patients with symptomatic carotid stenosis > 70%   PDF

Lange and von Boetticher, 2006   radial versus femoral in Coronary angiography or PCI   PDF

ACUITY (Stone) (bivalirudin alone), 2006   (NCT00093158)   bivalirudin versus heparin + GP2b3a inhibitors in patients with acute coronary syndromes   PDF

STEEPLE, 2006   (NCT00077844)   enoxaparin versus UFH in elective percutaneous coronary intervention.   PDF

Kusumanto, 2006   phVEGF165 versus placebo in patients with diabetes mellitus and critical limb ischemia   PDF

Vedin, 2006   off-pump versus on-pump in patients between 50 and 80 years with stable angina pectoris, ejection fraction >30%, serum creatinine <150 micromol/l, and lack of tight main stem stenosis   PDF

Jares, 2006   off-pump versus on-pump in patients scheduled for coronary bypass grafting   PDF

Tatoulis, 2006   off-pump versus on-pump in candidates for elective CABG   PDF

Paparella, 2006   off-pump versus on-pump in patient undergoing CABG   PDF

Niranjan, 2006   off-pump versus on-pump in patient undergoing CABG   PDF

Motallebzadeh b, 2006   off-pump versus on-pump in patients admitted for elective coronary artery bypass graft surgery   PDF

Michaux, 2006   off-pump versus on-pump in patients scheduled for elective coronary artery bypass surgery   PDF

Ascione, 2006   off-pump versus on-pump in patient undergoing CABG   PDF

Al-Ruzzeh b, 2006   off-pump versus on-pump in patients requiring primary isolated coronary artery bypass grafting surgery   PDF

Cheung, 2006   remote ischemic preconditioning versus control in children undergoing cardiac surgery for repair of congenital heart defects   PDF

Patti et al., 2006   preoperative atorvastatin versus placebo in patients undergoing elective cardiac surgery with cardiopulmonary bypass, without previous statin treatment or history of AF   PDF

Chello et al., 2006   preoperative atorvastatin versus placebo in elective CABG   PDF

SCANDSTENT (subgroup), 2006   sirolimus eluting stent versus bare-metal stent in patients with coronary artery disease and a total coronary occlusion > or = 15 mm in length   PDF

NORDIC , 2006   double stenting with SES versus single stenting in patients with a coronary bifurcation lesion   PDF

REVASC (Stewart), 2006   VEGF gene transfer versus control in patients with severe angina due to coronary artery disease and no conventional options for revascularization   PDF

OAT, 2006   late PTCA versus no PTCA in stable patients who had total occlusion of the infarct-related artery 3 to 28 days after myocardial infarction and who met a high-risk criterion (   PDF

TOSCA-2, 2006   (NCT00025766)   late PTCA versus no PTCA in patients with an occluded native infarct-related artery 3 to 28 days after MI   PDF

CREATE-ECLA , 2006   GIK infusion versus control in patients with STEMI within 12 hours of symptom onset   PDF

Bucciarelli-Ducci , 2006   GIK infusion versus placebo in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction   PDF

ASSENT-4 PCI (Van de Werf), 2006   (NCT00168792)   versus primary intervention in symptom duration <6 h   PDF

TAXUS V ISR, 2006   (NCT00287573)   paclitaxel eluting balloon versus brachytherapy in patients with restenotic lesions after prior stent implantation in native coronary arteries   PDF

Bellandi, 2006   Abciximab versus primary intervention in symptom duration <6h   PDF

ISAR-test (diabetics), 2006   paclitaxel eluting stent versus sirolimus eluting stent in diabetics patients with de novo lesions in native coronary vessels, excluding the left main trunk   PDF

REALITY (diabetics), 2006   sirolimus eluting stent versus paclitaxel eluting stent in   PDF

HELAS (warfarin vs placebo), 2006   warfarin versus placebo in HF due to dilated cardiomyopathy   PDF

PEP CHF, 2006   perindopril versus placebo in patients aged >=70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease   PDF

ISAR-TEST-1, 2006   (NCT00140530)   sirolimus eluting stent versus paclitaxel eluting stent in stable or unstable anginaor a positive stress test, stable or unstable anginaor a positive stress test   PDF

ENDEAVOR III, 2006   (NCT00217256)   zotarolimus eluting stent versus sirolimus eluting stent in single de novo lesions in native coronary arteries 2.5-3.5 mm in diameter   PDF

SPIRIT II, 2006   (NCT00180310)   everolimus eluting stent versus paclitaxel eluting stent in De novo lesions (maximim two)   PDF

ENDEAVOR II, 2006   zotarolimus eluting stent versus bare-metal stent in single de novo native coronary artery stenosis   PDF

VERITAS I, 2006   (NCT00525707)   tezosentan versus placebo in patients with acute heart failure   PDF

Han, 2006   sirolimus eluting stent versus paclitaxel eluting stent in Multivessel disease. Stable or unstable AP, no AMI   PDF

Cervinka, 2006   sirolimus eluting stent versus paclitaxel eluting stent in Complex lesionsand patients. Signs and/or symptoms myocardial ischaemia, including AMI   PDF

PROSIT, 2006   sirolimus eluting stent versus paclitaxel eluting stent in AMI or persistent ischaemia 12-24h   PDF

LONG DES II, 2006   sirolimus eluting stent versus paclitaxel eluting stent in Long lesions. AP or positive stress, no AMI   PDF

Zhang (SES vs PES), 2006   sirolimus eluting stent versus paclitaxel eluting stent in Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions   PDF

ISAR-SMART 3, 2006   (NCT00146575)   sirolimus eluting stent versus paclitaxel eluting stent in Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMI   PDF

REALITY, 2006   (NCT00235092)   sirolimus eluting stent versus paclitaxel eluting stent in Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries   PDF

FAME (Rasmussen), 2006   extended prophylaxis versus standard prophylaxis in > 18 years, major abdominal surgery of >1 hour duration   PDF

RRISC, 2006   (NCT00263263)   sirolimus eluting stent versus bare-metal stent in Stable or unstable AP, with previous coronary artery bypass surgery and degenerated vein grafts   PDF

TYPHOON, 2006   (NCT00232830)   sirolimus eluting stent versus bare-metal stent in AMI   PDF

SCANDSTENT, 2006   (NCT00151658)   sirolimus eluting stent versus bare-metal stent in Stable or unstable AP, recent AMI (non ST-elevation); with one or more de novo complex lesions in native coronary vessels (occluded, bifurcational, ostial or angulated)   PDF

PRISON II, 2006   (NCT00258596)   sirolimus eluting stent versus bare-metal stent in Chronic total occlusion, positive exercise stress test   PDF

HAAMU-STENT, 2006   paclitaxel eluting stent versus bare-metal stent in AMI - STEMI patients undergoing PCI   PDF

Wojnicz, 2006   atorvastatin versus control in patients with inflammatory dilated cardiomyopathy (DC) (positive immunohistochemistry results on endomyocardial biopsy)   PDF

Sola, 2006   atorvastatin versus placebo in patients with nonischemic HF and a left ventricular ejection fraction (LVEF) <=35%   PDF

Moulin, 2006   benfluorex versus placebo in Type 2 diabetic patients with HbA1c between 7-10% with maximum tolerated sulfonylurea dose and with a contraindication to or poor tolerance of metformin   PDF

PASSION, 2006   (ISRCTN65027270)   paclitaxel eluting stent versus bare-metal stent in Myocardial Infarction with ST-Segment Elevation   PDF

FUTURE II, 2006   everolimus eluting stent versus bare-metal stent in Patients with de novo lesions in vessels with a reference diameter of 2.75-4.0 mm and length PDF

WEST, 2006   systematic PCI (+stent) versus no systematic PCI in STEMI patients (> 4 mm ST-elevation/deviation) within 6 h of symptom onse   PDF

Palazzuoli, 2006   beta-erythropoietin versus placebo in patients with anemia and resistant CHF   PDF

EORTC 24971 (TAX 323), 2006   (NCT00003888)   TPF versus PF in patients with stage III or IV unresectable locally advanced SCCHN   PDF

DEAR-MI, 2006   (NCT00257153)   Pronto versus conventional PCI in patients with STEMI, admitted within 12 h of symptom onset   PDF

De Luca, 2006   Diver versus conventional PCI in patients with anterior ST elevation myocardial infarction   PDF

Kaltoft, 2006   Rescue versus conventional PCI in patients with ST-segment-elevation myocardial infarction lasting <12 hours undergoing primary PCI   PDF

AiMI, 2006   AngioJet versus conventional PCI in patients presenting within 12 h of symptom onset   PDF

REVIVAL-2 (Zohlnhöfer ), 2006   (NCT00126100)   G-CSF versus placebo in patients with acute myocardial infarction after successful mechanical reperfusion reduces infarct size   PDF

STEMMI (Ripa), 2006   G-CSF versus placebo in patients with ST-elevation myocardial infarction   PDF

G-CSF-STEMI (Engelmann), 2006   G-CSF versus placebo in patients with late revascularized subacute STEMI   PDF

MAGIC Cell-3-DES (Kang), 2006   G-CSF versus control in patients with recent or old myocardial infarction who underwent coronary revascularization with DES   PDF

Ellis, 2006   (NCT00215124)   G-CSF versus placebo in patients with large acute myocardial infarction   PDF

TCT-STAMI (Ge), 2006   autologous bone marrow stem cells versus control in patients admitted within 24 h after the onset of a first AMI   PDF

Huang, 2006   autologous bone marrow stem cells versus control in patients with first onset of acute inferior-wall myocardial infarction aged < or = 75, treated with emergent percutaneous coronary intervention   PDF

Janssens, 2006   autologous bone marrow stem cells versus placebo in patienst with successful percutaneous coronary intervention for STEMI   PDF

MAGIC Cell-3-DES (Kang), 2006   autologous bone marrow stem cells versus control in patients with myocardial infarction who underwent coronary revascularization with DES for the culprit lesion   PDF

ASTAMi (Lunde), 2006   autologous bone marrow stem cells versus control in patients with acute ST-elevation myocardial infarction of the anterior wall treated with percutaneous coronary intervention   PDF

Meluzin LD, 2006   autologous bone marrow stem cells versus control in patients with a first acute myocardial infarction   PDF

Meluzin HD, 2006   autologous bone marrow stem cells versus control in patients with a first acute myocardial infarction   PDF

REPAIR-AMI (Schachinger), 2006   (NCT00279175)   autologous bone marrow stem cells versus placebo in patients with acute myocardial infarction   PDF

Suzuki, 2006   G-CSF versus control in patients with angina or AMI   PDF

Deng, 2006   G-CSF versus control in   PDF

Burkhoff, 2006   TandemHeart versus intra-aortic balloon pump in patents within 24 hours of developing cardiogenic shock   PDF

TOPCARE-CHD, 2006   ( NCT00289822)   Bone marrow mononuclear cells versus control in patients with stable ischemic heart disease who had had a myocardial infarction at least 3 months previously   PDF

Hendrikx, 2006   Bone marrow mononuclear cells versus control in patients with a postinfarction nonviable scar   PDF

MICHELANGELO OASIS-6, 2006   (NCT00064428)   fondaparinux versus placebo in patients with STEMI   PDF

EORTC 24971 (TAX 323), 2006   (NCT00003888)   TPF versus PF in patients with stage III or IV unresectable locally advanced SCCHN   PDF

SPARCL, 2006   (NCT00147602)   atorvastatin versus placebo in patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 2.6 to 4.9 mmol per liter, and had no known coronary heart disease   PDF

PROLONG (Palarati), 2006   (NCT00264277)   VKA versus control in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months and with abnormal D-dimer testing 1 month after the discontinuation of anticoagulation   PDF

FX140, Simonneau G, 2006   nadroparin versus enoxaparin in   PDF

ACTIVE W, 2006   (NCT00243178)   aspirin + clopidogrel versus anticoagulant in Patients with atrial fibrillation plus one or more risk factor for stroke   PDF

Gelfer, 2006   CECT + aspirin versus LMWH in patients who underwent total hip or knee arthroplasty   PDF

ARTEMIS (Cohen), 2006   fondaparinux versus placebo in High-risk medical patients   PDF

Lederle, 2006   Enoxaparin versus placebo in Hospitalization in general medical unit   PDF

Hull, 2006   extended tinzaparin versus standard treatment in patients with cancer (solid or hematological) with proximal DVT with or without PE and with a minimum life expectancy of 3 months imag   PDF

Deitcher, 2006   extended enoxaparin versus standard treatment in patients with cancer with DVT and/or PE   PDF

NORVIT (folic acid + B12) (Bonaa), 2006   (NCT00266487)   folic acid, B12 versus control in men and women who had had an acute myocardial infarction within seven days before   PDF

APAF (Pappone), 2006   catheter ablation versus control in Drug-refractory paroxysmal AF >=6mo   PDF

CHARISMA, 2006   (NCT00050817)   clopidogrel versus placebo (on top aspirin) in patients with either clinically evident cardiovascular disease or multiple risk factors   PDF

NORVIT (vit B6) (Bonaa), 2006   (NCT00266487)   vit B6 versus control in men and women who had had an acute myocardial infarction within seven days   PDF

NORVIT (folic acid, B12 and vit B6) (Bonaa), 2006   (NCT00266487)   folic acid, vit B12 and vit B6 versus control in men and women who had had an acute myocardial infarction within seven days   PDF

CAFCOAF (Stabile), 2006   catheter ablation versus control in Drug-refractory or drug-intolerant paroxysmal or persistent AF   PDF

Ozaydin, 2006   atorvastatin versus control in Persistent AF and scheduled EC   PDF

Dernellis, 2006   atorvastatin versus placebo in Paroxysmal AF with CRP between 0.8 and 13 mg/L   PDF

ARMYDA-3 (AF ancillary study), 2006   atorvastatin versus placebo in patients with scheduled cardiac surgery without history of AF   PDF

Chello, 2006   atorvastatin versus placebo in patients with scheduled coronary bypass surgery   PDF

Oral, 2006   catheter ablation versus control in patients with chronic atrial fibrillation   PDF

Lakkireddy, 2006   catheter ablation versus control in   PDF

Japanese AF Trial, 2006   aspirin versus control in patients with nonvalvular atrial fibrillation   PDF

MEGA, 2006   (NCT00211705)   pravastatin versus control in patients with hypercholesterolaemia (total cholesterol 5·69–6·98 mmol/L) and no history of coronary heart disease or stroke   PDF

ASPEN, 2006   atorvastatin versus placebo in subjects with type 2 diabetes and LDL cholesterol levels below contemporaryguideline targets   PDF

PROVE IT TIMI 22 (diabetic sub group), 2006   pravastatin high dose versus pravastatin in patients hospitalized for an acute coronary syndrome within the preceding 10 days   PDF

TNT (diabetic sub group), 2006   atorvastatin high dose versus atorvastatin in patients with stable coronary heart disease   PDF

ASPEN, 2006   atorvastatin versus placebo in patients s with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets   PDF

Tang, 2006   metformin versus placebo in Obesity with PCO   PDF

Srinivasan, 2006   metformin versus placebo in Children and adolescents with obesity and insulin resistance   PDF

Bridger, 2006   metformin versus placebo in Adolescents with PCOS and insulin resistance   PDF

Ristic, 2006   gliclazide versus nateglinide (add on MET) in   PDF

Garber, 2006   glibenclamide versus rosiglitazone (add on MET) in patients with type 2 diabetes inadequately controlled on metformin monotherapy   PDF

Ristic, 2006   nateglinide versus gliclazide (add on MET) in Patients with inadequate glucose control on maximal doses of metformin   PDF

OASIS 5, 2006   (NCT00139815)   fondaparinux versus enoxaparin in patients with acute coronary syndromes   PDF

INTERACT, 2006   enoxaparin versus UFH (on top of aspirin) in high-risk patients with ACS receiving aspirin and eptifibatide   PDF

Pratley, 2006   vildagliptin monotherapy versus placebo in   PDF

Mimori, 2006   vildagliptin versus placebo in   PDF

Rosenstock (sit on top pio vs pbo), 2006   (NCT00086502)   sitagliptin versus placebo (on top PIO) in   PDF

Charbonnel, 2006   (NCT0086515)   sitagliptin versus placebo (add on MET) in   PDF

ACUITY (biva alone vs hep+aGP2b3a), 2006   (NCT00093158)   bivalirudin versus heparin + GP2b3a inhibitors in in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy.   PDF

ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006   (NCT00093158)   bivalirudin + GP2b3a inhibitors versus heparin + GP2b3a inhibitors in in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy.   PDF

HOPE-2 (Lonn), 2006   (NCT00106886)   folic acid, vit B12 and vit B6 versus placebo in patients 55 years of age or older who had vascular disease or diabetes and additional risk factors for atherosclerosis   PDF

PROTECT-TIMI 30, 2006   (NCT00250471)   bivalirudin versus eptifibatide + heparin in non ST elevation ACS patients undergoing PCI   PDF

ACTIVATE, 2006   (NCT00185042)   pactimibe versus placebo in patients with angiographicallydocumented coronary disease   PDF

Raz, 2006   sitagliptin monotherapy versus placebo in patients with type 2 diabetes mellitus and inadequate glycaemic control   PDF

EAGAR, 2006   (NCT00000605)   combined estrogen and progestogen versus placebo in Postmenopausal women who had undergone coronary artery bypass graft   PDF

ASPEN (primary prevention sub group), 2006   atorvastatin versus placebo in subjects with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets; primary prevention subgroup   PDF

Aschner, 2006   (NCT00087516)   sitagliptin monotherapy versus placebo in patients with type 2 diabetes   PDF

RIO-North America 20 mg, 2006   (NCT00029861)   rimonabant 20mg versus placebo in obese (body mass index >=30) or overweight (body mass index >=27 and treated or untreated hypertension or dyslipidemia) adult patients   PDF

MEGA (women subgroup) , 2006   Pravastatin versus placebo in patients with hypercholesterolaemia (total cholesterol 5.69-6.98 mmol/L) and no history of coronary heart disease or stroke- subgroup of women   PDF

RIO-North America 5mg, 2006   versus in   PDF

RIO-North America (20mg vs 5mg), 2006   versus in   PDF

IDDP (Ramachandran), 2006   lifestyle modification + metformin versus control in native Asian Indians with impaired glucose tolerance   PDF

Eriksson, 2006   glipizide versus placebo in first-degree relatives of patients with type 2 diabetes fulfilling WHO criteria for IGT (WHO criteria in 2006)   PDF

ADOPT, 2006   (NCT00279045)   rosiglitazone versus standard glucose-lowering drugs in Recently diagnosed type type 2 diabetes   PDF

WHISP, 2006   combined estrogen and progestogen versus placebo in post-menopausal women >55 years were enrolled between 2 and 28 days after an acute coronary syndrome   PDF

DREAM rosiglitazone, 2006   (NCT00095654)   rosiglitazone versus placebo in patients with impaired fasting glucose or impaired glucose tolerance, or both   PDF

DREAM ramipril, 2006   (NCT00095654)   ramipril versus placebo in patients with impaired fasting glucose or impaired glucose tolerance, or both, and no previous cardiovascular disease   PDF

Chang, 2006   sodium reduction versus control in elderly veterans   PDF

ODIXa-HIP 10mg, 2006   rivaroxaban versus enoxaparin (short duration) in patients undergoing elective total hip replacement   PDF

ADOPT, 2006   (NCT00279045)   metformin versus glyburide in recently diagnosed type 2 diabetes   PDF

Ratain, 2006   sorafenib versus placebo in patients with metastatic renal cell carcinoma   PDF

CLARICOR, 2006   (NCT00121550)   clarithromycin versus placebo in patients with adischarge diagnosis of myocardial infarction or angina pectoris   PDF

ERICA, 2006   (NCT00091429)   ranolazine 1000mg + amlodipine versus placebo + amlodipine in patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d)   PDF

Sandler, 2006   bevacizumab versus platinum based CT in   PDF

ISEL, 2006   gefitinib versus placebo in patients of Asian origin with refractory advanced non-small cell lung cancer   PDF

SIGN (Cufer), 2006   gefitinib versus docetaxel in previously treated advanced nonsmall-cell lung cancer   PDF

Chen, 2006   paclitaxel + carboplatin versus paclitaxel + cisplatin in against chemo-naive inoperable non-small cell lung cancer in the elderly   PDF

Zhao, 2006   TMR+CABG versus CABG in patients with diffusely diseased target vessels   PDF

SPIRIT, 2006   spinal cord stimulation versus percutaneous myocardial laser revascularization in Subjects with Canadian Cardiovascular Society class 3/4 angina and reversible perfusion defects   PDF

Bedikian, 2006   Oblimersen + dacarbazine versus in   PDF

INSPIRE, 2006   balloon angioplasty versus medical treatment in Stable survivors of MI, total perfusion defect size 20%, ischemic defect size 10% (by adenosine SPECT), EF 35%t   PDF

Bedikian, 2006   oblimersen versus in Patients with unresectable MM (stage III and IV)   PDF

Kim, 2006   versus in   PDF

Gennari, 2006   maintenance versus control in   PDF

Gasparini, 2006   trastuzumab + paclitaxel versus paclitaxel alone in patients with advanced breast cancer overexpressing HER-2.   PDF

Beex, 2006   intermittent tamoxifen versus Intermittent tamoxifen in first line endocrine treatment in advanced breast   PDF

Cice et al, 2006   telmisartan versus placebo in   PDF

Takahashi et al, 2006   candesartan versus usual care in chronic haemodialysis patients   PDF

Zannad et al, 2006   fosinopril versus placebo in chronic hemodialysis patients.   PDF

Khoo , 2006   split dose versus Every three weeks Paclitaxel in Metastatic patients with metastatic breast cancer (MBC) who had previously received anthracyclines   PDF

Frasci , 2006   Weekly Paclitaxel versus Every three weeks Paclitaxel in LABC   PDF

TROPHY, 2006   (NCT00227318)   candesartan versus placebo in subjects with repeated measurements of systolic pressure of 130 to 139 mm Hg and diastolic pressure of 89 mm Hg or lower, or systolic pressure of 139 mm Hg or lower and diastolic pressure of 85 to 89 mm Hg   PDF

Takahashi, 2006   candesartan versus control in patients on chronic haemodialysis in stable condition and with no clinical evidence of cardiac disorders   PDF

INITIATIVE (Tardif) 15mg, 2005   ivabradine versus atenolol in patients with stable angina   PDF

Leaf, 2005   fish oil versus placebo in   PDF

Gorski (LMWH vs hep spraygel), 2005   LMWH versus heparin spraygel in   PDF

Vesalio, 2005   nadroparin fixed-dose versus nadroparin weight-adjusted in patients with superficial vein thrombosis of the great saphenous vein with the thrombosis extending up to 3 cm from the sapheno-femoral junction   PDF

Gorski, 2005   heparin spraygel versus clexane in patients with symptomatic superficial venous thrombosis confirmed by ultrasonography with first symptoms not earlier than 72 hours   PDF

OUTCLAS , 2005   radial versus femoral in Outpatients referred for PCI   PDF

Achenbach , 2005   radial versus femoral in Patients age >75 undergoing coronary angiography   PDF

RADIAL AMI , 2005   radial versus femoral in Patients with STEMI for primary or rescue PCI   PDF

JUMBO-TIMI 26, 2005   prasugrel versus clopidogrel in patients undergoing elective or urgent percutaneous coronary intervention   PDF

Gaudino (RITA), 2005   right internal thoracic artery grafts versus saphenous vein grafts in coronary artery bypass patients with previous in-stent restenosis (n=60) or not (n=60)   PDF

PREVENT IV, 2005   (NCT00042081)   edifoligide pretreatment versus placebo in patients undergoing isolated CABG surgery with at least two vein grafts   PDF

Kobayashi, 2005   off-pump versus on-pump in patients referred for elective primary CABG   PDF

Ascionee, 2005   off-pump versus on-pump in patient undergoing CABG   PDF

Gaudino (radial A), 2005   radial artery grafts versus saphenous vein grafts in coronary artery bypass patients with previous in-stent restenosis (n=60) or not (n=60)   PDF

COMMIT, 2005   (NCT00222573)   clopidogrel versus placebo in patients admitted to hospital within 24 h of suspected acute MI onset   PDF

TINOX, 2005   titanium-nitride-oxide coated stent versus bare-metal stent in   PDF

EUROINJECT-ONE (Gyöngyösi), 2005   gene therapy versus placebo in patients with chronic myocardial ischemia   PDF

Agostoni, 2005   spironolactone versus placebo in stable chronic heart failure patients with reduced influences lung diffusion (DLCO)   PDF

Silva et al, 2005   late PTCA versus no PTCA in patients with occluded infarct-related artery between 12 h and 14 days post-anterior MI were   PDF

SENIORS, 2005   nebivolol versus placebo in patients aged
70 years with a history of heart failure (hospital admission for heart failure within the previous year or known ejection fraction 35%),   PDF

Krljanac, 2005   GIK infusion versus control in patients with ST-elevation myocardial infarction within 12 hours from symptom onset   PDF

CARE-HF, 2005   CRT versus no CRT in patients with NYHA class III or IV heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony   PDF

ISAR-DESIRE (PES vs PTCA), 2005   paclitaxel eluting stent versus balloon angioplasty in In-stent restenosis. AP and/or positive test, previously stented, no AMI   PDF

ISAR-DESIRE (SES vs PTCA), 2005   sirolimus eluting stent versus balloon angioplasty in In-stent restenosis. AP and/or positive test, previously stented, no AMI   PDF

INTAMI (Zeymer), 2005   Eptifibatide versus primary intervention in symptom duration <12h   PDF

ADVANCE-MI, 2005   Eptifibatide + tenecteplase versus primary intervention in symptom duration <4h   PDF

SIRTAX diabetics, 2005   (NCT00297661)   sirolimus eluting stent versus paclitaxel eluting stent in Sub groups of diabetics patients with either stable angina or an acute coronary syndrome   PDF

SIRTAX (small vessels subgroup), 2005   sirolimus eluting stent versus paclitaxel eluting stent in Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation   PDF

CREATE, 2005   Reviparin versus placebo in patients with acute myocardial infarction, STEMI or new LBBB, <=12 h   PDF

SPIRIT I, 2005   (NCT00180453)   everolimus eluting stent versus bare-metal stent in patients with de novo native coronary artery lesions   PDF

TAXUS VI (diabetics), 2005   (NCT00297804)   paclitaxel eluting stent versus bare-metal stent in Diabetic patients with stable or unstable AP, silent ischaemia with long, complex coronary artery lesions   PDF

TAXUS V (diabetics), 2005   paclitaxel eluting stent versus bare-metal stent in Diabetic patients with stable or unstable AP, silent ischaemia with complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)   PDF

TAXUS IV (diabetics), 2005   (NCT00292474)   paclitaxel eluting stent versus bare-metal stent in Diabetic patients with stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)   PDF

SES-SMARt (diabetics), 2005   sirolimus eluting stent versus bare-metal stent in Diabetic patients with de novo target lesion <=2.75 mm in diameter in a native coronary artery that could be completely covered by a single stent (maximum length 33 mm)   PDF

Strey, 2005   atorvastatin versus placebo in patients with stable, symptomatic heart failure (New York Heart Association Class II or III) and a left ventricular ejection fraction <40%   PDF

Hong, 2005   simvastatin versus control in patients with ischemic heart failure who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (left ventricular [LV] ejection fraction <40%)   PDF

Landmesser, 2005   simvastatin versus ezetimibe in patients with chronic heart failure   PDF

Di Lorenzo et al., 2005   sirolimus eluting stent versus paclitaxel eluting stent in ST-segment elevation myocardial infarction   PDF

BASKET (vs paclitaxel), 2005   sirolimus eluting stent versus paclitaxel eluting stent in Unselected patients; de-novo lesions   PDF

REACT (rescue PCI), 2005   rescue PTCA versus no rescue PTCA in patients with ST-segment elevation myocardial infarction and failed reperfusion (less than 50 percent ST-segment resolution) within 90 minutes after thrombolytic treatment   PDF

REACT (repeat fibrinolysis), 2005   repeat fibrinolysis versus no repeat fibrinolysis in patients with ST-segment elevation myocardial infarction and failed reperfusion (less than 50 percent ST-segment resolution) within 90 minutes after thrombolytic treatment   PDF

CORPAL, 2005   sirolimus eluting stent versus paclitaxel eluting stent in Documented myocardial ischaemia, no AMI   PDF

SIRTAX (Windecker), 2005   sirolimus eluting stent versus paclitaxel eluting stent in Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation   PDF

ISAR-DIABETES, 2005   sirolimus eluting stent versus paclitaxel eluting stent in Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel­   PDF

ISAR-DESIRE (SES vs PES), 2005   sirolimus eluting stent versus paclitaxel eluting stent in In-stent restenosis. AP and/or positive test, previously stented, no AMI   PDF

TAXi, 2005   sirolimus eluting stent versus paclitaxel eluting stent in Unselected patients   PDF

SCD-HeFT (ICD vs placebo), 2005   (NCT00000609)   ICD versus no ICD in patients with ischemic and nonischemic cardiomyopathy withEF<=0.35   PDF

DECODE, 2005   (NCT00489164)   sirolimus eluting stent versus bare-metal stent in Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels   PDF

SCD-HeFT (ICD vs amiodarone), 2005   (NCT00000609)   ICD versus no ICD in patients with ischemic and nonischemic cardiomyopathy withEF<=0.35   PDF

PEGASUS, 2005   fondaparinux versus enoxaparin in patients undergoing major abdominal surgery   PDF

CIBIS III, 2005   bisoprolol versus enalapril in patients with mild to moderate CHF and left ventricular ejection fraction <=35%   PDF

Pache et al, 2005   sirolimus eluting stent versus bare-metal stent in with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels   PDF

DIABETES, 2005   sirolimus eluting stent versus bare-metal stent in de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm   PDF

TAXUS VI, 2005   (NCT00297804)   paclitaxel eluting stent versus bare-metal stent in Stable or unstable AP, silent ischaemia with long, complex coronary artery lesions   PDF

TAXUS V (all patients), 2005   (NCT00301522)   paclitaxel eluting stent versus bare-metal stent in Stable or unstable AP, silent ischaemia with single coronary artery stenosis including complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)   PDF

CAPITAL AMI, 2005   thrombolysis + angioplasty versus immediate thrombolysis in high-risk MI patients within six hours of symptom onset   PDF

CAPITAL AMI, 2005   systematic PCI (+stent) versus no systematic PCI in patients with high-risk ST-segment elevation myocardial infarction   PDF

ZWOLLE 6, 2005   primary stenting versus balloon angioplasty in unselected patients with STEMI   PDF

Hitt (PF), 2005   PF versus no induction chemotherapy in patients with locally advanced, unresectable SCCHN   PDF

Hitt docetaxel, 2005   TPF versus PF in patients with locally advanced, unresectable SCCHN   PDF

ESCAPE, 2005   pulmonary artery catheter versus control in patients hospitalized with severe symptomatic and recurrent heart failure   PDF

Fonseca, 2005   TP versus PF in patients chemotherapy-naïve with locally advanced resectable and non-resectable SCCHN   PDF

Fonseca, 2005   TP versus PF in patients chemotherapy-naïve with locally advanced resectable and non-resectable SCCHN   PDF

Hitt paclitaxel, 2005   paclitaxel based CT versus PF in locally advanced head and neck cancer   PDF

REMEDIA, 2005   Diver versus conventional PCI in patients with ST-segment elevation acute myocardial infarction   PDF

Noel, 2005   Export versus conventional PCI in patients with acute myocardial infarction   PDF

EXPIRA, 2005   Export versus conventional PCI in patients with acute myocardial infarction   PDF

Sardella, 2005   Diver versus conventional PCI in patients with acute myocardial infarction   PDF

X AMINE ST, 2005   X-sizer versus conventional PCI in patients with AMI <12 h and initial TIMI flow grade 0 to 1 and who were treated by PCI   PDF

PROMISE, 2005   FilterWire versus conventional PCI in patients with myocardial infarction with and without ST-segment elevation   PDF

EMERALD, 2005   GuardWire versus conventional PCI in patients with ST-segment elevation myocardial infarction presenting within 6 hours of symptom onset and undergoing primary PCI or rescue intervention after failed thrombolysis   PDF

FIRSTLINE-AMI (Ince), 2005   G-CSF versus control in patients with ST-elevation myocardial infarction undergoing primary PCI with stenting and abciximab   PDF

Valgimigli, 2005   G-CSF versus placebo in patients with STEMI   PDF

senior PAMI, 2005   (NCT00136929)   primary PCI versus Thrombolysis in elderly (age >= 70 years) patients with acute myocardial infarction   PDF

Karpov, 2005   autologous bone marrow stem cells versus control in patients with acute myocardial infarction.   PDF

Ruan, 2005   autologous bone marrow stem cells versus control in with acute myocardial infarction and anterior descending coronary artery occlusion proven by angiography   PDF

REACT (rescue PCI vs repeat fibrinolysis), 2005   rescue PTCA versus repeat fibrinolysis in patients with ST-segment elevation myocardial infarction and failed reperfusion (less than 50 percent ST-segment resolution) within 90 minutes after thrombolytic treatment   PDF

Thiele, 2005   TandemHeart versus intra-aortic balloon pump in patients in cardiogenic shock following acute myocardial infarction   PDF

CAuSMIC, 2005   myoblasts versus control in patients with previous myocardial infarction and heart failure, New York Heart Association (NYHA) functional class II to IV   PDF

Patel, 2005   Bone marrow progenitor cells versus control in patients with ischemic cardiomyopathy and an ejection fraction of less than 35% who were scheduled for primary off-pump coronary artery bypass grafting   PDF

CLARITY-TIMI 28, 2005   clopidogrel versus placebo in patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction   PDF

Prévost, 2005   VP16 based CT versus PF in patient with unresectable advanced head and neck cancer   PDF

EVAR trial 1, 2005   (ISRCTN55703451)   endovascular repair versus open repair in aneurysms of at least 5·5 cm in diameter   PDF

EVAR trial 2, 2005   (ISRCTN55703451)   endovascular repair versus surveillance in patients aged 60 years or older who had aneurysms of at least5·5 cm in diameter and of poor health status considered unfit for major surgery.   PDF

DREAM, 2005   (NCT00421330)   endovascular repair versus open repair in abdominal aortic aneurysm of at least 5 cm in diameter and who were considered suitable candidates for both techniques.   PDF

SPORTIF V, 2005   ximelagatran versus warfarin standard dose in One or more stroke risk factor in addition to atrial fibrillation.High risk patients with non valvular atrial fibrillation.   PDF

Mahe, 2005   Nadroparin versus placebo in Congestive heart failure (NYHA III–IV), acute or respiratory disease, nonpulmonary sepsis, cancer   PDF

FIELD, 2005   (ISRCTN64783481)   fenofibrate versus placebo in participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry   PDF

Fiessinger , 2005   ximelagatran versus LMWH/VKA in patients with acute deep vein thrombosis   PDF

Daskalopoulos, 2005   LMWH at home versus UFH in hospital in patients with acute proximal DVT confirmed by colour duplex UScan not more than 1 week onset   PDF

Chong, 2005   LMWH at home versus UFH in hospital in patients with diagnosis of symptomatic lower extrimity DVT (proimal or distal) confirmed by either contrast venography and/or ultrasonography, be suitable for treatment in an outpatient setting   PDF

SAFE-T (amiodarone vs placebo), 2005   amiodarone versus placebo in Persistent AF lasting 3 days to 1 year   PDF

Wells (subgroup), 2005   tinzaparin versus dalteparin in study subgroup of patients with cancer treated for upper or lower extremity DVT or PE in the outpatient setting   PDF

SAFE-T (sotalol vs placebo), 2005   sotalol versus placebo in Persistent AF lasting 3 days to 1 year   PDF

Deutsche Diabetes Dialyse Studie (4D), 2005   atorvastatin versus placebo in patients with type 2 diabetes mellitus on maintenance hemodialysis   PDF

SAFE-T (amiodarone vs sotalol), 2005   amiodarone versus sotalol in Persistent AF lasting 3 days to 1 year   PDF

Wazni , 2005   catheter ablation versus control in Drug-naive monthly symptomatic AF >=3mo   PDF

WHI low fat, 2005   (NCT00000611)   diet versus usual diet in postmenopausal women, aged 50 to 79 years, without prior breast cancer   PDF

TNT, 2005   (NCT00327691)   atorvastatin high dose versus atorvastatin in Chronic coronary artery disease LDL cholesterol < 3.4 mmol/L   PDF

IDEAL, 2005   (NCT00159835)   atorvastatin high dose versus simvastatin in Men and women aged 80 years or younger with a history of a definite myocardial infarction and who qualified for statin therapy according to national guidelines   PDF

Women’s Health Study, 2005   aspirin versus placebo in initially healthy women 45 years of age or older   PDF

Vascular basis, 2005   atorvastatin high dose versus lovastatin in Chronic coronary artery disease   PDF

FIELD, 2005   (ISRCTN64783481)   fenofibrate versus placebo in aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry   PDF

SYNERGY, 2005   (NCT00043784)   enoxaparin versus UFH (on top of aspirin) in high-risk patients with acute coronary syndromes   PDF

Kendall 10µg/d, 2005   (NCT00035984)   exenatide 10µg/d versus placebo (add on SU+MET) in patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy   PDF

DeFronzo 20µg/d, 2005   (NCT00039013)   exenatide 20µg/d versus placebo (add on MET) in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses   PDF

Mari, 2005   nateglinide versus placebo in mild type 2 diabetic men and women (fasting glucose 7.0-8.3 mmol/l) on diet treatment   PDF

Inukai, 2005   glimepiride versus gliclazide or glibenclamide in Japanese type 2 diabetic patients (HbA1C > or = 7.0%), maintained on a conventional SU   PDF

Vitale, 2005   metformin versus placebo in Metabolic syndrome   PDF

Stakos, 2005   metformin versus placebo in African-Americans with insulin resistance and family history of diabetes   PDF

Orchard, 2005   metformin versus placebo in Impaired glucose tolerance   PDF

James, 2005   metformin versus control in Abdominal obesity with insulin resistance[   PDF

Matthews, 2005   gliclazide versus pioglitazone (add on MET) in Patients with poorly controlled type 2 diabetes   PDF

Feinglos, 2005   glipizide GITS versus placebo (add on MET) in type 2 diabetes inadequately controlled (A1c 7-8.5%) on metformin (> or =1000 mg/day for > or =3 months)   PDF

EVET, 2005   enoxaparin versus tinzaparin in patients with non-ST-segment elevation acute coronary syndromes   PDF

Kendall 20µg/d, 2005   (NCT00035984)   exenatide 20µg/d versus placebo (add on SU+MET) in patients with type 2 diabetes unable to achieve glycemic control with metformin-sulfonylurea combination therapy   PDF

DeFronzo 10µg/d, 2005   (NCT00039013)   exenatide 10µg/d versus placebo (add on MET) in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses   PDF

Heine, 2005   exenatide 20µg/d versus insulin (add on SU+MET) in   PDF

NQWMI (Eisenberg), 2005   routine invasive strategy versus concervative strategy in patients with non–Q-wave myocardial infarction   PDF

Feinglos, 2005   liraglutide other doses versus metformin in subjects with Type 2 diabetes   PDF

Ristic, 2005   vildagliptin monotherapy versus placebo in   PDF

HYRIM, 2005   fluvastatin versus placebo in drug-treated hypertensive men aged 40-74 years with total cholesterol 4.5-8.0 mmol/L, triglycerides <4.5 mmol/L, body mass index 25-35 kg/m2, and a sedentary lifestyle   PDF

PROactive, 2005   (NCT00174993)   glitazone versus conventional treatment in patients with type 2 diabetes who had evidence of macrovascular disease   PDF

Ukholkina, 2005   oxygen therapy versus control in patients with acute myocardial infarction   PDF

JDPP (Sakane), 2005   lifestyle modification versus control in patients with impaired glucose tolerance (WHO 1999 criteria)   PDF

WHS (diabetics sub group), 2005   aspirin versus placebo in healthy women 45 years of age or older - diabetics sub groups   PDF

Kosaka, 2005   lifestyle modification versus control in men with impaired glucose tolerance (WHO criteria 1980)   PDF

SUVIMAX, 2005   combination versus placebo in women aged 35-60 years and men aged 45-60 years   PDF

US DDP troglitazone (Knowler), 2005   troglitazone versus placebo in nondiabetic patients with elevated glucose and high risk for diabetes   PDF

WHS vitamin E, 2005   (NCT00000479)   vitamin E versus placebo in apparently healthy US women aged at least 45 years   PDF

RIO europe 20mg, 2005   rimonabant 20mg versus placebo in patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or bothtž-dt   PDF

Rio-lipid 20 mg, 2005   rimonabant 20mg versus placebo in overweight or obese patients (body-mass index 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men)   PDF

RIO europe 5mg, 2005   rimonabant 5mg versus placebo in patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or both   PDF

RIO europe (20 vs 5 mg), 2005   rimonabant 20mg versus rimonabant 5mg in   PDF

Wang, 2005   rosiglitazone versus control in patients with diabetes and CAD who had undergone percutaneous coronary intervention   PDF

PROactive, 2005   (NCT00174993)   pioglitazone versus placebo in Inadequately controlled patients with type 2 diabetes who had evidence of macrovascular disease   PDF

ODIXa-KNEE, 2005   rivaroxaban versus enoxaparin (US regimen) in patients undergoing elective total knee replacement   PDF

ACES, 2005   (NCT00000617)   Azithromycin versus placebo in Patients with stable CAD   PDF

PROVE-IT, 2005   Gatifloxacin versus placebo in Patients hospitalized with ACS in the preceding 10 d   PDF

ACTION, 2005   nifedipine SR versus placebo (on top standard treatment) in patients with treated stable symptomatic coronary disease   PDF

Rousseau, 2005   2) atenolol 100mg versus placebo in   PDF

Tsuboi, 2005   gefitinib versus placebo in patients with completely resected non-small cell lung cancer   PDF

Krempf, 2005   Orlistat versus placebo in otherwise healthy, overweight patients aged 18-65 y (BMI >or=28 kg/m2   PDF

Hong, 2005   PCI withdrug-eluting stents versus CABG in proximal left anterior descending (LAD) coronary artery stenosis   PDF

Kim, 2005   stent versus MIDCAB in patients with isolated proximal left anterior descending artery disease   PDF

Leon (high dose), 2005   TMR versus placebo in patients with severe angina   PDF

Lanza, 2005   spinal cord stimulation versus no spinal cord stimulation in patients with cardiac syndrome X   PDF

EORTC18952 (Eggermont), 2005   ID IFN alpha-2b (I M) versus observation in patients who had had a thick primary tumour (thickness4 mm) resected (stage IIb) or regional lymph node metastases dissected (stage III)   PDF

RAN080, 2005   ranolazine 1000mg versus placebo in patients who had symptom-limited exercise   PDF

Leon (low dose), 2005   TMR versus placebo in patients with severe angina   PDF

INITIATIVE (CL3-017, Tardif) 20mg, 2005   ivabradine 20mg versus atenolol in patients with stable angina   PDF

INITIATIVE (Tardif) 20mg, 2005   ivabradine versus atenolol in patients with stable angina   PDF

INITIATIVE (CL3-017, Tardif) 15mg, 2005   ivabradine 15mg versus atenolol in patients with stable angina   PDF

RAN080 (vs atenolol), 2005   ranolazine 1000mg versus atenolol in patients who had symptom-limited exercise   PDF

JCOG, 2005   docetaxel versus doxorubicin + cyclophosphamide in first-line chemotherapy in metastatic breast cancer   PDF

CECOG BM1, 2005   gemcitabine, epirubicin, paclitaxel versus fluorouracil, epirubicin, cyclophosphamide in first-line chemotherapy in metastatic breast cancer   PDF

Marty, 2005   (M77001)   trastuzumab + docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment   PDF

ASCOT-BPLA, 2005   amlodipine versus atenolol in patients with hypertension who were aged 40–79 years and had at least three other cardiovascular risk factors.ÿ   PDF

Bontenbal, 2005   docetaxel + doxorubicin versus fluorouracil, doxorubicin, cyclophosphamide in first-line chemotherapy in patients with metastatic breast cancer:   PDF

TOG, 2005   paclitaxel versus cisplatin, etoposide in   PDF

Feher, 2005   gemcitabine versus epirubicin in   PDF

Verma, 2005   capecitabine + docetaxel versus docetaxel alone in patients with anthracycline-pretreated metastatic breast carcinoma   PDF

Burstein, 2005   bevacizumab + methotrexate versus methotrexate in   PDF

AVF2119g (Miller) cape, 2005   bevacizumab + capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane   PDF

Frasci , 2005   Weekly Paclitaxel versus Every three weeks Paclitaxel in Metastatic   PDF

REIN-2, 2005   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in patients with non-diabetic proteinuric nephropathies receiving background treatment with the ACE inhibitor ramipril   PDF

Schmid, 2005   high-dose chemotherapy versus conventional-dose chemotherapy in   PDF

E-COST, 2005   candesartan versus conventional treatment in Japanese essential hypertensive subjects (sitting blood pressure 140-180/90-110 mmHg) aged 35-79 years   PDF

E-COST-R, 2005   candesartan versus conventional treatment in hypertensive subjects 60 to 75 years old with non-diabetic chronic renal insufficiency   PDF

SALTIRE, 2005   atorvastatin versus placebo in patients with calcific aortic stenosis   PDF

EUROPA (PERSUADE substudy), 2005   perindopril versus placebo in patients with known coronary artery disease and without heart failure, sub group of diabetic patients   PDF

MERIT-HF, 2005   metoprolol versus placebo in patients with CHF NYHA classe 2 to 4 and EF<=40% sub group of diabetic patients   PDF

Lacut, 2005   IPC + GCS versus GCS in patients with a documented intracerebral hemorrhage   PDF

Jacobs, 2005   compressions first versus defibrillation first in   PDF

PAD (Hallstrom), 2004   Automatic External Defibrillation versus Cardiopulmonary Resuscitation in   PDF

Wenzel, 2004   vasopressin versus epinephrine in adults who had had an out-of-hospital cardiac arrest   PDF

TICA, 2004   tenecteplase versus placebo in All victims of out of hospital cardiac arrest   PDF

CARMEN (carvedilol alone), 2004   carvedilol versus enalapril in patients with mild heart failure   PDF

SAPPHIRE (yadav), 2004   carotid artery stenting versus surgery in patients with coexisting conditions that potentially increased the risk posed by endarterectomy and who had either a symptomatic carotid-artery stenosis of at least 50 percent of the luminal diameter or an asymptomatic stenosis of at least 80 percent   PDF

Kentucky B (Brooks), 2004   carotid artery stenting versus surgery in patients with asymptomatic carotid stenosis of more than 80% were selected   PDF

ALIVE, 2004   azimilide versus placebo in post-MI patients with depressed LVF   PDF

Vazquez-Rodriguez, 2004   radial versus femoral in   PDF

Reddy , 2004   radial versus femoral in Diagnostic coronary angiography   PDF

OCTOPLUS , 2004   radial versus femoral in Patients age >80 undergoing coronary angiography or PCI   PDF

REPLACE-1, 2004   bivalirudin versus UFH in patients undergoing elective or urgent revascularization   PDF

Briguori, 2004   various statins versus placebo in   PDF

ARMYDA, 2004   atorvastatin versus placebo in Patients scheduled for elective PCI   PDF

Wan, 2004   off-pump versus on-pump in   PDF

Syed, 2004   off-pump versus on-pump in   PDF

Puskas, 2004   off-pump versus on-pump in   PDF

Gasz, 2004   off-pump versus on-pump in   PDF

Dorman, 2004   off-pump versus on-pump in   PDF

Selvanayagam, 2004   off-pump versus on-pump in patients undergoing multivessel CABG   PDF

Motallebzadeh, 2004   off-pump versus on-pump in patients admitted for CABG   PDF

Legare, 2004   (NCT00216957)   off-pump versus on-pump in patients undergoing CABG   PDF

Khan, 2004   off-pump versus on-pump in patient undergoing CABG   PDF

Alwan, 2004   off-pump versus on-pump in patients undergoing CABG   PDF

PRAGUE 4 (Widimsky), 2004   off-pump versus on-pump in cardiac surgery candidates   PDF

RAPS (Desai), 2004   (NCT00187356)   radial artery grafts versus saphenous vein grafts in patients undergoing bypass of the anterior circulation   PDF

Pan, 2004   double stenting with SES versus single stenting in patients with true coronary bifurcation lesions   PDF

Colombo, 2004   double stenting with SES versus single stenting in patients with coronary bifurcation lesions   PDF

Mottram, 2004   spironolactone versus placebo in hypertensive patients with diastolic heart failure   PDF

Macdonald, 2004   spironolactone versus placebo in patients with New York Heart Association class I-II congestive heart failure taking optimal treatment (including beta blockers)   PDF

DECOPI, 2004   late PTCA versus no PTCA in patients with a first Q-wave myocardial infarction and an occluded infarct vessel   PDF

Cicoira, 2004   spironolactone versus control in chronic heart failure patients   PDF

Zibaeenezhad, 2004   warfarin versus control (on top of aspirin) in Acute MI   PDF

WASH (warfarin), 2004   warfarin versus no treatment in patients with heart failure and left ventricular systolic dysfunction requiring diuretic therapy with LVEF<=35%   PDF

COMPANION (CRT vs MT), 2004   CRT versus no CRT in patients with advanced heart failure (NYHA III or IV) due to ischemic and non-ischemic cardiomyopathy with EF <=35% and QRS duration >120 ms   PDF

GRACIA (Fernandez-Aviles,), 2004   tenecteplase versus primary intervention in symptom duration <12h   PDF

On-Time (van’t Hof), 2004   Tirofiban versus primary intervention in symptom duration <6h   PDF

ReoPro-BRIDGING (Gyongyosi), 2004   Abciximab versus primary intervention in symptom duration <6h   PDF

BRAVE (Kastrati), 2004   Abciximab + reteplase versus primary intervention in symptom duration <12h   PDF

LoWASA, 2004   warfarin versus control (on top of aspirin) in AMI   PDF

DETAIL, 2004   Telmisartan versus Enalapril in pateintspatients with type 2 diabetes and early nephropathy   PDF

WASH (aspirin), 2004   aspirin versus no treatment in patients with heart failure and left ventricular systolic dysfunction requiring diuretic therapy with LVEF<=35%   PDF

Nakashima, 2004   magnesium versus placebo in patients with successful PCI weree, imag   PDF

Ravel (diabetics), 2004   sirolimus eluting stent versus bare-metal stent in sub groups of diabetic patients with de novo native coronary arterylesions 2.5 to 3.5 mm in diameter by visualassessment that could be covered by an 18-mm stent   PDF

Laufs, 2004   cerivastatin versus placebo in patients with heart failure NYHA II-III caused by non-ischemic dilated cardiomyopathy   PDF

Howard, 2004   Knee length GCS versus Thigh length GCS in Breast surgery, oncology, ENT, urology, vascular, neurosurgery. And gastrointestinal surgery   PDF

MERLIN, 2004   rescue PTCA versus no rescue PTCA in patients with STEMI and failed fibrinolysis   PDF

ExTraMATCH, 2004   Exercise training versus control in   PDF

MIRACLE-ICD-II, 2004   Combined CRT + ICD versus ICD alone in NYHA class II heart failure patients on optimal medical therapy with a left ventricular (LV) ejection fraction <=35%, a QRS >=130 ms, and a class I indication for an ICD   PDF

DEFINITE, 2004   ICD versus no ICD in patients with non ischemic cardiomyopathy with EF <0.36 and Nonsustained ventricular tachycardia or frequent premature ventricular complexes   PDF

COMPANION (CRT+ICD vs MT), 2004   Combined CRT + ICD versus no CRT no ICD in patients with advanced heart failure (NYHA III or IV) due to ischemic and non-ischemic cardiomyopathy with EF <=0.35 and QRS duration >120 ms   PDF

COMPANION (CRT+ICD vs CRT), 2004   Combined CRT + ICD versus CRT in patients with advanced heart failure (NYHA III or IV) due to ischemic and non-ischemic cardiomyopathy with EF <=0.35 and QRS duration >120 ms   PDF

Kurtoglu, 2004   IPC versus LMWH in head/spinal traumatized patients   PDF

DINAMIT, 2004   ICD versus no ICD in patients within 6–40 days of myocardial infarct ischemic with EF<=0.35 and cardiac autonomic modulation (depressed heart rate variability or increased mean 24-hour heart rate)   PDF

SES-SMART, 2004   sirolimus eluting stent versus bare-metal stent in Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test   PDF

FUTURE I, 2004   everolimus eluting stent versus bare-metal stent in de novo coronary lesions   PDF

ACTION, 2004   dactinomycin eluting stent versus bare-metal stent in Patients with stable angina pectoris orsilent ischemia and a single de novo lesion in a nativecoronary artery >=3.0 mm and <=4.0 mm in diameter thatcould be covered by an 18-mm stent   PDF

SCORE, 2004   paclitaxel eluting stent versus bare-metal stent in patients with focal, de novo coronary lesions   PDF

DELIVER, 2004   paclitaxel, non-polymeric eluting stent versus bare-metal stent in patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels   PDF

ELUTES, 2004   paclitaxel, non-polymeric eluting stent versus bare-metal stent in single de novo type A or type B1 lesions 15 mm length in a nativecoronary artery   PDF

TAXUS IV, 2004   (NCT00292474)   paclitaxel eluting stent versus bare-metal stent in Stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)   PDF

GRACIA-1, 2004   systematic PCI (+stent) versus no systematic PCI in patients with thrombolysed STEMI (with recombinant tissue plasminogen activator)   PDF

C-SIRIUS, 2004   (NCT00381420)   sirolimus eluting stent versus bare-metal stent in Stable or unstable AP, silent ischaemia   PDF

FUSION 1, 2004   (NCT00270361)   nesiritide versus standard care in outpatient with co-morbid advanced heart failure and renal insufficiency   PDF

MERLIN (Sutton), 2004   immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with STEMI and failed fibrinolysis   PDF

STOPAMI 3, 2004   primary stenting versus balloon angioplasty in patients with AMI ineligible for thrombolysis (lack of ST-segment elevation on the electrocardiogram, late presentation >12 h after symptom onset, and contraindications to thrombolysis)   PDF

STOPAMI 4, 2004   versus balloon angioplasty in patients with AMI referred for failed thrombolysis performed within the previous 24 h   PDF

Dudek, 2004   Rescue versus conventional PCI in patient with acute myocardial infarction with ST segment elevation   PDF

PIHRATE, 2004   Diver versus conventional PCI in patients with acute myocardial infarction   PDF

VAMPIRE, 2004   TVAC versus conventional PCI in patients with acute myocardial infarction   PDF

NONSTOP, 2004   Rescue versus conventional PCI in patients with acute myocardial infarction   PDF

Florence, 2004   AngioJet versus conventional PCI in patients with a first acute myocardial infarction   PDF

DIPLOMATE, 2004   Angioguard versus conventional PCI in patients with acute myocardial infarction   PDF

MAGIC (G-CSF) (Kang), 2004   G-CSF versus control in patients with myocardial infarction who underwent coronary stenting for the culprit lesion of infarction   PDF

MAGIC (cell infusion ), 2004   autologous bone marrow stem cells versus control in patients with myocardial infarction who underwent coronary stenting for the culprit lesion of infarction   PDF

BOOSt (Meyer), 2004   autologous bone marrow stem cells versus control in successful percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction   PDF

Nanasato, 2004   Guardwire versus conventional PCI in patients with acute myocardial infarction   PDF

Chen, 2004   autologous bone marrow stem cells versus control in   PDF

Tishler, 2004   a versus a in Patients atteints d'arthrose du genou   PDF

Sterner-Victorin, 2004   a versus a in Patients atteints d'arthrose de la hanche   PDF

HPS (post troke sub group), 2004   simvastatin versus placebo in adults with cerebrovascular disease, total cholesterol >=3·5 mmol/L and without coronaro disease (n=1820)   PDF

Western Australia Study, 2004   Screening versus non screening in   PDF

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004   triflusal+coumadin medium dose versus coumadin standard dose in Non valvular atrial fibrillation. Intermediate risk patients.   PDF

NASPEAF (triflusal vs coumadin standard dose)), 2004   triflusal versus coumadin standard dose in Non valvular atrial fibrillation. Intermediate risk patients.   PDF

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004   triflusal+coumadin medium dose versus triflusal in Non valvular atrial fibrillation. Intermediate risk patients   PDF

Hot cafe, 2004   electrical cardioversion versus rate control in patients with persistent atrial fibrillation   PDF

Channer, 2004   amiodarone versus placebo in patients with Persistent AF   PDF

REVERSAL, 2004   atorvastatin high dose versus pravastatin in Chronic coronary artery disease   PDF

Dogan, 2004   propafenone versus placebo in AF of duration 3 hours to 3 months ???   PDF

CARDS, 2004   (NCT00327418)   atorvastatin versus placebo in patients with type 2 diabetes without high concentrations of LDL-cholesterol and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension.   PDF

PROVE-IT, 2004   atorvastatin high dose versus pravastatin in acute myocardial infarction (with or without electrocardiographic evidence of ST-segment elevation) or highrisk unstable angina) in the preceding 10 days   PDF

PACT, 2004   pravastatin versus placebo in patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction <24 hours   PDF

Kochiadakis a, 2004   amiodarone versus propafenone in Any documented symptomatic previous or persistent AF   PDF

Kochiadakis b (propafenone vs placebo), 2004   propafenone versus placebo in Any documented symptomatic previous or persistent AF   PDF

MATISSE, 2004   fondaparinux versus enoxaparin in patients with acute symptomatic deep venous thrombosis   PDF

PAFAC (quinidine vs placebo), 2004   quinidine versus placebo in Persistent AF lasting > 7 daysil   PDF

Ramacciotti, 2004   LMWH at home versus UFH in hospital in patienst with DVT symptoms for greater than or equal to 10 days and proximal lower limb DVT confirmed by duplex ultrasound or venography   PDF

ELAET (Kearon), 2004   warfarin versus discontinuation in   PDF

SOPAT (quinidine vs placebo), 2004   quinidine versus placebo in Paroxysmal AF documented in the last 1 month@4   PDF

Leizorovicz, 2004   dalteparin versus placebo in Congestive heart failure (NYHA III–IV), acute or chronic respiratory disease, infectious and rheumatologic disease   PDF

Kochiadakis b (sotalol vs placebo), 2004   sotalol versus placebo in Any documented symptomatic previous or persistent AF   PDF

PEACE, 2004   (NCT00000558)   trandolapril versus placebo in patients with stable coronary artery disease and normal or slightly reduced left ventricular function   PDF

PAFAC (sotalol vs placebo), 2004   sotalol versus placebo in Persistent AF lasting > 7 daysil   PDF

CAMELOT (enalapril), 2004   enalapril versus placebo in patients with angiographically documented CAD (>20% stenosis by coronary angiography) and diastolic blood pressure <100 mm Hg   PDF

SOPAT (sotalol vs placebo), 2004   sotalol versus placebo in Paroxysmal AF documented in the last 1 month@4   PDF

PAFAC (quinidine vs sotalol), 2004   quinidine versus sotalol in Persistent AF lasting > 7 daysil   PDF

SOPAT (quinidine vs sotalol), 2004   quinidine versus sotalol in Paroxysmal AF documented in the last 1 month@4   PDF

Kochiadakis b (sotalol vs propafenome), 2004   sotalol versus propafenone in Any documented symptomatic previous or persistent AF   PDF

Tveit, 2004   pravastatin versus control in AF >48 h and scheduled EC   PDF

MIRACL (sub-group) (Schwartz), 2004   atorvastatin versus placebo in Acute coronary syndrome   PDF

Hot cafe (rate vs rythm control), 2004   rate control versus electrical cardioversion in patients with persistent atrial fibrillation   PDF

A to Z, 2004   simvastatin versus placebo in patient with an acute coronary syndrome (ACS)   PDF

PROVE IT - TIMI 22, 2004   atorvastatin versus pravastatin in patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days   PDF

Buse 20µg/d, 2004   exenatide 20µg/d versus placebo (add on SU) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy   PDF

Harder, 2004   liraglutide other doses versus placebo in obese subjects with type 2 diabetes   PDF

Rodriguez-Moctezuma, 2004   metformin versus placebo in Family history of diabetes   PDF

Rodriguez, 2004   metformin versus placebo in Obesity with insulin resistance   PDF

Hoeger, 2004   metformin versus placebo in Overweight with PCOSo[   PDF

Gambineri, 2004   metformin versus placebo in Obesity and PCOS   PDF

PACT, 2004   pravastatin versus placebo in patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction within 24 hours of the onset of symptoms   PDF

Baillargeon, 2004   metformin versus placebo in Non obese women with PCOS   PDF

ESTABLISH, 2004   atorvastatin versus usual care in patients with ACS undergoing emergency coronary angiography and percutaneous coronary intervention   PDF

PENTUA, 2004   fondaparinux versus enoxaparin in patients with ACS without persistent ST-segment elevation   PDF

Madsbad (vs placebo), 2004   liraglutide other doses versus placebo in Outpatients with type 2 diabetes   PDF

Buse 10µg/d, 2004   (NCT00039026)   exenatide 10µg/d versus placebo (add on SU) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy   PDF

Madsbad (vs Glimepiride), 2004   liraglutide other doses versus glimepiride in Outpatients with type 2 diabetes   PDF

Ahren, 2004   vildagliptin versus placebo (add on MET) in patients with type 2 diabetes   PDF

LoWASA, 2004   warfarin versus control (on top of aspirin) in AMI   PDF

Zibaeenezhad, 2004   warfarin versus control (on top of aspirin) in AMI   PDF

VISP (Toole), 2004   high dose - folic acid, vit B12 and vit B6 versus low dose - folic acid, vit B12 and vit B6 in adults with nondisabling cerebral infarction   PDF

PHYLLIS, 2004   pravastatin versus placebo in hypertensive, hypercholesterolemic patients with asymptomatic carotid atherosclerosis   PDF

PREVEND IT, 2004   pravastatin versus placebo in subjects with microalbuminuria   PDF

Dekleva, 2004   error versus control in   PDF

Sharifi, 2004   hyperbaric oxygen versus control in after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris   PDF

FOLARDA (Liem), 2004   folic acid versus control in patients with acute MI and total cholesterol >6.5 mmol/l   PDF

Tao, 2004   lifestyle modification versus control in patients with impaired glucose tolerance (WHO 1999 criteria)   PDF

HOPE renal insufficiency subgroup, 2004   vitamin E versus placebo in patients with either known cardiovascular disease or diabetes and at least one additional coronary risk factor and renal insufficiency (sub group)   PDF

Fang, 2004   lifestyle modification versus control in subject with impaired glucose tolerance   PDF

Fan, 2004   jiangtang bushen recipe versus control in patients with impaired glucose tolerance (WHO 1999 criteria)   PDF

ALLIANCE, 2004   versus in   PDF

Hanna, 2004   pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy   PDF

DISTAl 01 (Gridelli) , 2004   weekly docetaxel versus 3-weekly docetaxel in patients with advanced NSCLC patients, < or =75 years, ECOG PS < or =2   PDF

Johnson, 2004   bevacizumab versus platinum based CT in   PDF

INTACT 2, 2004   gefitinib paclitaxel and carboplatin versus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC   PDF

Hambrecht, 2004   PCI with or without stent versus medical treatment in male patients aged 70 years   PDF

AMIST (Reeves), 2004   angioplasty versus MIDCAB in single-vessel disease (at least 50% stenosis) of the left anterior descending coronary artery (LAD).   PDF

Galiñanes, 2004   TMR versus thoracic sympathectomy in patients with nonrevascularizable coronary arteries and intractable angina   PDF

Salem, 2004   TMR versus medical treatment in patients with stable angina pectoris (class III or IV) not amenable to conventional revascularization and with evidence of reversible ischemia, ejection fraction >/=25%, and myocardial wall thickness >/=8 mm   PDF

van der Sloot, 2004   TMR versus medical treatment in patients with refractory angina   PDF

EORTC18871/DKG 80-1 (Kleeberg), 2004   rIFN alpha-2b versus observation in High-risk stage II patients (thickness >3 mm) and stage III patients (positivelymph nodes) without distant metastasis   PDF

MARIZA, 2004   ranolazine 1000mg versus placebo in Patients with angina-limited exercise   PDF

CARISA 1000mg, 2004   ranolazine 1000mg versus placebo (on top standard treatment) in patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem   PDF

CAMELOT (amlodipine vs pbo), 2004   amlodipine versus placebo (on top standard treatment) in patientswith coronary artery disease and normal blood pressure   PDF

Ejlertsen, 2004   versus in   PDF

EU-1, 2004   versus in   PDF

Bonneterre, 2004   docetaxel + epirubicin versus fluorouracil, epirubicin, cyclophosphamide in   PDF

0025 (Howell), 2004   fulvestrant 250mg versus tamoxifen in advanced breast cancer in postmenopausal women previously untreated with endocrine therapy   PDF

Miles, 2004   capecitabine + docetaxel versus docetaxel alone in patients with anthracycline-pretreated advanced/metastatic breast cancer   PDF

VALUE, 2004   (NCT00129233)   valsartan versus amlodipine in patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events   PDF

Tabernero , 2004   Weekly Docetaxel versus Every three weeks Docetaxel in Metastatic   PDF

Prandoni, 2004   graduate compression stockings versus no compression in patients with a first episode of symptomatic proximal DVT who received conventional anticoagulant treatment   PDF

Partsch, 2004   elastic compression stockings versus no compression in patients with acute proximal DVT   PDF

JMIC-B (diabetic subgroup), 2004   nifedipine versus ACE inhibitor in outpatients aged under 75 years who had diagnoses of both hypertension and coronary artery disease   PDF

DETAIL, 2004   telmisartan versus enalapril in subjects with type 2 diabetes and early nephropathy   PDF

DETAIL, 2004   temisartan versus enalapril in subjects with type 2 diabetes and early nephropathy   PDF

DIABHYCAR, 2004   ramipril versus placebo in patients with type 2 diabetes who have microalbuminuria or proteinuria   PDF

GEMINI, 2004   carvedilol versus metoprolol in patients with hypertension and type 2 diabetes mellitus receiving renin-angiotensin system blockade   PDF

SPARE, 2004   rhenium-188 versus control in patient with successful catheter-based treatment of de novo or restenotic lesion   PDF

Wik, 2003   compressions first versus defibrillation first in   PDF

ALERT (diabetic sub group), 2003   fluvastatin versus placebo in renal transplant recipients with total cholesterol 4·0–9·0 mmol/L   PDF

ECRIS, 2003   rhenium-188 versus control in patients with de novo and restenotic lesions   PDF

Long-WRIST, 2003   iridium-92 versus placebo in patients with diffuse long in-stent restenosis in native coronary arteries (lesion length, 36 to 80 mm)   PDF

ASSENT Plus, 2003   Dalteparin versus UFH in Patients with AMI treated with alteplase   PDF

ASSENT 3 Plus, 2003   Enoxaparin versus UFH in patients with ST-elevation myocardial infarction   PDF

IBDIS, 2003   high-dose chemotherapy versus conventional-dose chemotherapy in   PDF

306 Study Group, 2003   docetaxel + doxorubicin versus doxorobicin + cyclophosphamide in first-line chemotherapy for metastatic breast cancer   PDF

ECOG E1193 (B), 2003   paclitaxel versus doxorubicin in patients with metastatic breast cancer   PDF

Nooij, 2003   maintenance versus control in non-progressing metastatic breast cancer patients after induction chemotherapy (CMF)   PDF

Glover, 2003   WR-2721 versus in Patients with progressive MM   PDF

WELL-HART (estrogen-progestin), 2003   (NCT00000559)   combined estrogen and progestogen versus placebo in Postmenopausal women with angiographically-documented coronary disease   PDF

Mornex, 2003   whole brain irradiation versus in Patients with metastatic malignant melanoma with brain metastases   PDF

Zimpfer, 2003   carboplatin + paclitaxel versus paclitaxel in Patients with stage IV melanoma   PDF

Kris, 2003   gefitinib versus gefitinib in Patients either stage IIIB or IV NSCLC for which they had received at least 2 chemotherapy regimens   PDF

Esteban, 2003   paclitaxel 80mg/m2 versus m2docetaxel 36 mg/ in patients with NSCLC previously treated with platinum-based chemotherapy   PDF

Yang, 2003   bevacizumab versus placebo in patients with metastatic renal-cell carcinoma   PDF

WIZARD, 2003   Azithromycin versus placebo in Patients with a history of MI of more than 6 weeks before and with C pneumoniae titers of >=1:16   PDF

ANTIBIO, 2003   Roxithromycin versus placebo in Patients with unstable angina or MI   PDF

AZACS, 2003   Azithromycin versus placebo in Patients with ACS   PDF

Borer 5mg, 2003   ivabradine 2.5 mg bid versus placebo in   PDF

Borer 10mg, 2003   ivabradine 5 mg bid versus placebo in   PDF

Borer 20mg, 2003   ivabradine 10 mg bid versus placebo in patients with a > or =3-month history of chronic stable angina   PDF

ALKK, 2003   PCI with or without stent versus medical treatment in patients with single vessel disease of the infarct vessel and no or minor angina pectoris in the subacute phase (1 to 6 weeks) after an acute myocardial infarction   PDF

ERACI II, 2003   stent versus CABG in multi vessel disease Angina CSS III-IV; no angina but large area of heart at risk; unstable =1 vessel to be treated Lesion>3.0mm   PDF

OCTOSTENT, 2003   (NCT00975858)   stent versus OPCAB in multi or single vessel disease Moderate LV function CABG or stenting to be considered feasible   PDF

Huikeshoven, 2003   TMR versus medical treatment in   PDF

Loubani, 2003   TMR+CABG versus CABG in Patients who had elective coronary artery bypass with one or more nongraftable coronary arteries   PDF

Gray, 2003   TMR versus medical treatment in with stable angina pectoris (class III or IV) who were unsuitable for conventional revascularization and had evidence of reversible ischemia by thallium-201 scintigraphy, ejection fraction of > or =25%, and myocardial wall thickness > or =8 mm   PDF

Borer (CL2-009) 5mg, 2003   ivabradine 5mg versus placebo in   PDF

Borer (CL2-009) 10mg, 2003   ivabradine 10mg versus placebo in   PDF

Borer (CL2-009) 20mg, 2003   ivabradine 20mg versus placebo in   PDF

CONVINCE, 2003   verapamil versus diuretic or beta-blocker in hypertension with 1 or more additional risk factors for cardiovascular disease   PDF

INVEST (Pepine), 2003   (NCT00133692)   verapamil versus atenolol in patients with hypertension and CAD   PDF

ANBP2, 2003   enalapril versus diuretics in subjects with hypertension 65 to 84 years   PDF

SHELL, 2003   lacidipine versus chlorthalidone in elderly patients with isolated systolic hypertension > or = 60 years   PDF

HYVET pilot, 2003   versus in patients older than 80 years and with a sustained blood pressure of 160-219/90-109 mmHg   PDF

SCOPE, 2003   candesartan versus placebo in patients aged 70–89 years, with systolic blood pressure 160– 179 mmHg, and/or diastolic blood pressure 90–99 mmHg, and a Mini Mental State Examination (MMSE) test score > 24   PDF

Cice et al, 2003   carvedilol versus placebo in dialysis patients with dilated cardiomyopathy   PDF

Li et al, 2003   ramipril versus usual care in patients with end-stage renal failure treated with peritoneal dialysis   PDF

SCOPE (diabetic subgroup), 2003   candesartan versus control in sub group of diabetic patients aged 70-89 years, with systolic blood pressure 160-179 mmHg, and/or diastolic blood pressure 90-99 mmHg, and a Mini Mental State Examination (MMSE) test score >or= 24   PDF

ALPINE, 2003   candesartan versus hydrochlorothiazide in newly detected hypertensives   PDF

INVEST (subgroup), 2003   verapamil versus control in hypertensive CAD patients aged 50 years or older   PDF

COMET, 2003   carvedilol versus metoprolol in chronic heart failure (NYHA II–IV) with a previous admission for a cardiovascular reason and ejection fraction of less than 0·35, and have been treated optimally with diuretics and angiotensinconverting enzyme inhibitors unless not tolerated.   PDF

PROACTION, 2003   nesiritide versus placebo in patients presenting to the ED with acutely decompensated HF and dyspnea at rest or with minimal activity   PDF

ARCH-J, 2003   candesartan versus placebo in patients with chronic heart failure who were not receiving ACE inhibitor therapy   PDF

CHARM-Added, 2003   candesartan+ACE inhibitor versus ACE inhibitor only in patients with New York Heart Association functional class II–IV CHF and left-ventricular ejection fraction40% or lower, and who were being treated with ACE inhibitors.   PDF

CHARM-Alternative, 2003   candesartan versus placebo in patients with symptomatic heart failure and left-ventricular ejection fraction 40% or less who were notreceiving ACE inhibitors because of previous intolerance   PDF

ACE, 2003   Abciximab versus in patients with AMI   PDF

Petronio, 2003   Abciximab versus control in   PDF

Mitrovic et al., 2003   candesartan versus placebo in patients with CHF (New York Heart Association class II or III) with impaired left ventricular function (ejection fraction <=40%) and pulmonary capillary wedge pressure >=13 mm Hg   PDF

EPHESUS, 2003   eplerenone versus placebo in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure   PDF

THE-PRINCE (Kleber), 2003   enoxaparin versus UFH in patients hospitalized for severe respiratory disease or heart failure (NYHA III, IV)   PDF

Node, 2003   simvastatin versus placebo in patients with symptomatic, nonischemic, dilated cardiomyopathy   PDF

RITZ-5, 2003   tezosentan versus placebo in patients with acute congestive heart failure   PDF

RITZ 4 importé, 2003   tezosentan versus placebo in patients with acute heart failure associated with acute coronary syndrome   PDF

MIRACLE-ICD-I, 2003   Combined CRT + ICD versus ICD alone in patients with NYHA class III or IV congestive HF despite appropriate medical management   PDF

AMIOVIRT, 2003   Combined CRT + ICD versus no CRT no ICD in patients with non ischemic cardiomyopathy with EF <=0.35 and Nonsustained ventricular tachycardia   PDF

ASCOT (diabetics sub group), 2003   atorvastatin versus placebo in hypertensive patients with no history of coronary heart disease (CHD) but at least three cardiovascular risk factors   PDF

AMIOVIRT, 2003   amiodarone versus ICD in patients with nonischemic dilated cardiomyopathy, asymptomatic nonsustained ventricular tachycardia, and left ventricular ejection fraction <=0.35   PDF

RD-CHF, 2003   CRT versus no CRT in patients with advanced heart failure   PDF

CHARM preserved, 2003   candesartan versus placebo in patients with NYHA II-IV heart failure and LVEF higher than 40%   PDF

REVIVE-I, 2003   levosimendan versus placebo in patienst with HF andsymptoms at rest   PDF

Foley, 2003   a versus a in Patients atteints d'arthrose de la hanche et/ou du genou diagnostiquée radiologiquement.   PDF

CONTAK-CD , 2003   Combined CRT + ICD versus ICD alone in patients with symptomatic heart failure, intraventricular conduction delay, and malignant ventricular tachyarrhythmias   PDF

SPORTIF III, 2003   ximelagatran versus warfarin standard dose in One or more stroke risk factor in addition to AF.High risk patients with non valvular atrial fibrillation.   PDF

SAFT(warfarin low dose + aspirin vs no treatment), 2003   warfarin low dose + aspirin versus control in Low-medium risk patients with non valvular atrial fibrillation.   PDF

ASCOT, 2003   atorvastatin versus placebo in hypertensive patients aged 40-79 years with at least three other cardiovascular risk factors   PDF

STAF, 2003   electrical cardioversion versus rate control in patients with persistent atrial fibrillation   PDF

AFFIRM Substudy (amiodarone vs sotalol), 2003   amiodarone versus sotalol in patients with AF likely to be recurrent and to cause ilness or deathpj   PDF

ASAP, 2003   Azimilide versus placebo in patients with previous AF documented in the last 2 years   PDF

DAFNE, 2003   dronedarone versus placebo in patients with Persistent AF   PDF

RAFT, 2003   propafenone versus placebo in Previous symptomatic AF documented in the last year   PDF

AFFIRM Substudy (amiodarone vs class I drugs), 2003   amiodarone versus class I drugs in patients with AF likely to be recurrent and to cause ilness or deathpj   PDF

AFFIRM Substudy (sotalol vs class I drugs), 2003   amiodarone versus class I drugs in patients with AF likely to be recurrent and to cause ilness or deathpj   PDF

Krittayaphong, 2003   catheter ablation versus control in drug-refractory amiodarone-naive paroxysmal or persistent AF >=6mo   PDF

Ueng, 2003   enalapril versus control in atrial fibrillation   PDF

ALERT, 2003   fluvastatin versus placebo in renal transplant recipients with total cholesterol 4.0-9.0 mmol/L   PDF

STAF (rate vs rythm control), 2003   rate control versus electrical cardioversion in patients with persistent atrial fibrillation   PDF

ISAR-COOL, 2003   early intervention versus early strategy in patients with symptoms of unstable angina plus either ST-segment depression or elevation of cardiac troponin T levels   PDF

ESTEEM, 2003   ximelagatran versus placebo in patients who had had recent ST-elevation or non-STelevation myocardial infarction   PDF

Derosa, 2003   Orlistat versus placebo in obese patients with hypercholesterolemia   PDF

Halpern, 2003   Orlistat versus placebo in Obese, non-insulin-dependent diabetic patients, aged 18-70 years old, with BMI > 27 kg/m2   PDF

Lucas, 2003   Orlistat versus placebo in   PDF

Bray, 2003   Topiramate versus placebo in   PDF

Caterson, 2003   Topiramate versus placebo in   PDF

Pud’homme, 2003   Topiramate versus placebo in   PDF

Rissanen, 2003   Topiramate versus placebo in   PDF

Stenlof, 2003   Topiramate versus placebo in   PDF

Tonstad, 2003   Topiramate versus placebo in   PDF

DelPrato, 2003   benfluorex versus placebo in diet-failed type 2 diabetic patients   PDF

VALIANT/Val+Cap, 2003   Valsartan + captopril versus Captopril in patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both   PDF

PENTHIFRA–PLUS (Eriksson), 2003   extended prophylaxis versus standard prophylaxis in patients undergoing hip fracture surgery   PDF

Platinum (Colwell), 2003   ximelagatran versus Enoxaparin in adults undergoing hip replacement   PDF

EXPRESS, 2003   ximelagatran versus Enoxaparin in hip or knee replacement   PDF

Ginzburg, 2003   IPC versus LMWH in Trauma patients >18 years old   PDF

Murakami, 2003   CECT versus IPC in Adult trauma patients recruited in emergency department   PDF

Canata, 2003   enoxaparin versus control in ACL reconstruction for symptomatic ACL-deficient knees   PDF

Kleber, 2003   enoxaparin versus UFH in severe respiratory disease or heart failure   PDF

Josse et al, 2003   versus placebo in elderly patients with type 2 diabetes   PDF

EDIT (Holman), 2003   metformin versus placebo in (WHO 1985 criteria)   PDF

Pan, 2003   error versus placebo in patients with impaired glucose tolerance (American Diabetes Association 1997 criteria)   PDF

DPS (Lindström), 2003   lifestyle modification versus control in Patients overweight with impaired glucose tolerance (WHO 1985 criteria)   PDF

Choux, 2003   metformin versus placebo in PCO   PDF

Bech, 2003   repaglinide versus placebo in pharmacotherapy-naive patients with Type 2 diabetes   PDF

Luis Bautista, 2003   glimepiride versus placebo in Mexican American Patients with type 2 diabetes mellitus   PDF

EUROPA, 2003   perindopril versus placebo in low-risk patients with stable coronary heart disease and no apparent heart failure   PDF

Tosi, 2003   glibenclamide versus control (add on MET) in   PDF

ALERT, 2003   fluvastatin versus placebo in renal transplant recipients with total cholesterol 4·0–9·0 mmol/L.   PDF

Garber, 2003   glyburide versus control (add on MET) in patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A(1C) (A1C), >7% and <12%) with diet and exercise alone   PDF

Cesarone, 2003   extended enoxaparin versus standard treatment in patients with cancer with DVT   PDF

CLOT (Lee), 2003   extended dalteparin versus standard treatment in patients with active cancer and with DVT or pulmonary embolism or both, and ECOG 1 or 2   PDF

Schulman (subgroup), 2003   ximelagatran versus placebo in study subgroup of patients with active cancer in the previous 5 years treated for DVT or pulmonary embolism for 6 months without recurrence   PDF

Agnelli, 2003   warfarin versus discontinuation in patients who had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding after a first episode of pulmonary embolism   PDF

PREVENT (Ridker), 2003   warfarin versus discontinuation in Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months   PDF

THRIVE III, 2003   ximelagatran versus discontinuation in patients with venous thromboembolism who had undergone six months of anticoagulant therapy   PDF

THRIVE I, 2003   ximelagatran (without LMWH) versus LMWH/VKA in Patients with acute DVT   PDF

PHS II beta carotene, 2003   (NCT00270647)   combination versus placebo in US male physicians enrolled, aged 50 years or older   PDF

Deitcher, 2003   Enoxaparin versus warfarin in patients with objective diagnosis of DVT   PDF

Kakkar, 2003   Bemiparin versus warfarin in patients with objective diagnosis of DVT by Venography/compression ultrasonography   PDF

Lee, 2003   Dalteparin versus warfarin in patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography   PDF

MATISSE PE, 2003   fondaparinux versus heparin in patients with acute symptomatic pulmonary embolism   PDF

ELATE, 2003   warfarin versus low intensity warfarin in patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism   PDF

PREVENT, 2003   low-intensity warfarin versus placebo in Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation   PDF

THRIVE 3, 2003   ximelagatran versus placebo in patients with venous thromboembolism who had undergone six months of anticoagulant therapy   PDF

WODIT PE, 2003   VKA versus control in patients after a first episode of pulmonary embolismwho had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding   PDF

RTOG 91-11 (I+RT vs RT alone), 2003   PF versus no induction chemotherapy in locally advanced cancer of the larynx requiring total laryngectomy   PDF

Licitra, 2003   (NCT00002747)   PF versus no induction chemotherapy in resectable untreated oral cavity squamous cell carcinoma   PDF

RTOG 91-11 (I+RT vs concurrent CRT), 2003   induction PF + RT versus concomittant chemoradiotherapy in locally advanced cancer of the larynx requiring total laryngectomy   PDF

Licitra, 2003   (NCT00002747)   PF versus no induction chemotherapy in resectable untreated oral cavity squamous cell carcinoma   PDF

SIRIUS, 2003   (NCT00232765)   sirolimus eluting stent versus bare-metal stent in Stable or unstable AP, signs of myocardial ischaemia   PDF

E-SIRIUS, 2003   (NCT00235144)   sirolimus eluting stent versus bare-metal stent in Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment   PDF

TAXUS I, 2003   paclitaxel eluting stent versus bare-metal stent in Stable or unstable AP, silent ischaemia; single de novo or restenotic coronary lesions   PDF

TAXUS II, 2003   (NCT00299026)   paclitaxel eluting stent versus bare-metal stent in Stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99%,   PDF

ASPECT, 2003   (NCT00196079)   paclitaxel, non-polymeric eluting stent versus bare-metal stent in patientswith discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter)   PDF

Mohler, 2003   atorvastatin versus placebo in patients with intermittent claudication   PDF

Pasceri, 2003   sirolimus eluting stent versus bare-metal stent in   PDF

TAXUS II (diabetics), 2003   paclitaxel eluting stent versus bare-metal stent in Diabetic patients with stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99%,   PDF

VALIANT/Val, 2003   Valsartan versus Captopril in patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both   PDF

Burr (DART 2), 2003   diet versus control in men being treated for angina   PDF

DANAMI-2, 2003   primary angioplasty versus immediate thrombolysis in patients with myocardial infarction with ST-segment elevation   PDF

PRAGUE-2, 2003   primary angioplasty versus immediate thrombolysis in patients with acute ST elevation myocardial infarction presenting within <12 h to the nearest community hospital without a catheter laboratory   PDF

SIRIUS (diabetics), 2003   sirolimus eluting stent versus bare-metal stent in sub group of diabetics patients of SIRIUS study   PDF

Murphy, 2003   roxifiban versus placebo in patients with stable coronary artery disease   PDF

AGENT-2 (Grines), 2003   fibroblast growth factor gene versus placebo in   PDF

VIVA (Henry), 2003   vascular endothelial growth factor versus placebo in patients with stable exertional angina, unsuitable for standard revascularization   PDF

SMART (Staton), 2003   off-pump versus on-pump in patients unselected for coronary anatomy, ventricular function, or comorbidities   PDF

DANAMI-2 , 2003   transfer for primary angioplasty versus immediate thrombolysis in patients with myocardial infarction with ST-segment elevation   PDF

PRAGUE-2 , 2003   transfer for primary angioplasty versus immediate thrombolysis in patients with acute ST elevation myocardial infarction presenting within <12 h to the nearest community hospital without a catheter laboratory   PDF

Carrier, 2003   off-pump versus on-pump in high-risk patients   PDF

Raja b, 2003   off-pump versus on-pump in patients undergoing CABG   PDF

Lingaas, 2003   off-pump versus on-pump in patient undergoing CABG   PDF

Lee, 2003   off-pump versus on-pump in patients undergoing CABG   PDF

Muneretto, 2003   off-pump versus on-pump in   PDF

Parolari, 2003   off-pump versus on-pump in   PDF

VALIANT (valsartan alone), 2003   Valsartan versus Captopril in patients within 10 days of a MI complicated by HF   PDF

VALIANT (valsartan+capropril), 2003   Valsartan+ACE inhibitor versus ACE inhibitor only in patients within 10 days of a MI complicated by HF   PDF

Parolari b, 2003   off-pump versus on-pump in   PDF

Sahlman, 2003   off-pump versus on-pump in   PDF

Velisaris, 2003   off-pump versus on-pump in   PDF

WELL-HART (estrogen alone), 2003   (NCT00000559)   estrogen versus placebo in Postmenopausal women with angiographically-documented coronary disease   PDF

Mondillo, 2003   simvastatin versus placebo in Stade de la maladie: II.   PDF

Mohler III, 2003   simvastatin versus placebo in Stade de la madie : II , stable pendant au moins 6 mois.   PDF

Aronow , 2003   simvastatin versus placebo in Stade II   PDF

Mondillo, 2003   simvastatin versus placebo in Stade de la maladie: II.   PDF

HPS (diabetic primary prevention sub group), 2003   simvastatin versus placebo in adults (aged 40-80 years) with diabetes (primary prevention subgroup)   PDF

Napodano, 2003   X-sizer versus conventional PCI in patients with AMI and angiographic evidence of intraluminal thrombus   PDF

Mohler III, 2003   atorvastatin versus placebo in Stade de la madie : II , stable pendant au moins 6 mois.   PDF

Wang, 2003   Angioguard versus conventional PCI in patients with acute myocardial infarction   PDF

Aronow , 2003   simvastatin versus placebo in Stade II   PDF

GOES (Liem), 2003   folic acid versus control in patients with stable coronary artery disease   PDF

Robinson BI, 2003   Dacron versus PTFE in - 129 patients (74 hommes, 55 femmes)dont 68 claudicants, 61 ischémie critique, 76 anastomose distale au dessus du genou, 53 patients anastomose distale au dessous du genou - âge moyen 69 ans (entre 51 et 89 ans).   PDF

PPP (diabetics sub group), 2003   aspirin versus no treatment in men and women with diabetes and without a previous cardiovascular event aged >50 with >=1 risk factors for cardiovascular disease - sub group of diabetic patients   PDF

Prager MR, 2003   Dacron versus PTFE in - 149 patients (67% claudicants, 15% douleur au repos, 18% gangrène) - 70% d'hommes - âge moyen 59 ans (entre 36 et 84 ans)   PDF

Castano, 2003   policosanol versus lovastatin in ICD 50 to 300 metres; ACD < 500 metresag   PDF

RAVE (Rajagopalan), 2003   AdVEGF121 versus placebo in subjects with unilateral exercise-limiting intermittent claudication during 2 qualifying treadmill tests, with peak walking time between 1 to 10 minutes   PDF

REPLACE-2, 2003   bivalirudin versus heparin + GP2b3a inhibitors in patients undergoing urgent or elective PCI   PDF

CRUISE, 2003   enoxaparin versus UFH in Urgent or elective PCI   PDF

Tepel, 2003   acetylcysteine versus placebo in patients undergoing maintenance hemodialysis for a minimum of 3 months 3 times weekly in an ambulatory center   PDF

Natarajan (without antiGp2b3a), 2003   dalteparin versus UFH in Elective or urgent PCI   PDF

Natarajan (+ antiGp2b3a), 2003   dalteparin versus UFH + anti Gp2b3a in   PDF

COMMA, 2003   pexelizumab versus placebo in patients with MI   PDF

COMPLY, 2003   pexelizumab versus placebo in patients with acute ST-segment elevation myocardial infarction receiving fibrinolysis   PDF

TIGER-PA (Lee), 2003   Tirofiban versus primary intervention in symptom duration <12h   PDF

ERAMI (Mesquita Gabriel), 2003   Abciximab versus primary intervention in symptom duration <12h   PDF

REOMOBILE (Arntz), 2003   Abciximab versus primary intervention in symptom duration <6h   PDF

TEMPURA , 2003   radial versus femoral in Patients with STEMI for primary PCI   PDF

Cutlip, 2003   Tirofiban versus primary intervention in symptom duration <12h   PDF

Tian , 2003   radial versus femoral in Diagnostic coronary angiography   PDF

ASCOT (women subgroup) , 2003   Atorvastatin versus placebo in hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) - subgroup of women   PDF

Steno 2, 2003   intensive glycemic control versus conventional treatment in patients with type 2 diabetes and microalbuminuria   PDF

Katzenschlager, 2003   liposomal heparin-spraygel versus enoxaparin in with ST diagosed by ultrasound with signs and symptoms lasting less than 72 hoursdaily)o   PDF

Lozano, 2003   Therapeutic LMWH versus saphenofemoral disconnection in patients with saphenous proximal thrombophlebitis   PDF

Stenox (enoxaparin 40mg), 2003   enoxaparin versus placebo in patients with ST of at least 5 cm on ultrasonography examination   PDF

STENOX (enoxaparin 1.5mg/hg), 2003   enoxaparin versus placebo in patients with St of at least 5 cm on ultrasonography examination   PDF

STENOX (tenoxicam vs PBO), 2003   tenoxicam versus placebo in   PDF

Katzenschlager (LMWH vs hep spraygel), 2003   LMWH versus heparin spraygel in   PDF

STENOX (enox fixed dose vs NSAIDS), 2003   Fixed-dose LMWH versus NSAIDs in   PDF

STENOX (prophylactic LMWH vs NSAIDs), 2003   Prophylactic LMWH versus NSAIDs in   PDF

ABCD target (N) , 2002   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in diabetes patients with diastolic blood pressure between 80 and 89mmHg   PDF

Moriyama , 2002   radial versus femoral in Diagnostic coronary angiography   PDF

LIDO, 2002   levosimendan versus dobutamine in patients with low-output heart failure   PDF

ALIVE, 2002   amiodarone versus lidocaine in out-of-hospital ventricular fibrillation resistant to three shocks, intravenous epinephrine, and a further shock; or recurrent ventricular fibrillation after initially successful defibrillation   PDF

HPS antioxidant, 2002   combination versus placebo in UK adults (aged 40–80) with coronary disease, other occlusive arterial disease, or diabetes   PDF

HEAVEN, 2002   valsartan versus enalapril in Men and women with mild/moderate heart failure stabilised on an angiotensin-converting enzyme inhibitor and left ventricular ejection fraction 0.45 or less   PDF

Bakris, 2002   Orlistat versus placebo in obese individuals with inadequately controlled hypertension.   PDF

Diegeler, 2002   stent versus MIDCAB in single vessel disease Lesion =75% stenosis in proximal LAD or between origin of left circumflex and 1st septal branch   PDF

Baird, 2002   Enoxaparin versus UFH in patients receiving fibrinolytic therapy following acute myocardial infarction   PDF

ENTIRE-TIMI 2, 2002   Enoxaparin versus UFH in Patients with ST-elevation MI presenting <6 hours from symptom onset were   PDF

Garber, 2002   glyburide versus placebo in patients with type 2 diabetes who had failed diet and exercise   PDF

Coccheri, 2002   sulodexide versus placebo in   PDF

US-DDP (lifestyle) (Knowler), 2002   lifestyle modification versus control in nondiabetic patients with elevated glucose and high risk for diabetes   PDF

ALLHAT (CCB vs ACEI), 2002   amlodipine versus lisinopril in participants aged 55 years or older with hypertension and at least 1 other CHD risk factor   PDF

MUSTIC AF, 2002   CRT versus no CRT in patients with NYHA class III left ventricular systolic dysfunction, chronic atrial fibrillation, slow ventricular rate necessitating permanent ventricular pacing, and a wide QRS complex (paced width >or=200 ms)   PDF

VMAC (24h), 2002   (NCT00083772)   nesiritide versus nitroglycerin in acutely decompensated heart failure requiring hospitalization   PDF

AASK (ramipril vs metoprolol), 2002   ramipril versus metoprolol in African Americans aged 18 to 70 years with hypertensive renal disease (GFR, 20-65 mL/min per 1.73 m(2))   PDF

Mohler, 2002   chronical beraprost versus placebo in Stade II pendant 6.5 ans   PDF

SVG-WRIST, 2002   iridium-92 versus placebo in patients with in-stent restenosis in saphenous-vein grafts   PDF

AMI-SK, 2002   Enoxaparin versus placebo in patients with evolving myocardial infarction, Age >=18 y, STEMI   PDF

EORTC 10961, 2002   paclitaxel + doxorubicin versus doxorobicin + cyclophosphamide in first-line chemotherapy in metastatic breast cancer   PDF

STOP-NIDDM (Chiasson), 2002   error versus placebo in patients with impaired glucose tolerance (WHO 1985 criteria)   PDF

Strandness, 2002   cilostazol versus placebo in AOMI stade II.   PDF

LIPS (diabetic sub group), 2002   fluvastatin versus placebo in patients (aged 18-80 years) with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 135 and 270 mg/dL   PDF

ALLHAT-LLT (diabetic sub group), 2002   pravastatin versus usual care in Ambulatory persons aged 55 years or older, with lowdensity lipoprotein cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL   PDF

AASK (amlodipine vs ramipril), 2002   amlodipine versus ramipril in African Americans aged 18 to 70 years with hypertensive renal disease (GFR, 20-65 mL/min per 1.73m2)   PDF

Belcaro, 2002   pentoxifylline versus placebo in Stade de la maladie: II avec durée de la claudication de: 3+/- 2 mois en moyenne.   PDF

LIFE, 2002   losartan versus atenolol in patients aged 55–80 years, with previously treated or untreated hypertension (sitting blood pressure 160–200/95–115 mm Hg) and ECG signs of LVH.   PDF

LEADER, 2002   bezafibrate versus placebo in men with lower extremity arterial disease   PDF

HPS, 2002   simvastatin versus placebo in adults (aged 40-80 years) with coronary disease, other occlusive arterial disease, or diabete   PDF

US-DPP (metformin) (Knowler), 2002   metformin versus placebo in nondiabetic patients with elevated glucose and high risk for diabetes   PDF

FAST Fukuoka pravastatin, 2002   pravastatin versus control in asymptomatic hypercholesterolemic patients   PDF

RUSSLAN, 2002   levosimendan versus placebo in patients with left ventricular failure complicating acute myocardial infarction   PDF

AGENT-1 (Grines), 2002   fibroblast growth factor gene versus placebo in   PDF

Marre (ass), 2002   glibenclamide versus control (add on MET) in patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy   PDF

Blonde, 2002   glyburide versus control (add on MET) in patients with inadequate glycaemic control on at least half-maximal dose of sulphonylurea   PDF

Konstantinides, 2002   rt-PA versus placebo in patients with acute pulmonary embolism and pulmonary hypertensionor right ventricular dysfunction but withoutarterial hypotension or shock   PDF

HPS (elderly subgroup), 2002   simvastatin versus placebo in Vascular disease or diabetes, subgroup of age 65-80 y   PDF

Broom, 2002   Orlistat versus placebo in obese patients with cardiovascular risk   PDF

VINO, 2002   routine invasive strategy versus concervative strategy in patients with non–ST-segment elevation acute coronary syndrome   PDF

STOPAMI 2, 2002   primary stenting versus immediate thrombolysis in patients with acute myocardial infarction within 12 h of onset of symptoms   PDF

Abu-Laban, 2002   t-PA versus placebo in Victims of cardiac arrest with pulseless electrical activity for more than one minute and had had no palpable pulse for more than three minutes during resuscitative efforts and at the time of the initiation of the study drug   PDF

Hareyama, 2002   PF versus no induction chemotherapy in locoregional carcinoma of the nasopharynx   PDF

Fowler, 2002   Exercise Therapy versus Control in 1400 hommes, 65-79 ans 26% stade I, 74% stade II   PDF

PRECEDENT, 2002   (NCT00270400)   nesiritide versus dobutamine in Symptomatic, Decompensated CHF   PDF

CADILLAC, 2002   Abciximab versus in patients with acute myocardial infarction   PDF

Petronio, 2002   Abciximab versus placebo in rescue PTCA within 24 hours from the onset of chest pain   PDF

Zoman, 2002   Abciximab versus placebo in   PDF

C-PORT, 2002   primary PCI versus accelerated t-PA in thrombolytic-eligible patients with acute MI of less than 12 hours' duration associated with ST-segment elevation   PDF

ENTIRE-TIMI23, 2002   Abciximab versus in   PDF

GUSTO V, 2002   Abciximab versus in   PDF

Cicoira, 2002   spironolactone versus control in patients with chronic heart failure   PDF

Sikov , 2002   Weekly Paclitaxel versus Every three weeks Paclitaxel in Metastatic   PDF

Viborg County Study, 2002   Screening versus non screening in   PDF

VMAC (intravenous neseritide), 2002   (NCT00083772)   nesiritide versus placebo in acutely decompensated heart failure requiring hospitalization   PDF

Marchiori, 2002   heparin versus low dose UFH in patients with ST of the great saphenous vein   PDF

RAVEL, 2002   (NCT00233805)   sirolimus eluting stent versus bare-metal stent in Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery   PDF

CAPTIM, 2002   primary angioplasty versus immediate thrombolysis in patients within 6 h of acute myocardial infarction with ST-segment elevation, initially managed by mobile emergency-care units   PDF

MASS, 2002   Screening versus non screening in   PDF

LIPS, 2002   fluvastatin versus placebo in patients (aged 18-80 years) with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 3.5-7.0 mmol/L and with fasting triglyceride levels of less than 4.5 mmol/L   PDF

ALLHAT, 2002   (NCT00000542)   pravastatin versus usual care in aged 55 years or older, moderately hypercholesterolemic, hypertensive participants with at least 1 additional CHD risk factor   PDF

AIR-PAMI, 2002   primary angioplasty versus immediate thrombolysis in Patients with high-risk AMI (age >70 years, anterior MI, Killip class II/III, heart rate >100 beats/min or systolic BP <100 mm Hg), eligible for thrombolytic therapy   PDF

PROSPER, 2002   pravastatin versus placebo in men and women aged 70-82 years with a history of, or risk factors for, vascular disease   PDF

AASK, 2002   more intensive blood pressure lowering strategie versus less intensive blood pressure lowering strategie in African-Americans,with diastolic blood pressure higher than 94mmHg and a glomerular filtration rate between 20 and 65 ml/min per 1.73 m2   PDF

METHRO III, 2002   ximelagatran versus Enoxaparin in hip or knee replacement   PDF

Saloranta, 2002   nateglinide versus placebo in patients with type 2 diabetes but only moderately elevated fasting plasma glucose (FPG = 7.0-8.3 mmol/liter)   PDF

AIR-PAMI , 2002   transfer for primary angioplasty versus immediate thrombolysis in Patients with high-risk AMI (age >70 years, anterior MI, Killip class II/III, heart rate >100 beats/min or systolic BP <100 mm Hg), eligible for thrombolytic therapy   PDF

OVERTURE, 2002   omapatrilat versus enalapril in patients with NYHA II-IV heart failure   PDF

Schulman (NHLBI) (estrogen-progestogen), 2002   (NCT00000601)   combined estrogen and progestogen versus placebo in Postmenopausal women with unstable angina   PDF

Hanefeld, 2002   Orlistat versus placebo in Overweight or obese adults (BMI >or= 28 kg/m2) with HbA1c of 6.5-11% and clinical type 2 diabetes   PDF

Naumov, 2002   Orlistat versus placebo in patients with stable angina pectoris concomitant with obesity and hyperlipemia   PDF

Kreienberg PB, 2002   PTFE avec veine versus V reconstituée in - 36 patients souffrant d'ischémie des membres inférieurs (pour 39 pontages) - âge moyen entre 66 et 73 ans (entre 50 et 91 ans) - 61,1 % d'hommes   PDF

Meyer, 2002   extended enoxaparin versus standard treatment in patients with cancer (solid or hematological; active or in remission but on treatment); with pulmonary embolism and/or DVT and a minimum life expectancy of 3 months   PDF

Miles, 2002   Orlistat versus placebo in overweight and obese patients with suboptimal control of type 2 diabetes   PDF

PROSPER diabetic (sub group), 2002   pravastatin versus placebo in mena and women aged 70–82 years with a history of, or risk factors for, vascular disease   PDF

PATI, 2002   versus placebo in   PDF

HPS (diabetic sub group), 2002   simvastatin versus placebo in Men and women diabetes aged about 40–80 years with non-fasting blood total cholesterol concentrations of at least 3·5 mmol/L (135 mg/dL)   PDF

Johnson, 2002   warfarin versus contrôle in stades II à IV 614 patients inclus   PDF

TXT Group, 2002   docetaxel versus fluorouracil, vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy   PDF

Talbot, 2002   pacclitaxel versus capecitabine in   PDF

Elsharawy, 2002   streptokinase versus no fibrinolysis in iliofemoral venous thrombosis confirmed by duplex or venography duration < 10 daysicatio   PDF

Jorgensen, 2002   tinzaparin versus control in patients over 18 years of age with planned plaster cast on a lower extremity of at least 3 weeks   PDF

PARAGON-B , 2002   Lamifiban versus placebo in   PDF

WHI, 2002   combined estrogen and progestogen versus placebo in postmenopausal women aged 50-79 years with an intact uterus at baseline   PDF

LIPS (elderly subgroup), 2002   fluvastatin versus placebo in CAD requiring PCI, subgroup of age 65-80 y   PDF

STAMINA (Amoxicillin), 2002   Amoxicillin versus placebo in Patients with ACS   PDF

PATENCY, 2002   paclitaxel, non-polymeric eluting stent versus bare-metal stent in Patients with de novo lesions of 2.7- to 4.0-mm diameter and 25-mm length received 3.0, 3.5, or 4.0 mm 10- or 15-mm   PDF

Berruti A, 2002   cisplatin + epirubicin versus lonidamine + epirubicin in   PDF

METHRO II, 2002   ximelagatran versus Dalteparin in undergoing hip or knee replacement   PDF

Berruti B, 2002   cisplatin + epirubicin versus lonidamine + epirubicin in   PDF

Sturrock, 2002   metformin versus placebo in PCO   PDF

METHRO I, 2002   ximelagatran versus Dalteparin in adults undergoing hip or knee replacement   PDF

CADILLAC (no abciximab), 2002   primary stenting versus balloon angioplasty in patients with acute myocardial infarction   PDF

CADILLAC abciximab., 2002   primary stenting versus balloon angioplasty in patients with acute myocardial infarction   PDF

SPORTIF II (ximelagatran vs warfarin standard dose), 2002   ximelagatran versus warfarin standard dose in Medium to high risk patients with chronic non valvular atrial fibrillation.   PDF

Kelley, 2002   Orlistat versus placebo in overweight or obese adults (BMI 28-40 kg/m(2)) with type 2 diabetes treated with insulin alone or combined with oral agents, but with suboptimal metabolic control (HbA(1c) 7.5-12.0%)   PDF

LIPS (sub groups), 2002   fluvastatin versus placebo in patients with unstable angina and successful first percutaneous coronary intervention   PDF

Michot, 2002   deltaparin versus control in patients requiring diagnostic or therapeutic arthoscopic knee surgery as outpatients; aged18 to 80 years.   PDF

STAMINA (Azithromycin), 2002   Azithromycin versus placebo in Patients with ACS   PDF

GREACE, 2002   atorvastatin versus usual care in patients with established coronary heart disease   PDF

Eton, 2002   biochemotherapy versus chemotherapy in Patients with advanced, unresectable nonchoroidal MM with indicator lesions   PDF

Sedky , 2002   Weekly Docetaxel versus Every three weeks Docetaxel in Metastatic   PDF

Lassen, 2002   reviparin versus placebo in patients who required immobilization in a plaster cast or brace for at least five weeks after a leg fracture or rupture of the Achilles tendon   PDF

Kocak, 2002   metformin versus placebo in PCO   PDF

Kelly, 2002   metformin versus placebo in PCO   PDF

Zhu, 2002   magnesium versus control in AMI   PDF

ENOXACAN II (Bergqvist), 2002   extended prophylaxis versus standard prophylaxis in > 40 years, open major abdominal oncologic elective surgery of >45 minutes duration (includes gynecological surgery)   PDF

PATH-CHF, 2002   CRT versus no CRT in patients with heart failure and ventricular conduction delay   PDF

Rosenfalck, 2002   Orlistat versus placebo in obese patients   PDF

RACE, 2002   electrical cardioversion versus rate control in patients with persistent atrial fibrillation after a previous electrical cardioversionio   PDF

HPS (sub group), 2002   simvastatin versus placebo in 32.85% des patients présentaient une artériopathie des membres inférieurs   PDF

PTT, 2002   pravastatin versus usual care in patients who underwent coronary balloon angioplasty of the infarct-related artery during the first month of acute myocardial infarction   PDF

AFFIRM, 2002   (NCT00000556)   pharmacological cardioversion versus rate control in patients with recurrent atrial fibrillation and who were at least 65 years of age or who had other risk factors for stroke or death   PDF

Fountzilas, 2002   PCb versus PE in   PDF

LEMANS, 2002   (NCT00375063)   stent versus CABG in patients with unprotected left main coronary artery stenosis   PDF

WAVE, 2002   (NCT00000555)   combined estrogen and progestogen versus placebo in Postmenopausal women, up to age 86, with angiographically documented coronary artery disease of at least 15 percent, but no more than 75 percent occlusion   PDF

AF-CHF, 2002   (NCT00597077)   pharmacological cardioversion versus rate control in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history of atrial fibrillation   PDF

Fleming, 2002   metformin versus placebo in PCO   PDF

Schulman (NHLBI) (estrogen alone), 2002   (NCT00000601)   estrogen versus placebo in Postmenopausal women with unstable angina   PDF

HPS (women subgroup) , 2002   Simvastatin versus placebo in UK adults (aged 40-80 years) with coronary disease,other occlusive arterial disease, or diabetes - subgroup of women without CHD   PDF

ESPRIT, 2002   estrogen versus placebo in postmenopausal women, age 50-69 years who had survived a first myocardial infarction   PDF

Icli, 2002   VP-16+P versus paclitaxel in   PDF

FLORIDA, 2002   fluvastatin versus placebo in patients with an AMI and total cholesterol of <6.5 mmol.l   PDF

Colivicchi, 2002   atorvastatin versus usual care in unstable angina pectoris or non-Q-wave myocardial infarction   PDF

0021 (Osborne), 2002   (NCT00635713)   fulvestrant 250mg versus anastrozole in postmenopausal women with advanced breast cancer   PDF

LIFE (diabetic subgroup), 2002   losartan versus atenolol in patients with diabetes (subgroup) , hypertension, and signs of left-ventricular hypertrophy on electrocardiograms   PDF

ALLHAT (lisi vs chlor, diabetic subgroup), 2002   lisinopril versus chlorthalidone in diabetic (subgroup) participants aged 55 years or older with hypertension   PDF

EPHESUS (Lassen), 2002   fondaparinux versus enoxaparin in elective hip replacement surgery   PDF

ALLHAT (women subgroup) , 2002   Pravastatin versus placebo in Ambulatory persons, aged 55 years or older, with low-density lipoprotein cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL- subgroup of women   PDF

Garrigue, 2002   CRT versus no CRT in patients with chronic atrial fibrillation, severe heart failure and QRS prolongation of > or = 140 ms   PDF

PROSPER (primary prevention subgroup), 2002   pravastatin versus placebo in men and women aged 70-82 years with a history of, or risk factors for, vascular disease; primary prevention subgroup   PDF

PENTATHLON (Turpie), 2002   fondaparinux versus enoxaparin in elective hip replacement surgery   PDF

HPS, 2002   simvastatin versus placebo in 32.85% des patients présentaient une artériopathie des membres inférieurs   PDF

Marre, 2002   nateglinide versus placebo in metformin-treated patients with HbA1c between 6.8% and 11%   PDF

Kamishirado, 2002   cilostazol + aspirin versus ticlopidine + aspirin in   PDF

Tang, 2002   off-pump versus on-pump in   PDF

0020 (Howell), 2002   fulvestrant 250mg versus anastrozole in   PDF

McMahon, 2002   Sibutramine versus placebo in   PDF

RITA 3, 2002   (ISRCTN07752711r)   routine invasive strategy versus concervative strategy in patients with non–ST-segment elevation acutecoronary syndrome   PDF

Hull, 2002   Tinzaparin versus warfarin in patients with objective diagnosis of DVT by Venography/compression ultrasonography   PDF

Meyer, 2002   Enoxaparin versus warfarin in patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography   PDF

SIAM III, 2002   systematic PCI (+stent) versus no systematic PCI in patients receiving thrombolysis in AMI (<12 h)   PDF

McKelvie et al, 2002   Exercise training versus control in patients in NYHA class I to III, with ejection fraction <40% and 6-minute walk distance <500 meters   PDF

AF-CHF (rate vs rythm control), 2002   (NCT00597077)   rate control versus pharmacological cardioversion in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history of atrial fibrillation   PDF

Zamvar, 2002   off-pump versus on-pump in patients undergoing coronary artery bypass graft surgery for triple vessel disease   PDF

AFFIRM (rate vs rythm control), 2002   (NCT00000556)   rate control versus pharmacological cardioversion in patients with recurrent atrial fibrillation and who were at least 65 years of age or who had other risk factors for stroke or death   PDF

PEGASE 03, 2002   high-dose chemotherapy versus conventional-dose chemotherapy in   PDF

RACE (rate vs rythm control), 2002   rate control versus electrical cardioversion in patients with persistent atrial fibrillation after a previous electrical cardioversionio   PDF

Stone, 2002   TMR versus medical treatment in patients with class III or IV angina caused by one or more chronically occluded native coronary arteries in which a percutaneous coronary intervention had failed   PDF

CHAOS-2, 2002   folic acid versus placebo in patient with CHD   PDF

MIRACLE, 2002   CRT versus no CRT in patients with moderate-to-severe symptoms of heart failure associated with an ejection fraction of 35 percent or less and a QRS interval of 130 msec   PDF

MADIT-II, 2002   ICD versus no ICD in patients with a prior myocardial infarction and EF<=0.30   PDF

OPTIMAAL, 2002   Losartan versus Captopril in patients within 10 days of a confirmed acute myocardial infarction and heart failure during the acute phase or a new Q-wave anterior infarction or reinfarction   PDF

ASPECT-2 (coumadin+asp vs asp), 2002   coumadin versus control (on top of aspirin) in UA, AMI   PDF

APRICOT-2, 2002   warfarin versus control (on top of aspirin) in STEMI   PDF

TOAT, 2002   late PTCA versus no PTCA in symptom-free patients after acute myocardial infarction   PDF

APRICOT-2, 2002   warfarin versus control (on top of aspirin) in Acute MI after thrombolytics   PDF

ASPECT-2 (coumadin alone), 2002   coumadin versus aspirin in Acute MI, unstable angina   PDF

WARIS II (warfarin alone), 2002   warfarin versus aspirin in patients hospitalized for acute myocardial infarction   PDF

CHAMP, 2002   warfarin versus control (on top of aspirin) in AMI   PDF

SOS, 2002   (NCT00475449)   stent versus CABG in multiple vessel disease Symptomatic 1 or more vessel suitable for stenting   PDF

MOST, 2002   (NCT00000561)   DDDR versus VVIR in AV block or SSS   PDF

WARIS, 2002   warfarin versus control (on top of aspirin) in AMI   PDF

Wagner, 2002   ramipril versus placebo in patients with acute myocardial infarction   PDF

Caputo, 2002   off-pump versus on-pump in patients undergoing coronary artery bypass grafting   PDF

ASPECT-2 (coumadin vs aspirin), 2002   coumadin versus aspirin in UA, AMI   PDF

CAT, 2002   ICD versus no ICD in patients with recent onset nonischemic cardiomyopathy withEF <=0.30   PDF

Madrid, 2002   irbesartan versus control in atrial fibrillation   PDF

OCTOPUS (van Dijk), 2002   off-pump versus on-pump in patients with predominantly single- or double-vessel coronary disease   PDF

Drenth, 2002   stent versus MIDCAB in single vessel disease Angina II Lesion (Grade B2 or C) of proximal LAD Suitable for CABG or stenting   PDF

Hareyama, 2002   PF versus no induction chemotherapy in locoregional carcinoma of the nasopharynx   PDF

Liao, 2002   AHA 2 diet versus AHA 1 diet in Japanese American subjects with impaired glucose tolerance (WHO criteria 1998)   PDF

Kovacs, 2002   a versus a in Patients atteints d'arthrose du genou bilatérale   PDF

IONA, 2002   nicorandil versus placebo (on top standard treatment) in patients with clearly established coronary heart disease or a positive exercise test with additional risk factors   PDF

BHACAS II (Angelini), 2002   off-pump versus on-pump in patients with myocardial infarction in the past month or who required grafting of the circumflex artery distal to the first obtuse marginal branch   PDF

Anderson, 2002   Bupropion versus placebo in obese adults   PDF

Beran, 2002   X-sizer versus conventional PCI in patients with ACS and suspected intracoronary thrombus   PDF

ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002   amlodipine versus chlorthalidone in diabetic (subgroup) participants aged 55 years or older with hypertension   PDF

Höijer, 2002   DDDR,DDIR versus VVI in AV block or SSS   PDF

Zorman, 2002   Abciximab versus primary intervention in symptom duration <12h   PDF

EPOCH, 2002   Pimobendan versus placebo in NYHA II,III   PDF

Croft, 2002   Bupropion versus placebo in patients with major depression responder to open-label treatment with bupropion SR   PDF

CHAMP, 2002   warfarin versus control (on top of aspirin) in AMI (patients enrolled within 14 days of infarction)   PDF

XENDOS (Chiasson), 2002   orlistat versus placebo in patients with impaired glucose tolerance (WHO 1994)   PDF

TRIPOD (Buchanan), 2002   troglitazone versus placebo in Hispanic women with previous gestational diabetes   PDF

ASPECT-2 (coumadin+ASA vs ASA), 2002   coumadin versus control (on top of aspirin) in Acute MI, unstable angina   PDF

WARIS II (warfarin+ASA), 2002   warfarin versus control (on top of aspirin) in patients hospitalized for acute myocardial infarction   PDF

FIRST (Simons), 2002   fibroblast growth factor versus placebo in patients with coronary artery disease   PDF

FATS Fukosawa (probucol), 2002   probucol versus control in asymptomatic patients with hypercholesterolemia   PDF

Jain, 2002   Bupropion versus placebo in Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30)   PDF

ALLHAT (ACEI vs chlorthalidone), 2002   lisinopril versus diuretics in participants aged 55 years or older with hypertension and at least 1 other CHD risk factor   PDF

TRAFFIC (Lederman), 2002   rFGF-2 versus placebo in patients with intermittent claudication caused by infra-inguinal atherosclerosis   PDF

COPERNICUS, 2002   carvedilol versus placebo in patients with symptoms of heart failure at rest or on minimal exertion and with an ejection fraction <25% (but not volume-overloaded)   PDF

Makinen, 2002   VEGF gene versus placebo in patients with chronic lower-limb ischemia and atherosclerotic infrainguinal occlusion or stenosis undergoing percutaneous transluminal angioplasty   PDF

WAVE (Waters), 2002   combination versus placebo in postmenopausal women with at least one 15% to 75% coronary stenosis   PDF

LIPS, 2002   fluvastatin versus placebo in patients with stable or unstable angina or silent ischemia and successful completion of their first PCI   PDF

Warwick à exclure, 2002   IPC versus LMWH in   PDF

SMART, 2002   aprindine versus placebo in Symptomatic paroxysmal AF having > 1 episode monthly or persistent AF lasting < 1 month   PDF

Kleiman, 2002   bivalirudin + eptifibatide versus heparin + GP2b3a inhibitors in patients who underwent elective percutaneous coronary intervention   PDF

AASK (ramipril vs amlodipine), 2002   ramipril versus amlodipine in African Americans aged 18 to 70 years with hypertensive renal disease (GFR, 20-65 mL/min per 1.73 m(2))   PDF

ALLHAT (ACEI vs amlodipine), 2002   lisinopril versus amlodipine in participants aged 55 years or older with hypertension and at least 1 other CHD risk fact   PDF

Bemelmans, 2002   fish oil versus control in patients with multiple cardiovascular risk factors (10 yr IHD risk ~20%)   PDF

JMIC-B, 2002   various ACEI versus nifedipine in HBP+CHD   PDF

Talbot, 2002   capecitabine versus paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines   PDF

O'Shaughnessy, 2002   capecitabine + docetaxel versus docetaxel alone in patients with advanced breast cancer   PDF

INHIBIT, 2002   P-32 versus placebo in patients with in-stent restenosis and successful coronary intervention   PDF

Maresta, 2002   Esapent versus placebo in undergoing planned PTCAB   PDF

AASK (amlodipine vs metoprolol), 2002   amlodipine versus metoprolol in African Americans aged 18 to 70 years with hypertensive renal disease (GFR, 20-65 mL/min per 1.73m2)   PDF

ALLHAT (CCB vs diu), 2002   amlodipine versus chlorthalidone in participants aged 55 years or older with hypertension and at least 1 other CHD risk factor   PDF

ELSA, 2002   lacidipine versus atenolol in patients with hypertension   PDF

SYMPHONY 2, 2001   Sibrafiban versus placebo in   PDF

De Sanctis, 2001   Essaven versus placebo in patients with superficial thrombophlebitis and varicose veins   PDF

Nilsson, 2001   Multiple risk factor interventions versus control in   PDF

Oldroyd, 2001   Multiple risk factor interventions versus control in   PDF

Madsbad, 2001   repaglinide versus glipizide in   PDF

Raskin, 2001   repaglinide versus on top rosiglitazone in   PDF

Raskin, 2001   repaglinide versus on top pioglitazone in   PDF

GUSTO-IV ACS Abciximab 48 h , 2001   Abciximab versus placebo in   PDF

GUSTO-IV ACS Abciximab 24 h , 2001   Abciximab versus placebo in   PDF

Mosorin, 2001   doxycycline versus placebo in   PDF

Vammen, 2001   roxithromycin versus placebo in   PDF

TOPPS, 2001   clopidogrel + aspirin versus ticlopidine + aspirin in   PDF

MIRACL, 2001   atorvastatin versus placebo in unstable angina or non–Q-wave acute MI   PDF

Piamsomboon, 2001   clopidogrel + aspirin versus ticlopidine + aspirin in   PDF

Ng, 2001   metformin versus placebo in PCO   PDF

WODIT DVT, 2001   VKA versus control in Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy   PDF

Lehtovirta, 2001   metformin versus placebo in Overweight with impaired glucose tolerance and family history of diabetes   PDF

Kay, 2001   metformin versus placebo in Adolescents with morbid obesity   PDF

PAIS, 2001   pravastatin versus placebo in patients with acute coronary syndromes   PDF

FFAACS , 2001   aspirin versus placebo (on top fluidione) in high risk patients with non valvular atrial fibrillation   PDF

Freemark, 2001   metformin versus placebo in Insulin resistance and family history of diabetes   PDF

WEST, 2001   estrogen versus placebo in postmenopausal women who had recently had an ischemic stroke or transient ischemic attack   PDF

Kozuma, 2001   cilostazol + aspirin versus ticlopidine + aspirin in   PDF

Bellandi (propafenone vs placebo), 2001   propafenone versus placebo in patients with paroxysmal recurrent or persistent AF   PDF

PSSAAMI (Scheller), 2001   primary stenting versus balloon angioplasty in patients within 24 hours after the onset of acute myocardial infarction   PDF

Charpentier, 2001   glimepiride monotherapy versus metformin in Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily for at least 4 weeks   PDF

DIAMOND, 2001   dofetilide versus placebo in Persistent AF in patients with heart failure or recent myocardial infarction and reduced LVEF   PDF

Lopez-Beret, 2001   Nadroparin versus acenocoumarol in patients with objective diagnosis of DVT by compression ultrasonography   PDF

CURE, 2001   clopidogrel + aspirin versus aspirin in acute coronary syndromes without ST-segment elevation within 24 hours after the onset of symptoms   PDF

CURE (PCI sub study), 2001   clopidogrel versus placebo in patients with non-ST-elevation acute coronary syndrome undergoing PCI   PDF

TACTICS-TIMI 18 elderly (sub group), 2001   routine invasive strategy versus concervative strategy in patients 65 years of age and older with unstable angina and non–STsegment elevation myocardial infarction   PDF

Huyhn, 2001   warfarin versus placebo (on top of aspirin) in UA, NSTEMI with prior CABG   PDF

OASIS-2 Warfarin Substudy, 2001   warfarin versus control (on top of aspirin) in UA   PDF

Stiell, 2001   vasopressin versus epinephrine in adults who had cardiac arrest and required drug therapy   PDF

Gerola, 2001   off-pump versus on-pump in low-risk patients undergoing CABG   PDF

EPAT, 2001   estrogen versus placebo in postmenopausal women 45 years of age or older without preexisting cardiovascular disease and with low-density lipoprotein cholesterol levels of 3.37 mmol/L or greater (>/=130 mg/dL)   PDF

MIRACL (AF ancillary study), 2001   atorvastatin versus placebo in Acute coronary syndrome; subgroup without history of AF   PDF

MAGIC, 2001   myoblasts versus placebo in patient with severe ischaemic heart failure   PDF

ASSENT 3, 2001   Enoxaparin versus UFH in patients with acute myocardial infarction   PDF

HART II, 2001   Enoxaparin versus UFH in patients undergoing reperfusion therapy with an accelerated recombinant tissue plasminogen activator regimen and aspirin for AMI   PDF

Lopez Beret, 2001   extended nadroparin versus standard treatment in patients with known malignancy treated for symptomatic DVT of the lower limb   PDF

REMATCH, 2001   pulsatile-flow versus medical treatment in patients with end-stage heart failure who were ineligible for cardiac transplantation   PDF

Moer, 2001   stent versus balloon angioplasty in patients with stable or unstable angina   PDF

Doucet, 2001   stent versus balloon angioplasty in symptomatic patients needing dilatation of 1 native coronary vessel between 2.3 and 2.9 mm in size   PDF

Koning, 2001   stent versus balloon angioplasty in symptomatic patients with de novo focal lesion located on a small coronary segment vessel (<3 mm)   PDF

COPERNICUS (elderly subgroup), 2001   Carvedilol versus placebo in Patients aged 59 years and older   PDF

BEST (elderly subgroup), 2001   Metoprolol versus placebo in Upper tertile age   PDF

HATS, 2001   combination versus placebo in patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol   PDF

OPTIMAAL, 2001   Losartan versus Captopril in patients 50 years of age or older, with confirmed acute myocardial infarction and heart failure during the acute phase or a new Q-wave anterior infarction or reinfarction   PDF

Broom,, 2001   Orlistat versus placebo in   PDF

Deerochanawong,, 2001   Orlistat versus placebo in   PDF

Gotfredsen, 2001   Orlistat versus placebo in   PDF

NCIC, 2001   high-dose chemotherapy versus conventional-dose chemotherapy in   PDF

CLARIFY, 2001   clarithromycin versus placebo in Patients with ACS   PDF

Leowattana et al, 2001   Roxithromycin versus placebo in Patients with ACS   PDF

GEFACA, 2001   amiodarone versus placebo in Persistent AF lasting > 2 months   PDF

HATS, 2001   niacin versus placebo (on top statin) in patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels   PDF

Muls, 2001   Orlistat versus placebo in obese hypercholesterolemic patients, BMI between 27-40 kg/m2 and low-density-lipoprotein cholesterol, LDL-C, between 4.1-6.7 mmol/l   PDF

Merli (once daily vs UFH), 2001   once daily enoxaparin versus UFH in patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE)   PDF

Reaven, 2001   Orlistat versus placebo in   PDF

Bech, 2001   PCI with or without stent versus medical treatment in patients with planned PTCA and no documented ischemia and with coronary pressure–derived fractional flow reserve >0.75   PDF

ARTS, 2001   stent versus CABG in Multi vessel disease with 2 or more de novo lesion in different major arteries Total occlusion < 1month   PDF

Grip, 2001   stent versus MIDCAB in single vessel disease engaging LAD Stable or unstable angina   PDF

Yan, 2001   paclitaxel + carboplatin versus paclitaxel + cisplatin in patients with non-small cell lung cancer   PDF

Sweeney, 2001   paclitaxel + carboplatin versus paclitaxel + cisplatin in   PDF

MUSTIC-SR, 2001   CRT versus no CRT in patients with severe heart failure (New York Heart Association class III) due to chronic left ventricular systolic dysfunction, with normal sinus rhythm and a duration of the QRS interval of more than 150 msec   PDF

PROGRESS (diabetic subgroup), 2001   perindopril versus placebo in hypertensive and non-hypertensive individuals with cerebrovascular disease, subgroup of diatebic patients   PDF

Ginsberg, 2001   elastic compression stockings versus placebo in patients with proximal deep venous thrombosis   PDF

DEFER, 2001   FFR-guided PCI versus no PCI in patients for whom PTCA was planned and who did not have documented ischemia and with fractional flow reserve >0.75   PDF

TIME, 2001   PCI with or without stent versus medical treatment in patients aged 75 years or older with chronic angina of at least Canadian Cardiac Society class II despite at least two antianginal drugs   PDF

TRIMPOL II (Szwed), 2001   trimetazidine + metoprolol versus metoprolol in patients with persistent angina despite therapy with 50mg twice a day metoprolol   PDF

Rissanen, 2001   Orlistat versus placebo in healthy obese women   PDF

Samama, 2001   Acenocoumarol versus Reviparin in THR   PDF

Chiarion, 2001   dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine in Patients with unresectable MM (stage III and IV)   PDF

Shi Yi, 2001   Orlistat versus placebo in   PDF

WALLSTENT (Alberts), 2001   carotid artery stenting versus surgery in   PDF

Tsutamoto, 2001   spironolactone versus placebo in patients with mild-to-moderate nonischemic congestive heart failure   PDF

Yee, 2001   spironolactone versus placebo in patients with New York Heart Association class II to IV congestive heart failure   PDF

STAT, 2001   primary stenting versus accelerated t-PA in patients with acute ST-elevation myocardial infarction   PDF

Merli, 2001   once daily enoxaparin versus twice daily enoxaparin in patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE)   PDF

Fitzgerald, 2001   Warfarin versus Enoxaparin in TKR   PDF

Covino, 2001   off-pump versus on-pump in   PDF

Penttila, 2001   off-pump versus on-pump in patients requiring CABG   PDF

Bellandi (sotalol vs placebo), 2001   sotalol versus placebo in patients with paroxysmal recurrent or persistent AF   PDF

Smith, 2001   Sibutramine versus placebo in   PDF

IRMA 2, 2001   irbesartan versus placebo in hypertensive patients with type 2 diabetes and microalbuminuria   PDF

Baker, 2001   off-pump versus on-pump in elective patients requiring surgery for double or triple vessel disease   PDF

CAVATAS-CEA, 2001   (ISRCTN01425573)   carotid artery stenting versus surgery in patients of any age with symptomatic or asymptomatic carotid artery stenosis suitable for surgery   PDF

Kentucky A (Brooks), 2001   carotid artery stenting versus surgery in patients presenting with cerebrovascular ischemia ipsilateral to carotid stenosis   PDF

Slamon, 2001   trastuzumab + standard chemotherapy versus standard chemotherapy alone in women with metastatic breast cancer that overexpressed HER2   PDF

Czerny b, 2001   off-pump versus on-pump in   PDF

Guler, 2001   off-pump versus on-pump in   PDF

PENTAMAKS (Bauer), 2001   fondaparinux versus enoxaparin in elective major knee surgery   PDF

PENTHIFRA (Eriksson), 2001   fondaparinux versus enoxaparin in hip fracture surgery   PDF

Phase II (Heit), 2001   ximelagatran versus Enoxaparin in adults (age>18 years and weight at least 40 kg) undergoing knee replacements   PDF

CAPRICORN, 2001   carvedilol versus placebo in proven acute myocardial infarction and a left-ventricular ejection fraction of <=40%   PDF

RENAAL, 2001   losartan versus placebo in patients with type 2 diabetes and nephropathy   PDF

IPDM (150mg), 2001   irbesartan versus placebo in hypertensive patients with type 2 diabetes and microalbuminuria   PDF

Wirth, 2001   reviparin versus control in elective knee arthroscopy   PDF

Comp, 2001   out of hospital Enoxaparin versus standard prophylaxis in THR or TKR   PDF

Milla-Santos, 2001   toremifene versus tamoxifen in postmenopausal women with advanced breast cancer, without previous systemic therapy   PDF

BCAPS, 2001   fluvastatin versus placebo in subjects who had carotid plaque but no symptoms of carotid artery disease   PDF

Devine C, 2001   Dacron versus PTFE in - 209 patients qui subissent une chirugie par pontage fémoropoplité ou tibiopéronié (33,5% de claudication, 66,15% d'ischémie critique) - 66,5% d'hommes - âge moyen 63,1 (entre 32 et 86 ans)   PDF

Gelin, 2001   Exercise Therapy versus Control in AOMI stade II   PDF

Gardner, 2001   Exercise Therapy versus Control in Stade de la maladie : II pendant 3.7 ans en moyenne.   PDF

Diamantopoulos, 2001   buflomédil versus placebo in Stade de la maladie: II de 3.4 ans en moyenne.   PDF

NIQOL belgium, 2001   naftidrofuryl versus placebo in Stade de la maladie :II pendant 4.1 ans en moyenne   PDF

NCIS, 2001   naftidrofuryl versus placebo in Stade de la maladie: II pendant 5.25 ans en moyenne   PDF

DAIS, 2001   fenofibrate versus placebo in men and women with type 2 diabetes and coronary atherosclerosis   PDF

Jassem, 2001   paclitaxel + doxorubicin versus fluorouracil, doxorubicin, cyclophosphamide in first-line therapy for women with metastatic breast cancer   PDF

Gorge and Kirstein, 2001   radial versus femoral in Coronary angiography or PCI   PDF

IDNT (irbesartan vs pbo), 2001   irbesartan versus placebo in hypertensive patients with nephropathy due to type 2 diabetes   PDF

IDNT (amlodipine vs PBO), 2001   amlodipine versus placebo in hypertensive patients with nephropathy due to type 2 diabetes   PDF

IDNT (irbesartan vs amlodipine), 2001   irbesartan versus amlodipine in hypertensive patients with nephropathy due to type 2 diabetes   PDF

D'Hooge D, 2001   naftidrofuryl IV versus placebo in - 235 patients - âge moyen 66,5 ans - 66,4% d'hommes   PDF

QUIET, 2001   quinapril versus placebo in patients with angiographic evidence of coronary artery disease without systolic leftventricular dysfunction   PDF

Castano, 2001   policosanol versus placebo in ICD 50 to 300 metres   PDF

REPLACE, 2001   telmisartan versus enalapril in ambulatory patients at least 21 years of age, in sinus rhythm, with chronic moderatesymptomatic heart failure (New York Heart Associatality.tion class II–III) and a left ventricular ejection fraction of 40% or lower   PDF

RENAAL, 2001   losartan versus placebo in patients with type 2 diabetes and nephropathy   PDF

Schühlen, 2001   rhenium-188 versus control in patients undergoing percutaneous transluminal coronary angioplasty for in-stent restenosis   PDF

Pinede, 2001   3-6 months versus 1.5-3 months in   PDF

GAIN, 2001   atorvastatin versus usual care in   PDF

LIPID (elderly sub group), 2001   Pravastatin versus placebo in MI or unstable angina, subgroup of age 65-75 y   PDF

AREDS, 2001   vitamin E versus placebo in patients with age-related lens opacities and visual acuity loss   PDF

PPP, 2001   vitamin E versus control in men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors   PDF

Moses, 2001   nateglinide versus placebo in patients with type 2 diabetes considered poorly controlled by diet, but without a history of previous antidiabetic medication   PDF

Namer, 2001   MV versus FAC/FEC in   PDF

GAMMA-ONE, 2001   iridium-92 versus placebo in patients with in-stent restenosis   PDF

ADEPT, 2001   eprosartan+ACE inhibitor versus ACE inhibitor only in patients with stable New York Heart Association class II-IV CHF receiving ACE inhibitor therapy   PDF

Primary Prevention Project, 2001   aspirin versus no treatment in men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors.   PDF

WRIST, 2001   iridium-92 versus placebo in presented with symptoms of angina and angiographic evidence of in-stent restenosis   PDF

Charpentier, 2001   glimepiride versus placebo (add on MET) in Type 2 diabetic patients aged 35-70 years inadequately controlled by metformin monotherapy 2550 mg daily   PDF

Turpie, 2001   fondaparinux versus enoxaparin in patients undergoing total hip replacement   PDF

Merli sub group, 2001   Enoxaparin versus unfractionated heparin in patients with confirmed pulmonary embolism   PDF

Galeote, 2001   enoxaparin versus UFH in PTCA patients with stable/unstable angina or AMI   PDF

Charpentier, 2001   versus in   PDF

Incandela, 2001   Essaven versus placebo in patients with ST associated with varicesm   PDF

Brox, 2001   fish oil versus control in dyslipidaemia   PDF

Drozd, 2001   enoxaparin versus UFH in PCI for stable angina   PDF

Oshaughnessy, 2001   capecitabine versus CMF in -line therapy for advanced/metastatic breast cancer   PDF

Dubek b (+abciximal), 2001   enoxaparin+abciximab versus UFH in   PDF

Browse pathologies - mechanisms - treatments - trials